Document:

EX-10.11

 Exhibit 10.11 

EXECUTION VERSION 
  

 
  

SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT 

dated as of 
 May 3,
2016 
 between 

VALERITAS, INC. 
 as
Borrower, 
 VALERITAS HOLDINGS, INC., 

as Guarantor,
 The
GUARANTORS from Time to Time Party Hereto, 
 and 

Capital Royalty Partners II L.P., Capital Royalty Partners II - Parallel Fund “A” L.P., 

Parallel Investment Opportunities Partners II L.P., Capital Royalty Partners II – Parallel 

Fund “B” (Cayman) L.P., and Capital Royalty Partners II (Cayman) L.P. 

as Lenders 
 U.S.
$50,000,000 
  
  

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
		
	 SECTION 1 DEFINITIONS
	  	 	2	 
			
	 1.01
	  	Certain Defined Terms	  	 	2	 
			
	 1.02
	  	Accounting Terms and Principles	  	 	20	 
			
	 1.03
	  	Interpretation	  	 	20	 
			
	 1.04
	  	Changes to GAAP	  	 	20	 
			
	 1.05
	  	Amendment and Restatement and Continuing Security	  	 	21	 
		
	 SECTION 2 THE Loans
	  	 	22	 
			
	 2.01
	  	Loans	  	 	22	 
			
	 2.02
	  	[Reserved]	  	 	22	 
			
	 2.03
	  	[Reserved]	  	 	22	 
			
	 2.04
	  	Notes	  	 	22	 
			
	 2.05
	  	Use of Proceeds	  	 	22	 
			
	 2.06
	  	Defaulting Lenders	  	 	23	 
			
	 2.07
	  	Substitution of Lenders	  	 	24	 
		
	 SECTION 3 PAYMENTS OF PRINCIPAL AND INTEREST
	  	 	25	 
			
	 3.01
	  	Repayment	  	 	25	 
			
	 3.02
	  	Interest	  	 	25	 
			
	 3.03
	  	Prepayments	  	 	26	 
		
	 SECTION 4 PAYMENTS, ETC.
	  	 	27	 
			
	 4.01
	  	Payments	  	 	27	 
			
	 4.02
	  	Computations	  	 	27	 
			
	 4.03
	  	Notices	  	 	27	 
			
	 4.04
	  	Set-Off	  	 	27	 
		
	 SECTION 5 YIELD PROTECTION, ETC.
	  	 	28	 
			
	 5.01
	  	Additional Costs	  	 	28	 
			
	 5.02
	  	Reserved	  	 	29	 
			
	 5.03
	  	Illegality	  	 	29	 
			
	 5.04
	  	Reserved	  	 	29	 
			
	 5.05
	  	Taxes	  	 	29	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
		
	 SECTION 6 CONDITIONS PRECEDENT
	  	 	32	 
			
	 6.01
	  	Conditions to Amendment and Restatement	  	 	32	 
			
	 6.02
	  	Acknowledgements	  	 	35	 
		
	 SECTION 7 REPRESENTATIONS AND WARRANTIES
	  	 	35	 
			
	 7.01
	  	Power and Authority	  	 	35	 
			
	 7.02
	  	Authorization; Enforceability	  	 	35	 
			
	 7.03
	  	Governmental and Other Approvals; No Conflicts	  	 	36	 
			
	 7.04
	  	Financial Statements; Material Adverse Change	  	 	36	 
			
	 7.05
	  	Properties	  	 	36	 
			
	 7.06
	  	No Actions or Proceedings	  	 	40	 
			
	 7.07
	  	Compliance with Laws and Agreements	  	 	40	 
			
	 7.08
	  	Taxes	  	 	40	 
			
	 7.09
	  	Full Disclosure	  	 	40	 
			
	 7.10
	  	Regulation	  	 	41	 
			
	 7.11
	  	Solvency	  	 	41	 
			
	 7.12
	  	Subsidiaries	  	 	41	 
			
	 7.13
	  	Indebtedness and Liens	  	 	41	 
			
	 7.14
	  	Material Agreements	  	 	41	 
			
	 7.15
	  	Restrictive Agreements	  	 	41	 
			
	 7.16
	  	Real Property	  	 	41	 
			
	 7.17
	  	Pension Matters	  	 	42	 
			
	 7.18
	  	Collateral; Security Interest	  	 	42	 
			
	 7.19
	  	Regulatory Approvals	  	 	42	 
			
	 7.20
	  	Small Business Concern	  	 	43	 
			
	 7.21
	  	Update of Schedules	  	 	43	 
		
	 SECTION 8 AFFIRMATIVE COVENANTS
	  	 	43	 
			
	 8.01
	  	Financial Statements and Other Information	  	 	43	 
			
	 8.02
	  	Notices of Material Events	  	 	45	 
			
	 8.03
	  	Existence; Conduct of Business	  	 	46	 
			
	 8.04
	  	Payment of Obligations	  	 	47	 
			
	 8.05
	  	Insurance	  	 	47	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 8.06
	  	Books and Records; Inspection Rights	  	 	48	 
			
	 8.07
	  	Compliance with Laws and Other Obligations	  	 	48	 
			
	 8.08
	  	Maintenance of Properties, Etc.	  	 	48	 
			
	 8.09
	  	Licenses	  	 	50	 
			
	 8.10
	  	Action under Environmental Laws	  	 	50	 
			
	 8.11
	  	Use of Proceeds	  	 	50	 
			
	 8.12
	  	Certain Obligations Respecting Subsidiaries and Parent; Further Assurances	  	 	50	 
			
	 8.13
	  	Termination of Non-Permitted Liens	  	 	52	 
			
	 8.14
	  	Intellectual Property	  	 	52	 
			
	 8.15
	  	Post-Closing Items	  	 	53	 
			
	 8.16
	  	Real Property Security Documents	  	 	53	 
		
	 SECTION 9 NEGATIVE COVENANTS
	  	 	53	 
			
	 9.01
	  	Indebtedness	  	 	53	 
			
	 9.02
	  	Liens	  	 	54	 
			
	 9.03
	  	Fundamental Changes and Acquisitions	  	 	56	 
			
	 9.04
	  	Lines of Business	  	 	57	 
			
	 9.05
	  	Investments	  	 	57	 
			
	 9.06
	  	Restricted Payments	  	 	57	 
			
	 9.07
	  	Payments of Indebtedness	  	 	58	 
			
	 9.08
	  	Change in Fiscal Year	  	 	58	 
			
	 9.09
	  	Sales of Assets, Issuances of Equity, Etc.	  	 	58	 
			
	 9.10
	  	Transactions with Affiliates	  	 	59	 
			
	 9.11
	  	Restrictive Agreements	  	 	60	 
			
	 9.12
	  	Amendments to Material Agreements	  	 	60	 
			
	 9.13
	  	Preservation of Borrower Lease; Operating Leases	  	 	60	 
			
	 9.14
	  	Sales and Leasebacks	  	 	61	 
			
	 9.15
	  	Hazardous Material	  	 	61	 
			
	 9.16
	  	Accounting Changes	  	 	62	 
			
	 9.17
	  	Compliance with ERISA	  	 	62	 
			
	 9.18
	  	Investment Company Act	  	 	62	 
			
	 9.19
	  	Parent	  	 	62	 
			
	 9.20
	  	Subsidiaries	  	 	62	 

  
 -iii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
		
	 SECTION 10 FINANCIAL COVENANTS
	  	 	62	 
			
	 10.01
	  	Minimum Cash	  	 	62	 
		
	 SECTION 11 EVENTS OF DEFAULT
	  	 	62	 
			
	 11.01
	  	Events of Default	  	 	62	 
			
	 11.02
	  	Remedies	  	 	65	 
		
	 SECTION 12 MISCELLANEOUS
	  	 	65	 
			
	 12.01
	  	No Waiver	  	 	65	 
			
	 12.02
	  	Notices	  	 	66	 
			
	 12.03
	  	Expenses, Indemnification, Etc.	  	 	66	 
			
	 12.04
	  	Amendments, Etc.	  	 	67	 
			
	 12.05
	  	Successors and Assigns	  	 	68	 
			
	 12.06
	  	Survival	  	 	69	 
			
	 12.07
	  	Captions	  	 	70	 
			
	 12.08
	  	Counterparts	  	 	70	 
			
	 12.09
	  	Governing Law	  	 	70	 
			
	 12.10
	  	Jurisdiction, Service of Process and Venue	  	 	70	 
			
	 12.11
	  	Waiver of Jury Trial	  	 	70	 
			
	 12.12
	  	Waiver of Immunity	  	 	71	 
			
	 12.13
	  	Entire Agreement	  	 	71	 
			
	 12.14
	  	Severability	  	 	71	 
			
	 12.15
	  	No Fiduciary Relationship	  	 	71	 
			
	 12.16
	  	Confidentiality	  	 	71	 
			
	 12.17
	  	USA PATRIOT Act	  	 	71	 
			
	 12.18
	  	Maximum Rate of Interest	  	 	71	 
			
	 12.19
	  	Certain Waivers	  	 	72	 
			
	 12.20
	  	Acknowledgment of Appointment of Agent	  	 	73	 
		
	 SECTION 13 GUARANTEE
	  	 	73	 
			
	 13.01
	  	The Guarantee	  	 	73	 
			
	 13.02
	  	Obligations Unconditional	  	 	74	 

  
 -iv- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 13.03
	  	 Reinstatement
	  	 	74	 
			
	 13.04
	  	 Subrogation
	  	 	75	 
			
	 13.05
	  	 Remedies
	  	 	75	 
			
	 13.06
	  	 Instrument for the Payment of Money
	  	 	75	 
			
	 13.07
	  	 Continuing Guarantee
	  	 	75	 
			
	 13.08
	  	 Rights of Contribution
	  	 	75	 
			
	 13.09
	  	 General Limitation on Guarantee Obligations
	  	 	76	 
			
	 13.10
	  	 Collateral and Guaranty Matters
	  	 	76	 

 SCHEDULES AND EXHIBITS 
  

					
	Schedule 1	  	 -
	    	Commitment/Outstanding Loans
	 Schedule 7.05(b)
	  	 -
	    	 Certain Intellectual Property

	 Schedule 7.05(c)
	  	 -
	    	 Material Intellectual Property

	 Schedule 7.06
	  	 -
	    	 Certain Litigation

	 Schedule 7.12
	  	 -
	    	 Information Regarding Subsidiaries

	 Schedule 7.13(a)
	  	 -
	    	 Existing Indebtedness of Parent, Borrower and its Subsidiaries

	 Schedule 7.13(b)
	  	 -
	    	 Liens Granted by the Obligors

	 Schedule 7.14
	  	 -
	    	 Material Agreements of Each Obligor

	 Schedule 7.15
	  	 -
	    	 Permitted Restrictive Agreements

	 Schedule 7.16
	  	 -
	    	 Real Property Owned or Leased by Parent, Borrower and Subsidiaries

	 Schedule 7.17
	  	 -
	    	 Pension Matters

	 Schedule 7.19
	  	 -
	    	 Regulatory Approvals

	 Schedule 9.05
	  	 -
	    	 Existing Investments

	 Schedule 9.14
	  	 -
	    	 Permitted Sales and Leasebacks

			
	 Exhibit A
	  	-	    	Form of Guarantee Assumption Agreement
	 Exhibit B
	  	-	    	[Reserved]
	 Exhibit C
	  	-	    	Form of Term Loan Note
	 Exhibit D
	  	-	    	Form of U.S. Tax Compliance Certificate
	 Exhibit E
	  	-	    	Form of Compliance Certificate
	 Exhibit F
	  	-	    	Form of Opinion from Corporate Counsel
	 Exhibit G
	  	-	    	Form of Landlord Consent
	 Exhibit H
	  	-	    	Form of Subordination Agreement

  
 -v- 

 SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT, dated as of May 3, 2016 (this
“Agreement”), among VALERITAS, INC., a Delaware corporation (“Borrower”), VALERITAS HOLDINGS, INC., a Delaware corporation (“Parent”), the GUARANTORS from time to time party
hereto and the Lenders from time to time party hereto. 
 WITNESSETH: 

WHEREAS, the Borrower and the Lenders were parties to a certain Term Loan Agreement dated as of May 24, 2013 (the “Initial
Term Loan Agreement”), which Initial Term Loan Agreement was subsequently amended and restated as that certain Amended and Restated Term Loan Agreement, dated as of August 5, 2014 (as so amended and restated, the
“Existing Term Loan Agreement”).
 WHEREAS, on April 3, 2015, the Lenders notified the Borrower that various Events
of Default had occurred and were continuing under the Existing Term Loan Agreement, and declared all Obligations of the Borrower under the Existing Term Loan Agreement to be immediately due and payable. 

WHEREAS, Valeritas Security became a Subsidiary Guarantor pursuant to that certain Joinder Agreement by Valeritas Security in favor of the
Lenders, dated as of April 16, 2015. 
 WHEREAS, the Borrower, the Subsidiary Guarantors party thereto and the Lenders entered into
that certain Limited Forbearance Agreement, dated as of May 18, 2015, pursuant to which the Lenders agreed to temporarily forbear from exercising certain default-related rights and remedies against the Borrower and the Subsidiary Guarantors. 

WHEREAS, the Borrower currently owes to the Lenders an amount of $16,574,604.12 of interest, fees and penalties on the unpaid principal
balance under the Existing Term Loan Agreement, which interest, fees and penalties the Lenders have agreed to convert on April 29, 2016, into shares of stock of the Borrower pursuant to the Conversion Agreements (as defined below). 

WHEREAS, the Borrower intends to enter into a reverse merger transaction (the “Reverse Merger”) on the date hereof
pursuant to which the Borrower shall become a Subsidiary of the Parent. 
 WHEREAS, in connection with the Reverse Merger, the Borrower and
the Lenders have agreed to amend and restate the Existing Term Loan Agreement as set forth herein and to add the Parent as an Obligor hereunder. 

NOW THEREFORE, accordingly, the parties hereto agree as follows: 

  
 1 

 SECTION 1 

DEFINITIONS 
 1.01 Certain Defined
Terms. As used herein, the following terms have the following respective meanings: 
 “Acquisition” means
any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a take-over bid, tender offer, amalgamation, merger, purchase of assets, or similar transaction having the same effect as any of the
foregoing, (a) acquires any business or all or substantially all of the assets of any Person engaged in any business, (b) acquires control of securities of a Person engaged in a business representing more than 50% of the ordinary voting power for
the election of directors or other governing body if the business affairs of such Person are managed by a board of directors or other governing body, or (c) acquires control of more than 50% of the ownership interest in any Person engaged in any
business that is not managed by a board of directors or other governing body. 
 “Affiliate” means, with respect to
a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 

“Agency Agreement” means that certain Agency Agreement, dated as of the date hereof, by and among the Lenders and CRG
Servicing LLC. 
 “Agreement” has the meaning set forth in the introduction hereto. 

“Asset Sale” is defined in Section 9.09. 

“Asset Sale Net Proceeds” means the aggregate amount of the cash proceeds received from any Asset Sale, net of any
bona fide fees, costs, expenses and amounts incurred or payable in connection with such Asset Sale (including, without limitation, any Indebtedness (other than the Obligations) that is required to be discharged in connection with such Asset Sale,
reasonable out-of-pocket costs and expenses incurred in connection with such Asset Sale and taxes reasonably estimated to be payable within two years of the date of the consummation of such Asset Sale), plus, the monetized amount of any non-cash
proceeds of an Asset Sale but only as and when so received. 
 “Assignment and Acceptance” means an assignment and
acceptance entered into by a Lender and an assignee of such Lender. 
 “Bankruptcy Code” means Title II of the
United States Code entitled “Bankruptcy.” 
 “Benefit Plan” means any employee benefit plan as defined in
Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise) to which any Obligor or Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise. 

“Borrower” has the meaning set forth in the introduction hereto. 

“Borrower Facility” means the premises located at 800 Boston Turnpike, Shrewsbury, Massachusetts, which are leased by
Borrower pursuant to the Borrower Lease. 

  
 2 

 “Borrower Landlord” means The Taming of the Shrewsbury, LLC, O’Neill
Partners, LLC and Chanski, LLC as tenants in common. 
 “Borrower Lease” means that certain lease dated as of
December 22, 2006 between the Borrower Landlord and Valeritas, LLC (predecessor to the Borrower), as amended, modified and in effect from time to time. 

“Borrowing” means a borrowing consisting of Loans made on the same day by the Lenders according to their respective
Commitments (including without limitation a borrowing of a PIK Loan). 
 “Borrowing Date” means the date of any
Borrowing. 
 “Business Day” means a day (other than a Saturday or Sunday) on which commercial banks are not
authorized or required to close in New York City. 
 “Capital Lease Obligations” means, as to any Person, the
obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital lease on a balance
sheet of such Person under GAAP and, for purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP. 

“Change of Control” means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any
“person” or “group” (as such terms are used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its
capacity as trustee, agent or other fiduciary or administrator of any such plan) other than the Specified Equityholders, acting jointly or otherwise in concert, of capital stock representing more than 50% of the aggregate ordinary voting power
represented by the issued and outstanding capital stock of the Parent or the Borrower or (b) the acquisition of direct or indirect Control of the Parent or the Borrower by any Person or group of Persons other than the Specified Equityholders, acting
jointly or otherwise in concert; in each case whether as a result of a tender or exchange offer, open market purchases, privately negotiated purchases or otherwise. 

“Claims” includes claims, demands, complaints, grievances, actions, applications, suits, causes of action, orders,
charges, indictments, prosecutions, informations (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments. 

“Closing Date” means April 29, 2016, the effective date of this Second Amended and Restated Term Loan Agreement. 

“Code” means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations
promulgated thereunder from time to time. 

  
 3 

 “Collateral” means the collateral provided for in the Security Documents.

 “Commitment” means, with respect to each Lender, the obligation of such Lender to make Loans to the Borrower in
accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender’s name on Schedule 1 under the caption “Commitment”, as such Schedule may be amended from time to
time pursuant to Section 12.05(c). The aggregate Commitments under this Agreement equal $50,000,000. As of the date hereof, all Loans (other than PIK Loans) under such Commitments have been made to the Borrower and the Commitments have
expired or been terminated. For purposes of clarification, the amount of any PIK Loans shall not reduce the amount of the available Commitment. 

“Commodities Account” is defined in the Security Agreement. 

“Compliance Certificate” has the meaning given to such term in Section 8.01(c). 

“Consent, Waiver, and Amendment Agreement” means that Consent, Waiver and Amendment Agreement dated as of
June 19, 2014 among Borrower and the Lenders. 
 “Contracts” means contracts, licenses, leases, agreements,
obligations, promises, undertakings, understandings, arrangements, documents, commitments, entitlements or engagements under which a Person has, or will have, any liability or contingent liability (in each case, whether written or oral, express or
implied). 
 “Control” means, in respect of a particular Person, the possession, directly or indirectly, of the
power to direct or cause the direction of the management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative
thereto. 
 “Control Agent” is defined in the Security Agreement. 

“Conversion Agreement” means (i) that certain Conversion Agreement for common stock, dated as of April 29, 2016,
between among the Lenders and the Borrower, and (ii) that certain Conversion Agreement for preferred stock, dated as of April 29, 2016, between among the Lenders and the Borrower. 

“Copyrights” is defined in the Security Agreement. 

“CRPPFA” means Capital Royalty Partners II – Parallel Fund “A” L.P., a Delaware limited partnership.

 “CRP (Cayman)” means Capital Royalty Partners II (Cayman) L.P., a Cayman Islands limited partnership. 

“CRPPFB (Cayman)” means Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P., a Cayman Islands
limited partnership. 
 “Cure Amount” has the meaning set forth in Section 10.01(b)(ii). 

  
 4 

 “Cure Right” has the meaning set forth in Section 10.01(b)(i)(B).

 “Default” means any Event of Default and any event that, upon the giving of notice, the lapse of time or both,
would constitute an Event of Default. 
 “Defaulting Lender” means, subject to Section 2.06, any Lender
that (a) has failed to perform any of its funding obligations hereunder, including in respect of its Loans, within three (3) Business Days of the date required to be funded by it hereunder, (b) has notified the Borrower or any Lender that it does
not intend to comply with its funding obligations or has made a public statement to that effect with respect to its funding obligations hereunder or under other agreements in which it commits to extend credit, or (c) has, or has a direct or indirect
parent company that has, (i) become the subject of an Insolvency Proceeding, (ii) had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business
or a custodian appointed for it, or (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment; provided that a Lender shall not be a Defaulting Lender solely by virtue of
the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority. 

“Deposit Account” is defined in the Security Agreement. 

“Disqualified Securities” means any Equity Interest which, by its terms (or by the terms of any security or other
Equity Interest into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition, (a) matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or is redeemable at the
option of the holder thereof, in whole or in part, on or prior to the Maturity Date, (b) is convertible in or exchangeable for (i) debt securities or (ii) any Equity Interests referred to in clause (a) above, in each case, at any time prior to the
Maturity Date, (c) contains any repurchase obligations which may come into effect prior to payment in full of all Obligations (other than Warrant Obligations, and customary contingent indemnification claims), or (d) requires the payment of cash
dividends or distributions prior to the Maturity Date. 
 “Dollars” and “$” means lawful
money of the United States of America. 
 “Domestic Subsidiary” means any Subsidiary that is a corporation, limited
liability company, partnership or similar business entity incorporated, formed or organized under the laws of the United States, any State of the United States or the District of Columbia. 

“Environmental Law” means any federal, state, provincial or local governmental law, rule, regulation, order, writ,
judgment, injunction or decree relating to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release or handling of hazardous materials, and all local laws and regulations related to environmental
matters and any specific agreements entered into with any competent authorities which include commitments related to environmental matters. 

“Equity Interest” shall mean, with respect to any Person, any and all shares, interests, participations or other
equivalents, including membership interests (however designated, whether 

  
 5 

 voting or nonvoting), of equity of such Person, including, if such Person is a partnership, partnership interests
(whether general or limited) and any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of property of, such partnership, but excluding debt securities convertible or
exchangeable into such equity. 
 “Equivalent Amount” means, with respect to an amount denominated in one currency,
the amount in another currency that could be purchased by the amount in the first currency determined by reference to the Exchange Rate at the time of determination. 

“ERISA” means the United States Employee Retirement Income Security Act of 1974. 

“ERISA Affiliate” means, collectively, any Obligor, Subsidiary thereof, and any Person under common control, or
treated as a single employer, with any Obligor or Subsidiary thereof, within the meaning of Section 414(b), (c), (m) or (o) of the Code. 

“ERISA Event” means (i) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan,
excluding, however, such events as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within 30 days of the occurrence of such event; (ii) the applicability of the requirements of Section
4043(b) of ERISA with respect to a contributing sponsor, as defined in Section 4001(a)(13) of ERISA, to any Title IV Plan where an event described in paragraph (9), (10), (11), (12) or (13) of Section 4043(c) of ERISA is reasonably expected to
occur with respect to such plan within the following 30 days; (iii) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the termination of any Title IV Plan resulting in liability under Sections 4063 or 4064 of ERISA;
(iv) the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete or partial withdrawal (within the meaning of Section 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by
any Obligor or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it is in reorganization or insolvency pursuant to Section 4241 or 4245 of ERISA; (v) the filing of a notice of intent to terminate, the treatment of a plan
amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Title IV Plan or Multiemployer Plan; (vi) the imposition of liability on any Obligor or any ERISA Affiliate thereof
pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (vii) the failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Plan, or the failure to meet the
minimum funding standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430 of
the Code with respect to any Title IV Plan or the failure to make any required contribution to a Multiemployer Plan; (viii) the determination that any Title IV Plan is considered an at-risk plan or a plan in endangered to critical status within the
meaning of Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA; (ix) an event or condition which might reasonably be expected to constitute grounds under Section 4042 of ERISA for the termination of, or the
appointment of a trustee to administer, any Title IV Plan or Multiemployer Plan; (x) the imposition of any liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any
Obligor or any ERISA Affiliate thereof; (xi) an application for a funding waiver under Section 303 of ERISA or an extension of 

  
 6 

 any amortization period pursuant to Section 412 of the Code with respect to any Title Plan; (xii) the occurrence
of a non-exempt prohibited transaction under Sections 406 or 407 of ERISA for which any Obligor or any Subsidiary thereof may be directly or indirectly liable; (xiii) a violation of the applicable requirements of Section 404 or 405 of ERISA or the
exclusive benefit rule under Section 401(a) of the Code by any fiduciary or disqualified person for which any Obligor or any ERISA Affiliate thereof may be directly or indirectly liable; (xiv) the occurrence of an act or omission which could
give rise to the imposition on any Obligor or any ERISA Affiliate thereof of fines, penalties, taxes or related charges under Chapter 43 of the Code or under Sections 409, 502(c), (i) or (1) or 4071 of ERISA; (xv) the assertion of a material
claim (other than routine claims for benefits) against any Plan or the assets thereof, or against any Obligor or any Subsidiary thereof in connection with any such plan; (xvi) receipt from the IRS of notice of the failure of any Qualified Plan to
qualify under Section 401(a) of the Code, or the failure of any trust forming part of any Qualified Plan to fail to qualify for exemption from taxation under Section 501(a) of the Code; (xvii) the imposition of any lien (or the fulfillment of the
conditions for the imposition of any lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Title I or IV, including Section 302(f) or 303(k) of ERISA or to Section 401(a)(29)
or 430(k) of the Code; or (xviii) the establishment or amendment by any Obligor or any Subsidiary thereof of any “welfare plan”, as such term is defined in Section 3(1) of ERISA, that provides post-employment welfare benefits in a
manner that would increase the liability of any Obligor. 
 “Event of Default” has the meaning set forth in
Section 11. 
 “Exchange Rate” means the rate at which any currency (the “Pre-Exchange
Currency”) may be exchanged into another currency (the “Post-Exchange Currency”), as set forth on such date on the relevant Reuters screen at or about 11:00 a.m. (Central time) on such date. In the event that
such rate does not appear on the Reuters screen, the “Exchange Rate” with respect to exchanging such Pre-Exchange Currency into such Post-Exchange Currency shall be determined by reference to such other publicly available service for
displaying exchange rates as may be agreed upon by the Borrower and the Majority Lenders or, in the absence of such agreement, such Exchange Rate shall instead be determined by the Majority Lenders by any reasonable method as they deem applicable to
determine such rate, and such determination shall be conclusive absent manifest error. 
 “Excluded Accounts” means
accounts used in the ordinary course of business for payroll, payroll taxes and other employee wage and benefit payments, pension fund accounts, 401(k) accounts, trust accounts, the certificates of deposit referred to in Section 9.02(p),
and the segregated deposit accounts referred to in Section 9.02(q). 
 “Excluded Taxes” means any of the
following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in each
case imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax, (b) Other Connection Taxes, (c)
U.S. federal withholding Taxes that are imposed on amounts payable to a Lender to the extent that the obligation to withhold amounts existed on the date that such Lender became a “Lender” under 

  
 7 

 this Agreement, except in each case to the extent such Lender is a direct or indirect assignee of any other
Lender that was entitled, at the time the assignment of such other Lender became effective, to receive additional amounts under Section 5.05, (d) any Taxes imposed in connection with FATCA, and (e) Taxes attributable to such
Recipient’s failure to comply with Section 5.05(e). 
 “Existing Term Loan Agreement” has the
meaning set forth in the recitals hereto. 
 “FATCA” means Sections 1471 through 1474 of the Code, as of the date of
this Agreement (or any amended or successor version that is substantively comparable and not more onerous to comply with), any regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the
Internal Revenue Code. 
 “First Borrowing Date” means August 15, 2013. 

“Forbearance Agreement” means that Limited Forbearance Agreement, dated as of May 18, 2015, as amended to date,
among the Borrower and the Lenders.
 “Foreign Lender” means a Lender that is not a U.S. Person. 

“Foreign Subsidiary” means a Subsidiary of Borrower that is not a Domestic Subsidiary. 

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time,
set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and in such other statements
by such other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination. Subject to Section 1.02, all references to “GAAP”
shall be to GAAP applied consistently with the principles used in the preparation of the financial statements described in Section 7.04(a). 

“Governmental Approval” means any consent, authorization, approval, order, license, franchise, permit, certificate,
accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 

“Governmental Authority” means any nation, government, branch of power (whether executive, legislative or judicial),
state, province or municipality or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to government, including without limitation
regulatory authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law-, rule- or regulation-making organizations or entities of any
State, territory, county, city or other political subdivision of the United States. 
 “Guarantee” of or by any
Person (the “guarantor”) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the
“primary obligor”) in any manner,

  
 8 

 
whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such
Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such
Indebtedness or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or
other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; provided, that the term Guarantee shall not include endorsements for collection or deposit in the
ordinary course of business. 
 “Guarantee Assumption Agreement” means a Guarantee Assumption Agreement
substantially in the form of Exhibit A by an entity that, pursuant to Section 8.12(a), is required to become a “Guarantor” hereunder in favor of the Lenders. 

“Guarantors” means, collectively, the Subsidiary Guarantors and the Parent and their respective successors and
permitted assigns.
 “Hazardous Material” means any substance, element, chemical, compound, product, solid, gas,
liquid, waste, by-product, pollutant, contaminant or material which is hazardous or toxic, and includes, without limitation, (a) asbestos, polychlorinated biphenyls and petroleum (including crude oil or any fraction thereof) and (b) any material
classified or regulated as “hazardous” or “toxic” or words of like import pursuant to an Environmental Law. 

“Hedging Agreement” means any interest rate exchange agreement, foreign currency exchange agreement, commodity price
protection agreement or other interest or currency exchange rate or commodity price hedging arrangement. 

“Indebtedness” of any Person means, without duplication, (a) all obligations of such Person for borrowed money or
obligations of such Person with respect to deposits or advances of any kind by third parties, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person upon which interest
charges are customarily paid, (d) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all obligations of such Person in respect of the deferred purchase price of
property or services (excluding current accounts payable incurred in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be
secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h) all Capital Lease Obligations of such Person, (i)
all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (j) obligations under any Hedging Agreement in respect of currency swaps, forwards, futures or derivatives
transactions, and (k) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership or joint venture in
which such Person is a general partner or a joint venturer) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such
Indebtedness provide that such Person is not liable therefor. 

  
 9 

 “Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed
on or with respect to any payment made by or on account of any Obligation and (b) to the extent not otherwise described in clause (a), Other Taxes. 

“Initial Term Loan Agreement” has the meaning set forth in the recitals hereto. 

“Insolvency Proceeding” means (i) any case, action or proceeding before any court or other Governmental Authority
relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, or (ii) any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other,
similar arrangement in respect of any Person’s creditors generally or any substantial portion of such Person’s creditors, in each case undertaken under U.S. Federal, state or foreign law, including the Bankruptcy Code.

“Intellectual Property” means all Patents, Trademarks, Copyrights, and Technical Information, whether registered or
not, domestic and foreign. Intellectual Property shall include all: 
 (a) applications or registrations relating to such Intellectual
Property; 
 (b) rights and privileges arising under applicable Laws with respect to such Intellectual Property; 

(c) rights to sue for past, present or future infringements of such Intellectual Property; and 

(d) rights of the same or similar effect or nature in any jurisdiction corresponding to such Intellectual Property throughout the world. 

“Interest-Only Period” means the period from and including the First Borrowing Date and through and including the
nineteenth (19th) Payment Date after the Closing Date. 
 “Interest
Period” means, with respect to any Borrowing, initially, the period commencing on the Borrowing Date therefor and ending on the next Payment Date, and thereafter, each period beginning on the last day of the immediately preceding
Interest Period and ending on March 31, June 30, September 30 and December 31, as the case may be; provided that (i) any Interest Period that would otherwise end on a day that is not a Business Day shall end on the next
preceding Business Day and (ii) the term “Interest Period” shall include any period selected by the Majority Lenders from time to time in accordance with Section 3.02(c). 

“Invention” means any novel, inventive and useful art, apparatus, method, process, machine (including article or
device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device), manufacture or composition of matter. 

  
 10 

 “Investment” means, for any Person: (a) the acquisition (whether for
cash, property, services or securities or otherwise) of capital stock, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any such acquisition (including any
“short sale” or any sale of any securities at a time when such securities are not owned by the Person entering into such sale); (b) the making of any deposit with, or advance, loan or other extension of credit to, any other Person
(including the purchase of property from another Person subject to an understanding or agreement, contingent or otherwise, to resell such property to such Person), but excluding any such advance, loan or extension of credit having a term not
exceeding 90 days arising in connection with the sale of inventory or supplies by such Person in the ordinary course of business; (c) the entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other
liability of any other Person and (without duplication) any amount committed to be advanced, lent or extended to such Person; or (d) the entering into of any Hedging Agreement. 

“IRS” means the U.S. Internal Revenue Service or any successor agency, and to the extent relevant, the U.S. Department
of the Treasury. 
 “Knowledge” means, with respect to the Borrower, any Obligor or any of their Subsidiaries, the
actual knowledge of the Chief Executive Officer, the President and Chief Commercial Officer, the Chief Financial Officer, the Controller, the Executive Vice President (Manufacturing, Operations and R&D), and the Vice President (Human Resources)
of the Borrower. Furthermore, “Knowledge” shall be deemed to be the actual knowledge of any such Person (and not the implied, constructive or imputed knowledge of any such Person) as of the applicable times expressly indicated, and without
any obligation to make any independent investigation of, or any implied duty to investigate, such matters, or to make any inquiry of any other Person, or to search or to examine any files, records books, correspondence and the like. There shall be
no personal liability on the part of any individual referred to above arising out of the Loan Documents. 
 “Landlord
Consent” means a Landlord Consent substantially in the form of Exhibit G. 
 “Laws” means,
collectively, all international, foreign, federal, state, provincial, territorial, municipal and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the
interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits
of, and agreements with, any Governmental Authority, in each case whether or not having the force of law. 

“Lenders” means Capital Royalty Partners II L.P., CRPPFA, PIOP, CRP (Cayman) and CRPPFB (Cayman), together with their
successors and each assignee of a Lender pursuant to Section 12.05(b) and “Lender” means any one of them. 

“Lien” means any mortgage, lien, pledge, charge, encumbrance or other security interest, leases, title retention
agreements, mortgages, restrictions, easements, rights-of-way, options or adverse claims (of ownership or possession) or encumbrances of any kind or character whatsoever or any preferential arrangement that has the practical effect of creating a
security interest. 

  
 11 

 “Loan” means (i) each loan advanced by a Lender pursuant to
Section 2.01 and (ii) each PIK Loan deemed to have been advanced by a Lender pursuant to Section 3.02(d). For purposes of clarification, any calculation of the aggregate outstanding principal amount of Loans on any date of
determination shall include both the aggregate principal amount of loans advanced pursuant to Section 2.01 and not yet repaid, and all PIK Loans deemed to have been advanced and not yet repaid, on or prior to such date of determination.

 “Loan Documents” means, collectively, this Agreement, the Notes, the Security Documents, each Warrant, any
subordination agreement or any intercreditor agreement entered into by Lenders with any other creditors of Obligors, the Valeritas Security Side Letter, the Agency Agreement and any other present or future agreement executed by Obligors for the
benefit of Lenders in connection with this Agreement or any of the other Loan Documents, all as amended, restated, or otherwise modified. 

“Loss” means judgments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether
liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all costs
incurred in investigating or pursuing any Claim or any proceeding relating to any Claim. 
 “Majority Lenders”
means, at any time, Lenders having at such time in excess of 50% of the aggregate Commitments (or, if such Commitments are terminated, the outstanding principal amount of the Loans) then in effect, ignoring, in such calculation, the Commitments of
and outstanding Loans owing to any Defaulting Lender. 
 “Management Gross Revenue” means for any period, revenues
arrived at during such period by multiplying the wholesale acquisition cost per kit paid by the relevant customer by the number of Product commercial kits sold in a bona fide transaction and consistent with past practices. 

“Management Net Revenue” means for any period, Management Gross Revenue during such period less each of the following
deductions during such period: 
 1. Service fees, which are recorded based on the customer that purchased the Product; 

2. Prompt pay discounts or rebates, which are recorded based on the customer that purchased the Product;

3. Returns, which are based on industry norms, estimated at 1.5% of Management Gross Revenue; unless the Borrower’s actual history of
returns is materially higher than 1.5%, in which case such higher amount shall be used; 
 4. Managed care mix discount or rebate, which is
based on the estimated end user payor mix and related contractual rebates;
 5. Part D mix discount or rebate, which is based on the
estimated end user payor mix and related contractual rebates; and 
 6. Actual costs associated with copay card redemptions plus estimated
projected redemption costs based on Product sold to customers but not yet in the hands of the end user (patient). 

  
 12 

 “Margin Stock” means “margin stock” within the meaning of
Regulations U and X. 
 “Material Adverse Change” and “Material Adverse Effect” mean a
material adverse change in or effect on (i) the business, financial condition, operations, performance or Property of Parent, Borrower and their Subsidiaries taken as a whole, (ii) the ability of any Obligor to perform its obligations under the Loan
Documents, or (iii) the legality, validity, binding effect or enforceability of the Loan Documents or the rights and remedies of the Lenders under any of the Loan Documents. “Material Adverse Change” and “Material Adverse Effect”
shall not include any change or effect relating generally to national or regional economic conditions, financial markets, and/or the industry in which the Borrower engages in business, except that any such change or effect may constitute, and shall
be taken into account in determining whether there has been or would be, a Material Adverse Change or Material Adverse Effect if such changes or effects have, in any material respect, a disproportionate impact on Parent, Borrower and their
Subsidiaries, taken as a whole, relative to other companies in the industry in which Parent, Borrower and their Subsidiaries operate. 

“Material Agreements” means (i) the agreements which are listed in Schedule 7.14 and (ii) all other
agreements held by the Obligors from time to time, the absence or termination of any of which would reasonably be expected to result in a Material Adverse Effect, provided however that “Material Agreements” exclude all: (i) licenses
implied by the sale of a product; and (ii) paid-up licenses for commonly available software programs under which an Obligor is the licensee. “Material Agreement” means any one such agreement. If, at any time following May 24. 2013,
any agreement set forth on Schedule 7.14 ceases to constitute an agreement of the type described in clause (ii) above, such agreement shall, at such time, no longer constitute a “Material Agreement”.

“Material Indebtedness” means, at any time, any Indebtedness of any Obligor the outstanding principal amount of which,
individually or in the aggregate, exceeds $1,000,000 (or the Equivalent Amount in other currencies). 
 “Material Intellectual
Property” means, the Obligor Intellectual Property described in Schedule 7.05(c) and any other Obligor Intellectual Property after May 24, 2013 the loss of which would reasonably be expected to have a Material Adverse
Effect. 
 “Maturity Date” means the earlier to occur of (i) the twentieth (20th) Payment Date following the Closing Date, and (ii) the date on which the Loans are accelerated pursuant to Section 11.02. 

“Multiemployer Plan” means any multiemployer plan, as defined in Section 400l(a)(3) of ERISA, to which any ERISA
Affiliate incurs or otherwise has any obligation or liability, contingent or otherwise. 

  
 13 

 “Note” means a promissory note executed and delivered by the Borrower to
the Lenders in accordance with Section 2.04 or 3.02(d). 
 “Obligations” means, with respect to
any Obligor, all amounts, obligations, liabilities, covenants and duties of every type and description owing by such Obligor to any Lender, any other indemnitee hereunder or any participant, arising out of, under, or in connection with, any Loan
Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any
instrument or for the payment of money, including, without duplication, (i) if such Obligor is the Borrower, all Loans, (ii) all interest, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any
insolvency, reorganization or similar proceeding, and whether or not a claim for post-filing or post-petition interest is allowed in any such proceeding, and (iii) all other fees, expenses (including reasonable and documented fees, charges and
disbursement of counsel), interest, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan Document. 

“Obligor Intellectual Property” means Intellectual Property owned by or licensed to any of the Obligors. 

“Obligors” means, collectively, the Borrower and the Guarantors and their respective successors and permitted assigns.

 “Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former
connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or
perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document). 

“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes
that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes
that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 5.05(g)). 

“Parent” has the meaning set forth in the introduction hereto. 

“Parent Security Agreement Joinder Agreement” means the Security Agreement Joinder Agreement, dated as of the date
hereof, among the Parent and the Lenders, joining the Parent as a Grantor under the Security Agreement. 
 “Patents”
is defined in the Security Agreement. 
 “Payment Date” means each of March 31, June 30,
September 30, December 31 and the Maturity Date; provided that, other than with respect to the Payment Date that is the Maturity Date, if any such date shall occur on a day that is not a Business Day, the applicable Payment Date
shall be the next preceding Business Day. 

  
 14 

 “PBGC” means the United States Pension Benefit Guaranty Corporation and
any successor thereto. 
 “Permitted Cash Equivalent Investments” means (i) marketable direct obligations issued or
unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than two (2) years from the date of acquisition, (ii) time deposits or insured certificates of deposit or bankers’ acceptances
having maturities of not more than two (2) years from the date of acquisition maintained with any commercial bank organized under the laws of the United States of America that is a member of the Federal Reserve System, (iii) commercial paper
maturing no more than one (1) year after its creation and having the highest or second highest rating from either Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc. and (iv) Investments in money market investment
programs administered by reputable financial institutions, the portfolios of which are limited solely to Investments of the character, quality and maturity described in the foregoing clauses (i) through (iii). 

“Permitted Indebtedness” means any Indebtedness permitted under Section 9.01. 

“Permitted Lien” means any Lien permitted under Section 9.02. 

“Permitted Refinancing” means, with respect to any Indebtedness, any extensions, renewals and replacements of such
Indebtedness; provided that such extension, renewal or replacement (i) shall not increase the outstanding principal amount of such Indebtedness except by an amount equal to accrued interest and a reasonable premium or other amount paid, and
fees and expenses reasonably incurred in connection therewith, (ii) contains terms relating to outstanding principal amount, amortization, maturity, collateral (if any) and subordination (if any), and other material terms taken as a whole no less
favorable in any material respect to the Parent, Borrower and their Subsidiaries or the Lenders than the terms of any agreement or instrument governing such existing Indebtedness, (iii) shall have an applicable interest rate which does not exceed
the greater of (a) rate of interest of the Indebtedness being replaced and (b) the then applicable market interest rate, and (iv) shall not contain any new requirement to grant any lien or security or to give any guarantee that was not an existing
requirement of such Indebtedness. 
 “Permitted Restrictive Agreements” has the meaning set forth in
Section 7.15. 
 “Permitted Senior Liens” means those Liens permitted under Sections 9.02(e)
and (i). 
 “Permitted Shareholder Debt” means all Indebtedness evidenced by that (i) certain Amended and
Restated Note dated as of May 3, 2016 by the Borrower as maker and WCAS Capital Partners IV, L.P. (or any Affiliate or transferee thereof), as holder, or (ii) any additional notes issued by the Borrower as maker to WCAS Capital Partners IV,
L.P. (or any Affiliate or transferee thereof), as holder, in each case as amended, amended and restated, supplemented or modified; provided that such Indebtedness shall be at all times subject to the terms and conditions of a Subordination
Agreement, substantially in the form attached hereto as Exhibit H, 

  
 15 

 
among the Lenders and the holders of such Note; provided further that in the case of any additional notes issued by the Borrower as described in clause (ii) above, such notes shall be on
substantially the same terms as that certain Amended and Restated Note dated as of May 3, 2016 by the Borrower as maker and WCAS Capital Partners IV, L.P. (or any Affiliate or transferee thereof), as holder. 

“Permitted Subordinated Debt” means the Permitted Shareholder Debt in an aggregate outstanding principal amount not to
exceed $37,500,000 (plus interest paid-in-kind thereon) at any time. 
 “Person” means any individual, corporation,
company, voluntary association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature. 

“PBGC” means the Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity
performing similar functions. 
 “PIK Loan” has the meaning set forth in Section 3.02(d). 

“PIK Period” means the period beginning on the First Borrowing Date through and including the nineteenth (19th) Payment Date after the Closing Date. 
 “PIOP” means Parallel
Investment Opportunities Partners II L.P., a Delaware limited partnership. 
 “Plan” means any employee pension
benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA, and in respect of which Borrower or any ERISA Affiliate is (or, if such plan were terminated, would
under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA. 
 “Post-Default
Rate” has the meaning set forth in Section 3.02(b). 
 “Product” means V-Go® and EZ Fill
(and their respective successors), in a form substantially similar to that approved by the U.S. Food and Drug Administration in December 2010. 

“Property” of any Person means any property or assets, or interest therein, of such Person. 

“Proportionate Share” means, with respect to any Lender, the percentage obtained by dividing (a) the sum of the
Commitment (or, if the Commitments are terminated, the outstanding principal amount of the Loans) of such Lender then in effect by (b) the sum of the Commitments (or, if the Commitments are terminated, the outstanding principal amount of the Loans)
of all Lenders then in effect. 
 “Qualified Plan” means an employee benefit plan (as defined in Section 3(3) of
ERISA) other than a Multiemployer Plan (i) that is or was at any time maintained or sponsored by any 

  
 16 

 
Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has ever made, or was ever obligated to make, contributions, and (ii) that is intended to be tax
qualified under Section 401(a) of the Code. 
 “Real Property Security Documents” means the Landlord Consent and any
collateral access agreements and security documents, including mortgages but excluding deeds of trust, required under Section 8.16 to be executed or delivered by an Obligor; provided that Real Property Security Documents shall not
include any mortgages with respect to any leasehold interest in real property. 
 “Recipient” means any Lender or
any other recipient of any payment to be made by or on account of any Obligation. 
 “Redemption Date” has the
meaning set forth in Section 3.03(a). 
 “Redemption Price” has the meaning set forth in Section
3.03(a). 
 “Register” has the meaning set forth in Section 12.05(d). 

“Regulation T” means Regulation T of the Board of Governors of the Federal Reserve System, as amended. 

“Regulation U” means Regulation U of the Board of Governors of the Federal Reserve System, as amended. 

“Regulation X” means Regulation X of the Board of Governors of the Federal Reserve System, as amended. 

“Regulatory Approvals” means any registrations, licenses, authorizations, permits or approvals issued by any
Governmental Authority and applications or submissions related to any of the foregoing. 
 “Requirement of Law”
means, as to any Person, any statute, law, treaty, rule or regulation or determination, order, injunction or judgment of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its
Properties or revenues. 
 “Responsible Officer” of any Person means the President, Chief Executive Officer, Chief
Financial Officer or Treasurer of such Person. 
 “Restricted Payment” means any dividend or other distribution
(whether in cash, securities or other property) with respect to any shares of any class of capital stock of the Parent, Borrower or any of their Subsidiaries, or any payment (whether in cash, securities or other property), including any sinking fund
or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such shares of capital stock of the Parent, Borrower or any of their Subsidiaries or any option, warrant or other right to
acquire any such shares of capital stock of the Parent, Borrower or any of their Subsidiaries. 

  
 17 

 “Revenue” means for any period, Management Net Revenue during such period
that is recognized at the time the Product sold (in a bona fide transaction) to, and legal title transfers to, the Borrower’s customers, third-party wholesalers and medical supply distributors, consistent with past practices and consistently
applied. 
 “Reverse Merger” has the meaning set forth in the recitals hereto. 

“SBA” means U.S. Small Business Administration. 

“SBIC” means Small Business Investment Company. 

“SBIC Act” means Small Business Investment Act of 1958, as amended. 

“Security Agreement” means the Security Agreement, dated as of May 24, 2013, among the Obligors and the Lenders,
granting a security interest in the Obligors’ personal Property in favor of the Lenders. 
 “Security
Documents” means, collectively, the Security Agreement, the Parent Security Agreement Joinder Agreement, each Short-Form IP Security Agreement, each Real Property Security Document, and each other security document, control agreement or
financing statement required or recommended to perfect Liens in favor of the Lenders. 
 “Securities Account” is
defined in the Security Agreement. 
 “Short-Form IP Security Agreements” means short-form copyright, patent or
trademark (as the case may be) security agreements entered into by one or more Obligors in favor of the Lenders, each in form and substance reasonably satisfactory to the Majority Lenders (and as amended, modified or replaced from time to time).

 “Solvent” means, with respect to any Person at any time, that (a) the present fair saleable value of the Property
of such Person is greater than the total amount of liabilities (including contingent liabilities) of such Person, (b) the present fair saleable value of the Property of such Person is not less than the amount that will be required to pay the
probable liability of such Person on its debts as they become absolute and matured, (c) such Person has not incurred and does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay as
such debts and liabilities mature and (d) such Person would not be unable to obtain a letter from its auditors that did not contain a going concern qualification. 

“Specified Equityholders” means WCAS Valeritas Holdings, LLC, WCAS XI Co- Investors, LLC, WCAS Capital Partners IV,
L.P., WCAS Management Corporation, their respective Affiliates and any other holders of the Borrower’s Series C Preferred Stock, as determined as of May 24, 2013. 

“Specified Licensing Arrangements” means any exclusive licensing arrangement (i) with respect to the sale of the
Product to end-users outside the United States only or (ii) with respect to any products developed, manufactured or sold that is not in connection with the treatment of diabetes. 

  
 18 

 “Subsidiary” means, with respect to any Person (the
“parent”) at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial
statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity (a) of which securities or other ownership interests
representing more than 50% of the equity or more than 50% of the ordinary voting power or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled or held, or (b) that is, as of such
date, otherwise Controlled, by the parent or one or more subsidiaries of the parent or by the parent and one or more subsidiaries of the parent. 

“Subsidiary Guarantors” means each of the Subsidiaries of the Borrower identified under the caption “SUBSIDIARY
GUARANTORS” on the signature pages hereto and each Subsidiary of the Borrower that becomes, or is required to become, a “Subsidiary Guarantor” after the date hereof pursuant to Section 8.12(a) or (b). 

“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup
withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 

“Technical Information” means all trade secrets and other proprietary or confidential information, public information,
non-proprietary know-how, any information of a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations, discoveries, Invention disclosures, all documented research,
developmental, demonstration or engineering work and all other information, data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, know-how, technical information, systems, methodologies, computer programs,
information technology and any other information. 
 “Title IV Plan” means an employee benefit plan (as defined in
Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was at any time maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has ever made, or was obligated to
make, contributions, and (ii) that is or was subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA. 

“Trademarks” is defined in the Security Agreement. 

“Transactions” means the execution, delivery and performance by each Obligor of this Agreement and the other Loan
Documents to which such Obligor is intended to be a party and the Borrowing (and the use of the proceeds of the Loans). 
 “U.S.
Person” means a “United States Person” within the meaning of Section 7701(a)(30) of the Code. 

“Valeritas Security” means Valeritas Security Corporation, a Delaware corporation. 

“Valeritas Security Side Letter” means the side letter dated as of May 24, 2013 among the Borrower, Valeritas Security
and the Lenders.

  
 19 

 “Warrant” means each warrant to purchase capital stock of Borrower,
issued by Borrower to the Lenders in connection with the transactions contemplated by the Existing Term Loan Agreement. 

“Warrant Obligations” means, with respect to any Obligor, all Obligations arising out of, under or in connection with,
any Warrant. 
 “Withdrawal Liability” means, at any time, any liability incurred (whether or not assessed) by any
ERISA Affiliate and not yet satisfied or paid in full at such time with respect to any Multiemployer Plan pursuant to Section 4201 of ERISA. 
 1.02
Accounting Terms and Principles. All accounting determinations required to be made pursuant hereto shall, unless expressly otherwise provided herein, be made in accordance with GAAP. All components of financial calculations made to determine
compliance with this Agreement, including Section 10, shall be adjusted to include or exclude, as the case may be, without duplication, such components of such calculations attributable to any Acquisition consummated after the first day of
the applicable period of determination and prior to the end of such period, as determined in good faith by the Borrower based on assumptions expressed therein and that were reasonable based on the information available to the Borrower at the time of
preparation of the Compliance Certificate setting forth such calculations. 
 1.03 Interpretation. For all purposes of this Agreement, except as
otherwise expressly provided herein or unless the context otherwise requires, (a) the terms defined in this Agreement include the plural as well as the singular and vice versa; (b) words importing gender include all genders; (c) any reference to a
Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to, this Agreement; (d) any reference to “this Agreement” refers to this Agreement, including all Annexes, Schedules and Exhibits hereto, and the
words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision; (e) references to
days, months and years refer to calendar days, months and years, respectively; (f) all references herein to “include” or “including” shall be deemed to be followed by the words “without limitation”; (g) the word
“from” when used in connection with a period of time means “from and including” and the word “until” means “to but not including”; and (h) accounting terms not specifically defined herein shall be construed in
accordance with GAAP (except for the term “property”, which shall be interpreted as broadly as possible, including, in any case, cash, securities, other assets, rights under contractual obligations and permits and any right or interest in
any property, except where otherwise noted). Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent
amendments, restatements, extensions, supplements and other modifications thereto, permitted by the Loan Documents. 
 1.04 Changes to GAAP. If,
after the date hereof, any change occurs in GAAP or in the application thereof and such change would cause any amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant to Section 8, 9
or 10 to be materially different than the amount that would be determined prior to such change, then: 
 (a) the Borrower will provide a
detailed notice of such change (an “Accounting Change Notice”) to the Lenders within 30 days of such change; 

  
 20 

 (b) either the Borrower or the Majority Lenders may indicate within 90 days following the date of
the Accounting Change Notice that they wish to revise the method of calculating such financial covenants or amend any such amount, in which case the parties will in good faith attempt to agree upon a revised method for calculating the financial
covenants;
 (c) until the Borrower and the Majority Lenders have reached agreement on such revisions, (i) such financial covenants or
amounts will be determined without giving effect to such change and (ii) all financial statements, Compliance Certificates and similar documents provided hereunder shall be provided together with a reconciliation between the calculations and amounts
set forth therein before and after giving effect to such change in GAAP; 
 (d) if no party elects to revise the method of calculating the
financial covenants or amounts, then the financial covenants or amounts will not be revised and will be determined in accordance with GAAP without giving effect to such change; and 

(e) any Event of Default arising as a result of such change which is cured by operation of this Section 1.04 shall be deemed to be of
no effect ab initio. 
 1.05 Amendment and Restatement and Continuing Security. 

(a) As stated in the recitals hereof, this Agreement amends, restates and supersedes the Existing Term Loan Agreement, without
novation. Upon the Closing Date, all references in any Loan Document and all other agreements, documents and instruments delivered by the Borrower, any Subsidiary Guarantor, any of the Lenders or any other Person to (i) the Existing Term
Loan Agreement shall be deemed to refer to this Agreement (except where the context otherwise requires) and (ii) a “Lender” or the “Control Agent” shall mean such terms as defined in this Agreement. Upon the date hereof, all
references in any Loan Document and all other agreements, documents and instruments delivered by the Parent to (i) the Existing Term Loan Agreement shall be deemed to refer to this Agreement (except where the context otherwise requires) and (ii) a
“Lender” or the “Control Agent” shall mean such terms as defined in this Agreement. As to all periods occurring on or after the Closing Date, all of the terms and conditions set forth in the Existing Term Loan Agreement shall be
of no further force and effect; it being understood that all obligations of each Obligor under the Existing Term Loan Agreement shall be governed by this Second Amended and Restated Term Loan Agreement from and after the Closing Date. 

(b) The parties hereto acknowledge and agree that all principal, interest, fees, costs, reimbursable expenses and indemnification obligations
accruing or arising under or in connection with the Existing Term Loan Agreement which remain unpaid and outstanding as of the Closing Date shall be and remain outstanding and payable as an obligation under this Agreement and the other Loan
Documents. 

  
 21 

 (c) Borrower hereby ratifies, affirms and acknowledges all of its obligations in respect of the
Existing Term Loan Agreement, as amended and restated hereby, and the related documents and agreements delivered by it thereunder. 
 (d) It
is the intention of each of the parties hereto that the Existing Term Loan Agreement be amended and restated by the provisions hereof so as to preserve the perfection and priority of all security interests securing indebtedness and obligations under
the Existing Term Loan Agreement and that all indebtedness and obligations of the Obligors hereunder shall be secured by the Security Documents and that this Agreement does not constitute a novation of the obligations and liabilities existing under
the Existing Term Loan Agreement provided that the foregoing shall not affect the amendment and addition of new obligations effected by this Agreement after the date hereof. Borrower hereby confirms that the validity, effect and enforceability of
all Collateral and the guarantee of the Obligations by any Subsidiary Guarantors shall remain unaffected by this amendment and restatement. The parties agree that the Obligations secured by the Collateral and the guarantee of any Subsidiary
Guarantors shall include the obligations under or in connection with this amendment and restatement (including any term loans). 
 SECTION
2 
 THE LOANS 
 2.01 Loans.
Each Lender has severally, on and subject to the terms and conditions of this Agreement, made a term loan of $50,000,000 in aggregate principal amount to the Borrower on the First Borrowing Date in accordance with such Lender’s Proportionate
Share of such Loan. Amounts of Loans repaid may not be reborrowed. As of the date hereof, all Commitments of the Lenders have expired or been terminated. If within 100 days of the Closing Date (a) a petition under the Bankruptcy Code is filed by or
against the Borrower, or (b) the Borrower enters into an assignment for the benefit of creditors, the principal amount of the Loans shall be deemed to have increased by the full amount of interest and fees converted pursuant to the Conversion
Agreements.
 2.02 [Reserved]. 
 2.03
[Reserved]. 
 2.04 Notes. If requested by any Lender, the Loans of such Lender shall be evidenced by one or more promissory notes (each a
“Note”). The Borrower shall prepare, execute and deliver to the Lenders such promissory note(s) payable to the Lenders (or, if requested by the Lenders, to the Lenders and their registered assigns) and in the form attached
hereto as Exhibit C. Thereafter, the Loans and interest thereon shall at all times (including after assignment pursuant to Section 12.05) be represented by one or more promissory notes in such form payable to the payee named
therein (or, if such promissory note is a registered note, to such payee and its registered assigns). 
 2.05 Use of Proceeds. The Borrower shall use
the proceeds of the Loans for general working capital and corporate purposes and to pay fees, costs and expenses incurred in connection with the Transactions; provided that the Lenders shall have no responsibility as to the use of any

  
 22 

 
proceeds of Loans in the amount made by PIOP. No portion of any proceeds of Loans in the amount made by PIOP (i) will be used to acquire realty or to discharge an obligation relating to the prior
acquisition of realty; (ii) will be used outside of the United States (except to pay for services to be rendered outside the United States and to acquire from abroad inventory, material and equipment or property rights for use or sale in the United
States, unless prohibited by Part 107.720 of the United States Code of Federal Regulations); or (iii) will be used for any purpose contrary to the public interest (including but not limited to activities which are in violation of law) or
inconsistent with free competitive enterprise, in each case, within the meaning of Part 107.720 of Title 13 of the United States Code of Federal Regulations. The Borrower will use the proceeds of the Loans in the amount made by PIOP for only those
purposes specified in the SBA Form 1031 provided to the Lenders. 
 2.06 Defaulting Lenders. 

(a) Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then,
until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable law: 
 (i) Waivers and
Amendments. Such Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in Section 12.04. 

(ii) Reallocation of Payments. Any payment of principal, interest, fees or other amounts received by the Lenders for the account of
such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 11 or otherwise), shall be applied at such time or times as follows: first, as the Borrower may request (so long as no Default exists), to the funding of
any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement; second, if so determined by the Majority Lenders and the Borrower, to be held in a non-interest bearing deposit account and
released in order to satisfy obligations of such Defaulting Lender to fund Loans under this Agreement; third, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender
against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; fourth, so long as no Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a
court of competent jurisdiction obtained by the Borrower against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and fifth, to such Defaulting Lender or as otherwise directed by a
court of competent jurisdiction; provided that if (A) such payment is a payment of the principal amount of any Loans in respect of which such Defaulting Lender has not fully funded its appropriate share and (B) such Loans were made at a time when
the conditions set forth in Section 6 were satisfied or waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of such Defaulting
Lender. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender pursuant to this Section 2.06(a)(ii) shall be deemed paid to and redirected by
such Defaulting Lender, and each Lender irrevocably consents hereto.

  
 23 

 (b) Defaulting Lender Cure. If the Borrower and the Majority Lenders agree in writing in
their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, that Lender will, to the extent applicable, purchase that portion of outstanding Loans of the other Lenders or take such other actions as necessary
to cause the Loans to be held on a pro rata basis by the Lenders in accordance with their Proportionate Share, whereupon that Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to
fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and provided further that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting
Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender. 

2.07 Substitution of Lenders. 
 (a)
Substitution Right. In the event that any Lender (an “Affected Lender”), (i) becomes a Defaulting Lender or (ii) does not consent to any amendment, waiver or consent to any Loan Document for which the consent of the
Majority Lenders is obtained but that requires the consent of other Lenders (a “Non-Consenting Lender”), either (x) the Borrower may pay in full such Affected Lender with respect to all Obligations owing to such Affected
Lender or (y) such Affected Lender may be substituted by any willing Lender or Affiliate of any Lender or transferee (in each case, a “Substitute Lender”); provided that any substitution of a Non-Consenting Lender
shall occur only with the reasonable consent of Majority Lenders. 
 (b) Procedure. To substitute such Affected Lender or pay in full
the Obligations owed to such Affected Lender, the Borrower shall deliver a notice to such Affected Lender. The effectiveness of such payment or substitution shall be subject to the delivery by the Borrower (or, as may be applicable in the case of a
substitution, by the Substitute Lender) of (i) payment for the account of such Affected Lender, of, to the extent accrued through, and outstanding on, the effective date for such payment or substitution, all Obligations owing to such Affected Lender
and (ii) in the case of a substitution, an Assignment and Acceptance whereby the Substitute Lender shall, among other things, agree to be bound by the terms of the Loan Documents. 

(c) Effectiveness. Upon satisfaction of the conditions set forth in Section 2.07(a) and (b), the Control Agent shall
record such substitution or payment in the Register, whereupon (i) in the case of any payment in full of an Affected Lender pursuant to Section 2.07(b)(i), such Affected Lender’s Commitments shall be terminated and (ii) in the case
of any substitution of an Affected Lender, (A) such Affected Lender shall sell and be relieved of, and the Substitute Lender shall purchase and assume, all rights and claims of such Affected Lender under the Loan Documents, except that (1) the
Affected Lender shall retain such rights expressly providing that they survive the repayment of the Obligations and the termination of the Commitments and (2) a Non-Consenting Lender shall be permitted to retain any Warrants issued to such
Non-Consenting Lender, (B) such Substitute Lender shall become a “Lender” hereunder and (C) such Affected Lender shall execute and deliver an Assignment and Acceptance to evidence such substitution; provided, however, that
the failure of any Affected Lender to execute any such Assignment and Acceptance shall not render such sale and purchase (or the corresponding assignment) invalid. 

  
 24 

 SECTION 3 

PAYMENTS OF PRINCIPAL AND INTEREST 

3.01 Repayment. 
 (a) Repayment.
During the Interest-Only Period, no payments of principal of the Loans shall be due. Borrower agrees to repay to the Lenders the outstanding principal amount of the Loans on the Maturity Date. 

(b) Application. Any optional or mandatory prepayment of the Loans shall be applied to the installments thereof under
Section 3.01(a) in the inverse order of maturity. To the extent not previously paid, the principal amount of the Loans, together with all other outstanding Obligations (other than Warrant Obligations), shall be due and payable on the
Maturity Date. 
 3.02 Interest. 
 (a)
Interest Generally. Subject to Section 3.02(d), Borrower agrees to pay to the Lenders interest on the unpaid principal amount of the Loans and the amount of all other outstanding Obligations, in the case of the Loans, for the period
from the date hereof and in the case of any other Obligation, from the date such other Obligation is due and payable, in each case, until paid in full, at a rate per annum equal to 11.00%. 

(b) Default Interest. Notwithstanding the foregoing, upon the occurrence and during the continuance of any Event of Default, the
interest payable pursuant to Section 3.02(a) shall increase automatically by 4.00% per annum (such aggregate increased rate, the “Post-Default Rate”). Notwithstanding any other provision herein (including
Section 3.02(d)), if interest is required to be paid at the Post-Default Rate, it shall be paid entirely in cash. If any Obligation is not paid when due under the applicable Loan Document, the amount thereof shall accrue interest at a rate
equal to 4.00% per annum (without duplication of interest payable at the Post-Default Rate). 
 (c) Interest Payment Dates.
Accrued interest on the Loans shall be payable in arrears on the last day of each Interest Period in cash, and upon the payment or prepayment thereof (on the principal amount so paid or prepaid); provided that interest payable at the
Post-Default Rate shall be payable from time to time on demand. 
 (d) Paid In-Kind Interest. Notwithstanding Section 3.02(a),
at any time during the PIK Period as of the date hereof, the Borrower may elect to pay the interest on the outstanding principal amount of the Loans payable pursuant to Section 3.02 as follows: (i) only 8.00% of the 11.00% per annum
interest in cash and (ii) 3.00% of the 11.00% per annum interest as compounded interest, added to the aggregate principal amount of the Loans on the last day of each Interest Period (the amount of any such compounded interest being a
“PIK Loan”); provided that, on or prior to the eighth (8th) Payment Date following the Closing Date, Borrower may elect to pay such interest on the outstanding
principal amount of the Loans entirely in the form of PIK Loans. If requested by any Lender, each PIK Loan shall be evidenced by a Note delivered pursuant to Section 2.04 for the applicable Borrowing in respect thereof. The principal amount
of each PIK Loan shall accrue interest in accordance with the provisions of this Agreement applicable to the Loans. 

  
 25 

 3.03 Prepayments. 

(a) Optional Prepayments. The Borrower shall have the right optionally to prepay the outstanding principal amount of the Loans in whole
or in part on any Payment Date (a “Redemption Date”) for an amount equal to the aggregate principal amount of the Loans being prepaid plus any accrued but unpaid interest and any fees which are due and owing (such aggregate
amount, the “Redemption Price”). 
 (b) Mandatory Prepayments. 

(i) Asset Sales. In the event of any contemplated Asset Sale not permitted under Section 9.09, the Borrower shall provide 10
days’ prior written notice of such Asset Sale to the Lenders and, if within such notice period Majority Lenders advise the Borrower that a prepayment is required pursuant to this Section 3.03(b)(i), the Borrower shall: (x) if the assets
sold represent substantially all of the assets or revenues of the Borrower, or represent any specific line of business which either on its own or together with other lines of business sold over the term of this Agreement account for Revenue
generated by such lines of business exceeding 10% of the Revenue of the Borrower in the immediately preceding year (in each case, other than with respect to Asset Sales in connection with or pursuant to Specified Licensing Arrangements), prepay the
aggregate outstanding principal amount of the Loans in an amount equal to the Redemption Price applicable on the date of such Asset Sale in accordance with Section 3.03(a), and (y) in the case of all other Asset Sales (including, without
limitation, all Asset Sales in connection with or pursuant to Specified Licensing Arrangements) not permitted by Section 9.09 and not described in the foregoing clause (x), prepay the Loans in an amount equal to the lesser of (a) the
outstanding principal amount of the Loans in an amount equal to the Redemption Price applicable on the date of such Asset Sale in accordance with Section 3.03(a) and (b) the entire amount of the Asset Sale Net Proceeds of such Asset
Sale, plus any accrued but unpaid interest and any fees which are due and owing, credited in the following order: 
 (A) first, in
reduction of the Borrower’s obligation to pay any unpaid interest and any fees which are due and owing; 
 (B) second, in reduction of
the Borrower’s obligation to pay any Claims or Losses referred to in Section 12.03; 
 (C) third, in reduction of the
Borrower’s obligation to pay any amounts due and owing on account of the unpaid principal amount of the Loans; 
 (D) fourth, in
reduction of any other Obligation; and 
 (E) fifth, to the Borrower or such other Persons as may lawfully be entitled to or directed by
the Borrower to receive the remainder. 

  
 26 

 (ii) Change of Control. In the event of a Change of Control, the Borrower shall
immediately provide notice of such Change of Control to the Lenders and, if within 10 days of receipt of such notice Majority Lenders notify the Borrower in writing that a prepayment is required pursuant to this Section 3.03(b)(ii), the
Borrower shall prepay the aggregate outstanding principal amount of the Loans in an amount equal to the Redemption Price applicable on the date of such Change of Control in accordance with Section 3.03(a). 

SECTION 4 
 PAYMENTS,
ETC. 
 4.01 Payments. 
 (a)
Payments Generally. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any other Loan Document shall be made in Dollars, in immediately available funds, without deduction, set off or
counterclaim, to an account to be designated by the Majority Lenders by notice to the Borrower, not later than 4:00 p.m. (Central time) on the date on which such payment shall become due (each such payment made after such time on such due date to be
deemed to have been made on the next succeeding Business Day). 
 (b) Application of Payments. Each Obligor shall, at the time of
making each payment under this Agreement or any other Loan Document, specify to the Lenders the amounts payable by such Obligor hereunder to which such payment is to be applied (and in the event that Obligors fail to so specify, or if an Event of
Default has occurred and is continuing, the Lenders may apply such payment in the manner they determine to be appropriate). 
 (c)
Non-Business Days. If the due date of any payment under this Agreement (other than of principal of or interest on the Loans) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business
Day, and, in the case of any payment accruing interest, interest thereon shall be payable for the period of such extension. 
 4.02 Computations. All
computations of interest and fees hereunder shall be computed on the basis of a year of 360 days and actual days elapsed (including the first day but excluding the last day) occurring in the period for which payable. 

4.03 Notices. Each notice of optional prepayment shall be effective only if received by the Lenders not later than 4:00 p.m. (Central time) on the date
one Business Day prior to the date of prepayment. Each notice of optional prepayment shall specify the amount to be prepaid and the date of prepayment. 

4.04 Set-Off. 
 (a) Set-Off
Generally. Upon the occurrence and during the continuance of any Event of Default, the Lenders and each of their Affiliates are hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any
and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Lenders or such Affiliate to or for the credit or the account of the

  
 27 

 
Borrower against any and all of the Obligations (other than Warrant Obligations), whether or not the Lenders shall have made any demand and although such obligations may be unmatured. The Lenders
agree promptly to notify the Borrower after any such set-off and application, provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Lenders and their Affiliates under this
Section 4.04 are in addition to other rights and remedies (including other rights of set-off) that the Lenders and their Affiliates may have. 

(b) Exercise of Rights Not Required. Nothing contained herein shall require the Lenders to exercise any such right or shall affect the
right of the Lenders to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation of Borrower. 

SECTION 5 
 YIELD
PROTECTION, ETC. 
 5.01 Additional Costs. 

(a) Change in Requirements of Law Generally. If, on or after the date hereof, the adoption of any Requirement of Law, or any change in
any Requirement of Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by any of the Lenders (or its lending office)
with any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve
System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof, against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending
office) or shall impose on a Lender (or its lending office) any other condition affecting the Loans or the Commitment, and the result of any of the foregoing is to increase the cost to such Lender of making or maintaining the Loans, or to reduce the
amount of any sum received or receivable by such Lender under this Agreement or any other Loan Document, by an amount deemed by such Lender to be material (other than (i) Indemnified Taxes and (ii) Taxes described in clause (c) or (d)
of the definition of “Excluded Taxes”), then the Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender for such increased cost or reduction. 

(b) Change in Capital Requirements. If a Lender shall have determined that, on or after the date hereof, the adoption of any
Requirement of Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration thereof, or any request or directive
regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after the date hereof, has or would have the effect of reducing the rate of return on capital of a Lender (or
its parent) as a consequence of a Lender’s obligations hereunder or the Loans to a level below that which a Lender (or its parent) could have achieved but for such adoption, change, request or directive by an amount reasonably deemed by it to
be material, then the Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender (or its parent) for such reduction. 

  
 28 

 (c) Notification by Lender. The Lenders will promptly notify the Borrower of any event of
which it has knowledge, occurring after the date hereof, which will entitle a Lender to compensation pursuant to this Section 5.01. Before giving any such notice pursuant to this Section 5.01(c) such Lender shall designate a different
lending office if such designation (x) will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to such
Lender. A certificate of the Lender claiming compensation under this Section 5.01, setting forth the additional amount or amounts to be paid to it hereunder, shall be conclusive and binding on the Borrower in the absence of manifest
error.
 (d) Notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all
requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any
successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute a change in Requirements of Law for all purposes of this Section 5,
regardless of the date enacted, adopted or issued. 
 5.02 Reserved. 

5.03 Illegality. Notwithstanding any other provision of this Agreement, in the event that on or after the date hereof the adoption of or any change in
any Requirement of Law or in the interpretation or application thereof by any competent Governmental Authority shall make it unlawful for a Lender or its lending office to make or maintain the Loans (and, in the opinion of such Lender, the
designation of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such Lender), then such Lender shall promptly notify the Borrower thereof following which (a) the Lender’s Commitment shall be
suspended until such time as such Lender may again make and maintain the Loans hereunder and (b) if such Requirement of Law shall so mandate, the Loans shall be prepaid by the Borrower on or before such date as shall be mandated by such Requirement
of Law in an amount equal to the Redemption Price applicable on the date of such prepayment in accordance with Section 3.03(a). 
 5.04
Reserved. 
 5.05 Taxes. 
 (a)
Payments Free of Taxes. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith
discretion of an applicable withholding agent) requires the deduction or withholding of any Tax from any such payment by a withholding agent, then the applicable withholding agent shall be entitled to make such deduction or withholding and shall
timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the Obligor shall be increased as necessary so that

  
 29 

 
after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 5) the applicable Recipient receives
an amount equal to the sum it would have received had no such deduction or withholding been made. 
 (b) Payment of Other Taxes by the
Borrower. The Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of each Lender, timely reimburse it for, Other Taxes. 

(c) Evidence of Payments. As soon as practicable after any payment of Taxes by the Borrower to a Governmental Authority pursuant to
this Section 5, the Borrower shall deliver to each Lender the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment. 

(d) Indemnification. The Borrower shall reimburse and indemnify each Recipient, within 10 days after demand therefor, for the full
amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 5) payable or paid by such Recipient or required to be withheld or deducted from a payment to such
Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such
payment or liability delivered to the Borrower by a Lender shall be conclusive absent manifest error. 
 (e) Status of Lenders. 

(i) Any Lender that is entitled to an exemption from, or reduction of withholding Tax with respect to payments made under any Loan Document
shall timely deliver to the Borrower such properly completed and executed documentation reasonably requested by the Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding; provided that, other than
in the case of U.S. Federal withholding Taxes, such Lender has received written notice from the Borrower advising it of the availability of such exemption or reduction and containing all applicable documentation. In addition, any Lender shall
deliver such other documentation prescribed by applicable law as reasonably requested by the Borrower as will enable the Borrower to determine whether or not such Lender is subject to backup withholding or information reporting
requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 5.05(e)(ii)(A), (B) or
(D)) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position
of such Lender. 
 (ii) Without limiting the generality of the foregoing, in the event that Borrower is a U.S. Person: 

(A) any Lender that is a U.S. Person shall deliver to the Borrower on or prior to the date on which such Lender becomes a Lender under this
Agreement (and from time to time thereafter upon the reasonable request of the Borrower), executed originals of IRS Form W-9 (or successor form) certifying that such Lender is exempt from U.S. Federal backup withholding tax; 

  
 30 

 (B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the
Borrower (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower),
whichever of the following is applicable: 
 (1) in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the
United States is a party (x) with respect to payments of interest under any Loan Document, executed originals of IRS Form W-8BEN (or successor form) establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant to the
“interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN (or successor form) establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant
to the “business profits” or “other income” article of such tax treaty; 
 (2) executed originals of IRS Form W-8ECI
(or successor form); 
 (3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section
881(c) of the Code, (x) a certificate substantially in the form of Exhibit D to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the
Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed originals
of IRS Form W-8BEN (or successor form); or 
 (4) to the extent a Foreign Lender is not the beneficial owner, executed originals of IRS
Form W-8IMY (or successor form), accompanied by IRS Form W-8ECI (or successor form), IRS Form W-8BEN (or successor form), a U.S. Tax Compliance Certificate, IRS Form W-9 (or successor form), and/or other certification documents from each beneficial
owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance
Certificate on behalf of each such direct and indirect partner;
 (C) any Foreign Lender shall, to the extent it is legally entitled to do
so, deliver to the Borrower (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of
the Borrower), executed originals of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. Federal withholding Tax, duly completed, together with such supplementary documentation as may be
prescribed by applicable law to permit the Borrower to determine the withholding or deduction required to be made; and 
 (D) any Foreign
Lender shall deliver to the Borrower any forms and information necessary to establish that the Foreign Lender is not subject to withholding tax under FATCA. 

  
 31 

 Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or
inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower in writing of its legal inability to do so. 

(f) Treatment of Certain Refunds. If any party determines, in its sole discretion exercised in good faith, that it has received a
refund of any Taxes as to which it has been indemnified pursuant to this Section 5 (including by the payment of additional amounts pursuant to this Section 5), it shall pay to the indemnifying party an amount equal to such refund (but
only to the extent of indemnity payments made under this Section 5 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any
interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (plus any
penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this
Section 5.05(f), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 5.05(f) the payment of which would place the indemnified party in a less favorable net after-Tax
position than the indemnified party would have been in if the indemnification payments or additional amounts giving rise to such refund had never been paid. This Section 5.05(f) shall not be construed to require any indemnified party to make
available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. 

(g) Mitigation Obligations. If the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any
Governmental Authority for the account of any Lender pursuant to Section 5.01 or this Section 5.05, then such Lender shall (at the request of the Borrower) use commercially reasonable efforts to designate a different lending office for
funding or booking its Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation
would (i) eliminate or reduce amounts payable pursuant to Section 5.01 or this Section 5.05, as the case may be, in the future, (ii) not subject such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous
to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation. 

SECTION 6 
 CONDITIONS
PRECEDENT 
 6.01 Conditions to Amendment and Restatement. The effectiveness of the amendment and restatement of the Existing Term Loan Agreement
is subject to the following conditions precedent: 
 (a) Reverse Merger. The documentation for the Reverse Merger and all related
filings and registrations with any Governmental Authority shall have been in agreed form for completion of the Reverse Merger. 

  
 32 

 (b) Conversion of Accrued Fees and Interest. All interest (other than default interest)
accrued to the date hereof by the Borrower under the Existing Term Loan Agreement shall have been converted into and exchanged for the Borrower’s Series AB preferred stock at a per share conversion price of $1.25. All default interest, fees and
prepayment penalties accrued to the date hereof by the Borrower under the Existing Term Loan Agreement shall have been converted into and exchanged for the Borrower’s common stock at a per share conversion price of $1.25. 

(c) Payment of Fees. Borrower shall have paid or reimbursed Lenders for Lenders’ reasonable out of pocket costs and expenses
incurred in connection with this Agreement, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of this Agreement. 

(d) Updated Lien Searches. Lenders shall be reasonably satisfied with updated Lien searches provided by the Borrower or its counsel to
the Lenders in respect of each Obligor. 
 (e) Documentary Deliveries. The Lenders shall have received the following documents, each
of which shall be in form and substance reasonably satisfactory to the Lenders: 
 (i) Agreement. This Agreement duly executed and
delivered by the Borrower and each of the other parties hereto. 
 (ii) Security Documents. 

(A) The Parent Security Agreement Joinder Agreement, duly executed and delivered by the Parent; 

(B) Each Security Document previously delivered by the applicable Obligor shall remain in full force and effect; 

(C) UCC-1 financing statements against each Obligor in its jurisdiction of formation or incorporation, as the case may be, shall have been
filed or, with respect to the Parent, be in ready form for filing; 
 (D) Without limitation, all other documents and instruments
reasonably required to perfect the Lenders’ Lien on, and security interest in, the Collateral (including account control agreements and any capital stock certificates and undated stock powers executed in blank) shall have been duly executed and
delivered and be in proper form for filing, and shall create in favor of the Lenders, a perfected Lien on, and security interest in, the Collateral, subject to no Liens other than Permitted Liens. 

(iii) Notes. Any Notes requested in accordance with Section 2.04. 

  
 33 

 (iv) Corporate Documents. Certified copies of the constitutive documents of each Obligor
(if publicly available in such Obligor’s jurisdiction of formation) and of resolutions of the Board of Directors (or shareholders, if applicable) of each Obligor authorizing the making and performance by it of the Loan Documents to which it is
a party. 
 (v) Incumbency Certificate. A certificate of each Obligor as to the authority, incumbency and specimen signatures of the
persons who have executed the Loan Documents and any other documents in connection herewith on behalf of the Obligors. 
 (vi)
Officer’s Certificate. A certificate, dated the date hereof and signed by the President, a Vice President or a financial officer of Borrower, confirming compliance with the conditions set forth in Section 6.01(f). 

(vii) Opinions of Counsel. A favorable opinion, dated the date hereof, of counsel to each Obligor reasonably satisfactory to the
Lenders and their counsel substantially in the form of Exhibit F. 
 (viii) Insurance. Certificates of insurance evidencing
the existence of all insurance required to be maintained by the Borrower pursuant to Section 8.05 and the designation of the Lenders as the loss payees or additional named insured, as the case may be, thereunder. 

(ix) Stock Certificate and Stock Power. All original stock certificates of stock evidencing the Parent’s ownership interest in the
Borrower, accompanied by stock powers undated and endorsed in blank shall be in agreed form for delivery to the Lenders promptly following the Reverse Merger.

(x) Valeritas Security Side Letter. The Valeritas Security Side Letter shall have been terminated and superseded by this Agreement.

 (xi) Forbearance Agreement. The Forbearance Agreement shall have been terminated. 

(xii) Conversion Documents. The documents necessary for the conversion to Series AB preferred stock and common stock of the Borrower of
the outstanding fees and interest described in Section 6.01(b), duly executed and delivered by the Borrower and each of the other parties thereto. 

(xiii) Agency Agreement. The Lenders shall have received a duly executed copy of that certain Agency Agreement, dated as of the date
hereof, by and among the Lenders and CRG Servicing LLC. 
 (xiv) Subordination Agreement. The Lenders shall have received a duly
executed copy of that certain Second Amended and Restated Subordination Agreement, dated as of the date hereof, by and among the Lenders and WCAS Capital Partners IV, L.P. 

  
 34 

 (f) No Default; Representations and Warranties. Both immediately prior to the amendment
and restatement of the Existing Term Loan Agreement and after giving effect thereto and to the intended use thereof: 
 (i) no Default other
than the Designated Defaults (as defined in the Forbearance Agreement) shall have occurred and be continuing; and 
 (ii) the
representations and warranties made by the Borrower in Section 7 shall be true on and as of the date hereof in all material respects (taking into account any changes made to the schedules updated in accordance with Section 7.21 or
attached to the Parent Security Agreement Joinder Agreement), except that such representations and warranties that refer to a specific earlier date were true in all material respects on such earlier date. 

6.02 Acknowledgements 
 The parties
hereto acknowledge and agree that the initial Borrowing of $50,000,000 occurred on August 15, 2013, being the First Borrowing Date, and that the conditions precedent to the second and third term Borrowings contained in the Initial Term Loan
Agreement were not satisfied, and therefore, no Lender has any Commitment to fund the second and third term Borrowings thereunder. As of the date hereof, the Lenders’ Commitments have either expired or been terminated. 

SECTION 7 

REPRESENTATIONS AND WARRANTIES 

The Borrower represents and warrants to the Lenders that: 

7.01 Power and Authority. Each of the Parent, Borrower and their Subsidiaries (a) is a duly organized and validly existing under the laws of its
jurisdiction of organization, (b) has all requisite corporate or other power, and has all material governmental licenses, authorizations, consents and approvals necessary to own its assets and carry on its business as now being or as proposed to be
conducted except to the extent that failure to have the same would not reasonably be expected to have a Material Adverse Effect, (c) is qualified to do business and is in good standing in all jurisdictions in which the nature of the business
conducted by it makes such qualification necessary and where failure so to qualify could (either individually or in the aggregate) have a Material Adverse Effect, and (d) has full power, authority and legal right to make and perform each of the Loan
Documents to which it is a party and, in the case of the Borrower, to borrow the Loans hereunder. 
 7.02 Authorization; Enforceability. The
Transactions are within each Obligor’s corporate powers and have been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and delivered by each Obligor and
constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding obligation of such Obligor, enforceable against each Obligor in accordance with its
terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (b) the application of general principles
of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 

  
 35 

 7.03 Governmental and Other Approvals; No Conflicts. The Transactions (a) do not require any consent or
approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for (i) such as have been obtained or made and are in full force and effect and (ii) filings and recordings in respect of the
Liens created pursuant to the Security Documents, (b) will not violate any applicable law or regulation or the charter, bylaws or other organizational documents of Parent, Borrower and their Subsidiaries or any order of any Governmental Authority,
other than any such violations that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect, (c) will not, in any material respect, violate or result in a default under any indenture, material agreement
or other material instrument binding upon Parent, Borrower and their Subsidiaries or assets, or give rise to a right thereunder to require any material payment to be made by any such Person, and (d) except for the Liens created pursuant to the
Security Documents, will not result in the creation or imposition of any Lien on any asset of Parent, Borrower and their Subsidiaries. 
 7.04 Financial
Statements; Material Adverse Change. 
 (a) Financial Statements. The Borrower has heretofore furnished to the Lenders certain
financial statements as provided for in Section 8.01. Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows of the Parent, Borrower and their Subsidiaries as
of such dates and for such periods in accordance with GAAP, subject to year-end audit adjustments and the absence of footnotes in the case of the statements previously-delivered statements of the type described in Section 8.01(b). Neither the
Parent, Borrower nor any of their Subsidiaries has any material contingent liabilities or unusual forward or long-term commitments not disclosed in the aforementioned financial statements that are required to be disclosed therein under GAAP. 

(b) No Material Adverse Change. Since December 31, 2012, there has been no Material Adverse Change other than as has been
described in the Forbearance Agreement. 
 7.05 Properties. 

(a) Property Generally. Each Obligor has good and marketable fee simple title to, or valid leasehold interests in, all its real and
personal property material to its business, subject only to Permitted Liens and except for minor defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilize such properties for their intended
purposes. 
 (b) Intellectual Property. The Obligors represent and warrant to the Lenders as of the date hereof as follows, and the
Obligors acknowledge that the Lenders are relying on such representations and warranties in entering into this Agreement: 
 (i) Schedule
7.05(b) contains: 
 (A) a complete and accurate list of all applied for or registered Patents, including the jurisdiction and patent
number; 

  
 36 

 (B) a complete and accurate list of all applied for or registered Trademarks, including the
jurisdiction, trademark application or registration number and the application or registration date; and 
 (C) a complete and accurate
list of all applied for or registered Copyrights; 
 (ii) Each Obligor is the absolute beneficial owner of all right, title and interest in
and to Material Intellectual Property listed on Schedule 7.05(c) as owned by such Obligor with good and marketable title, free and clear of any Liens of any kind whatsoever other than Permitted Liens. Without limiting the foregoing, and
except as set forth in Schedule 7.05(b): 
 (A) other than with respect to the Material Agreements, or as permitted by Section
9.09 below, the Obligors have not transferred ownership of Material Intellectual Property listed on Schedule 7.05(c) as owned by such Obligors, in whole or in part, to any other Person who is not an Obligor; 

(B) other than (i) the Material Agreements, (ii) customary restrictions in in-bound licenses of Intellectual Property and non-disclosure
agreements, or (iii) as would have been or is permitted by Section 9.09 below, there are no judgments, covenants not to sue, permits, grants, licenses, Liens (other than Permitted Liens), or other agreements or arrangements relating to
Borrower’s Material Intellectual Property, including any development, submission, services, research, license or support agreements, which bind, obligate or otherwise restrict the Obligors in any manner that would reasonably be expected to have
a Material Adverse Effect;
 (C) the use of any of the Obligor Intellectual Property in the business of the Borrower as currently conducted
or as currently contemplated to be conducted, to the Borrower’s Knowledge, does not breach, violate, infringe or interfere with or constitute a misappropriation of any valid rights arising under any Intellectual Property of any other Person;

 (D) except as listed on Schedule 7.05(b), there are no pending or, to Borrower’s Knowledge, threatened in writing Claims
against the Obligors asserted by any other Person relating to the Obligor Intellectual Property owned by or exclusively licensed to Obligors, including any Claims of adverse ownership, invalidity, infringement, misappropriation, violation or other
opposition to or conflict with such Intellectual Property, except as would not reasonably be expected to have a Material Adverse Effect; the Obligors have not received any written notice from any Person that the Borrower’s business, the use of
the Obligor Intellectual Property in the business of the Borrower as currently conducted, or the manufacture, use or sale of any product or the performance of any service by the Borrower infringes upon, violates or constitutes a misappropriation of,
or may infringe upon, violate or constitute a misappropriation of, or otherwise interfere with, any other Intellectual Property of any other Person; 

  
 37 

 (E) except as listed on Schedule 7.05(b), the Obligors have no Knowledge that the Obligor
Intellectual Property owned by or exclusively licensed to Obligors is being infringed, violated, misappropriated or otherwise used by any other Person without the express authorization of the Obligors. Without limiting the foregoing, the Obligors
have not put any other Person on notice of actual or potential infringement, violation or misappropriation of any of the Material Intellectual Property owned by or exclusively licensed to Obligors; the Obligors have not initiated the enforcement of
any Claim with respect to any of the Obligor Intellectual Property owned by or exclusively licensed to Obligors; 
 (F) all relevant
current and former employees and contractors of Borrower have executed written confidentiality and invention assignment Contracts with Borrower that irrevocably assign to Borrower or its designee all of their rights to any Inventions relating to
Borrower’s business that are conceived or reduced to practice by such employees within the scope of their employment or by such contractors within the scope of their contractual relationship with Borrower, to the extent permitted by applicable
law;
 (G) to the Knowledge of the Obligors, the Obligor Intellectual Property is all the valid Intellectual Property necessary for the
operation of the Borrower’s business as it is currently conducted or as currently contemplated to be conducted, except for such Intellectual Property the absence of which would not reasonably be expected to have a Material Adverse Effect; 

(H) the Obligors have taken commercially reasonable precautions to protect the secrecy, confidentiality and value of its Material
Intellectual Property consisting of trade secrets and confidential information, except as would not reasonably be expected to have a Material Adverse Effect. 

(I) each Obligor has delivered to the Lenders accurate and complete copies of all Material Agreements relating to the Obligor Intellectual
Property; 
 (J) there are no pending or, to the Knowledge of any of the Obligors, threatened in writing Claims against the Obligors
asserted by any other Person relating to the Material Agreements, including any Claims of breach or default under such Material Agreements, except as would not reasonably be expected to have a Material Adverse Effect; 

(iii) With respect to the Material Intellectual Property owned by or for which prosecution is controlled by Obligors consisting of Patents,
except as set forth in Schedule 7.05(b), and without limiting the representations and warranties in Section 7.05(b)(ii): 

(A) each of the issued claims in such Patents, to Borrower’s Knowledge, is valid and enforceable; 

(B) the inventors claimed in such Patents have executed written Contracts with the Borrower or its predecessor-in-interest that properly and
irrevocably assigns to Borrower or predecessor-in-interest all of their rights to any of the Inventions claimed in such Patents to the extent permitted by applicable law; 

  
 38 

 (C) none of the Patents, or the Inventions claimed in them, have been dedicated to the public
except as a result of intentional decisions made by the applicable Obligor; 
 (D) to Borrower’s Knowledge, all prior art material to
such Patents was disclosed to or considered by the respective patent offices during prosecution of such Patents to the extent required by applicable law or regulation; 

(E) subsequent to the issuance of such Patents, neither the Borrower nor any Guarantor or their predecessors in interest, have filed any
disclaimer or filed any other voluntary reduction in the scope of the Inventions claimed in such Patents; 
 (F) no allowable or allowed
subject matter of such Patents, to Borrower’s Knowledge, is subject to any competing conception claims of allowable or allowed subject matter of any patent applications or patents of any third party and have not been the subject of any
interference, re-examination or opposition proceedings, nor are the Obligors aware of any basis for any such interference, re-examination or opposition proceedings; 

(G) no such Patents, to Borrower’s Knowledge, have ever been finally adjudicated to be invalid, unpatentable or unenforceable for any
reason in any administrative, arbitration, judicial or other proceeding, and, with the exception of publicly available documents in the applicable Patent Office recorded with respect to any Patents, the Obligors have not received any written notice
asserting that such Patents are invalid, unpatentable or unenforceable; if any of such Patents is terminally disclaimed to another patent or patent application, all patents and patent applications subject to such terminal disclaimer are included in
the Collateral; 
 (H) the Obligors have not received an opinion, whether preliminary in nature or qualified in any manner, which concludes
that a challenge to the validity or enforceability of any of such Patents is more likely than not to succeed; 
 (I) the Obligors have no
Knowledge that they or any prior owner of such Patents or their respective agents or representatives have engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate or render unpatentable or unenforceable
any such Patents; and 
 (J) all maintenance fees, annuities, and the like due or payable on the Patents have been timely paid or the
failure to so pay was the result of an intentional decision by the applicable Obligor or would not reasonably be expected to result in a Material Adverse Change. 

(c) Material Intellectual Property. Schedule 7.05(c) contains an accurate list of the Obligor Intellectual Property that is
material to the Borrower’s business with an indication as to whether the applicable Obligor owns or has an exclusive or non-exclusive license to such Obligor Intellectual Property. 

  
 39 

 7.06 No Actions or Proceedings. 

(a) Litigation. There is no litigation, investigation or proceeding pending or, to the Borrower’s Knowledge, threatened with
respect to the Parent, Borrower or their Subsidiaries by or before any Governmental Authority or arbitrator (i) that either individually or in the aggregate would reasonably be expected to have a Material Adverse Effect, except as specified in
Schedule 7.06 or (ii) that involves this Agreement or the Transactions. 
 (b) Environmental Matters. The operations and
Property of Parent, Borrower and their Subsidiaries comply with all applicable Environmental Laws, except to the extent the failure to so comply (either individually or in the aggregate) would not reasonably be expected to have a Material Adverse
Effect. 
 (c) Labor Matters. The Borrower has not engaged in unfair labor practices and there are no material labor actions or
disputes, pending or ongoing, involving the employees of the Borrower that would reasonably be expected to have a Material Adverse Effect. 
 7.07
Compliance with Laws and Agreements. Each of the Obligors is in compliance with all laws, regulations and orders of any Governmental Authority applicable to it or its property and all indentures, agreements and other instruments binding
upon it or its property, except where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. No Default has occurred and is continuing. 

7.08 Taxes. Each of the Obligors has timely filed or caused to be filed all tax returns and reports required to have been filed and has paid or
caused to be paid all taxes required to have been paid by it, except taxes that are being contested in good faith by appropriate proceedings and for which such Obligor has set aside on its books adequate reserves with respect thereto in accordance
with GAAP and in each case, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect. 
 7.09 Full
Disclosure. The Borrower has disclosed to the Lenders all Material Agreements to which any Obligor is subject, and all other matters to their Knowledge, that, individually or in the aggregate, would reasonably be expected to result in a Material
Adverse Effect. None of the reports, financial statements, certificates or other information furnished by or on behalf of the Obligors to the Lenders in connection with the negotiation of this Agreement and the other Loan Documents or delivered
hereunder or thereunder, in each case, taken as a whole (as modified or supplemented by other information so furnished) contains any material misstatement of material fact or, to the Borrower’s Knowledge, omits to state any material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial information and other forward looking information, the Borrower
represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time, and it being understood that such projected financial information and forward looking information are not to be viewed as
facts, that actual results during the period or periods covered thereby may materially differ from the projected results. 

  
 40 

 7.10 Regulation. 

(a) Investment Company Act. Neither Parent, Borrower nor any of their Subsidiaries is an “investment company” as defined in,
or subject to regulation under, the Investment Company Act of 1940. 
 (b) Margin Stock. Neither Parent, Borrower nor any of
their Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part of the proceeds of the
Loans will be used to buy or carry any Margin Stock in violation of Regulation T, U or X. 
 7.11 Solvency. Borrower is and, immediately after
giving effect to the Borrowing and the use of proceeds thereof will be, Solvent. 
 7.12 Subsidiaries. Schedule 7.12 is a complete and
correct list of all Subsidiaries of the Parent and Borrower as of the date hereof, each such Subsidiary is duly organized and validly existing under the jurisdiction of its organization shown in said Schedule 7.12, and the percentage
ownership by Borrower of each such Subsidiary is as shown in said Schedule 7.12. 
 7.13 Indebtedness and Liens. Schedule 7.13(a)
is a complete and correct list of all Material Indebtedness of each Obligor outstanding as of the date hereof. Schedule 7.13(b) is a complete and correct list of all Liens granted by the Borrower and other Obligors to secure the payment
or performance of Material Indebtedness with respect to their respective Property and outstanding as of the date hereof. 
 7.14 Material
Agreements. Schedule 7.14 is a complete and correct list of (i) each Material Agreement existing on the date hereof and (ii) each agreement creating or evidencing any Material Indebtedness. No Obligor is in material default under any
such Material Agreement or agreement creating or evidencing any Material Indebtedness. Except as otherwise disclosed on Schedule 7.14, all material vendor purchase agreements and provider contracts of the Obligors are in full force and
effect without material modification from the form in which the same were disclosed to the Lenders. 
 7.15 Restrictive Agreements. None of the
Obligors is subject to any indenture, agreement, instrument or other arrangement of the type described in Section 9.11, except for any indenture, agreement, instrument or other arrangement described on Schedule 7.15 or otherwise
permitted under Section 9.11 (each, a “Permitted Restrictive Agreement”). 
 7.16 Real Property. 

(a) Generally. Neither Parent, Borrower nor any of their Subsidiaries owns or leases (as tenant thereof) any real property, except as
described on Schedule 7.16. 
 (b) Borrower Lease. 

(i) Borrower has delivered a true, accurate and complete copy of the Borrower Lease to Lenders. 

  
 41 

 (ii) The Borrower Lease is in full force and effect and no default has occurred under the
Borrower Lease that would reasonably be expected to have a Material Adverse Effect and, to the Knowledge of Borrower, there is no existing condition which, but for the passage of time or the giving of notice, would reasonably be expected to result
in a default under the terms of the Borrower Lease that would reasonably be expected to have a Material Adverse Effect. 
 (iii) Borrower is
the tenant under the Borrower Lease and has not transferred, sold, assigned, conveyed, disposed of, mortgaged, pledged, hypothecated, or encumbered any of its interest in, the Borrower Lease except for Permitted Liens. 

7.17 Pension Matters. Schedule 7.17 sets forth, as of the date hereof, a complete and correct list of, and that separately identifies, (a)
all Title IV Plans, (b) all Multiemployer Plans and (c) all material Benefit Plans. Each Benefit Plan, and each trust thereunder, intended to qualify for tax exempt status under Section 401 or 501 of the Code or other Requirements of Law so
qualifies. Except for those that could not, in the aggregate, have a Material Adverse Effect, (x) each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Requirements of Law and (y) there are no existing or pending
(or to the Knowledge of any Obligor or Subsidiary thereof, threatened) claims (other than routine claims for benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigation involving any Benefit Plan to which any
Obligor or Subsidiary thereof incurs or otherwise has or could have an obligation or any liability or Claim. Borrower and each of its ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to each Title IV
Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained. As of the most recent valuation date for any Title IV Plan, the funding target attainment percentage (as defined in Section
430(d)(2) of the Code) is at least 60%, and to the Borrower’s Knowledge, no facts or circumstances exist that could reasonably be expected to cause the funding target attainment percentage to fall below 60%. As of the date hereof, no ERISA
Event has occurred in connection with which obligations and liabilities (contingent or otherwise) remain outstanding. No ERISA Affiliate would have any Withdrawal Liability as a result of a complete withdrawal from any Multiemployer Plan on the date
this representation is made. 
 7.18 Collateral; Security Interest. Each Security Document is effective to create in favor of the Lenders a
legal, valid and enforceable security interest in the Collateral subject thereto and each such security interest will be perfected to the extent required by (and has the priority required by) the applicable Security Document subject to the taking of
the actions described in such Security Documents. The Security Documents collectively are effective to create in favor of the Lenders a legal, valid and enforceable security interest in all of the Borrower’s and the Guarantors’ assets,
which security interests are first-priority except for Permitted Senior Liens. 
 7.19 Regulatory Approvals. Except as listed on Schedule
7.19, Parent, Borrower and their Subsidiaries hold, and will continue to hold, either directly or through licensees and agents, all material Regulatory Approvals, licenses, permits and similar governmental authorizations of a Governmental
Authority necessary or required for Parent, Borrower and their Subsidiaries to conduct their operations and business in the manner currently conducted. 

  
 42 

 7.20 Small Business Concern. The Borrower’s primary business activity does not involve, directly
or indirectly, making loans to others, the purchase or discounting of debt obligations, factoring or long term leasing of equipment with no provision for maintenance or repair, and the Borrower is not classified under Major Group 65 (Real Estate) or
Industry No. 1531 (Operative Builders) of the SIC Manual. Borrower acknowledges that it has been advised that PIOP is a Small Business Investment Company and licensee under the SBIC Act. The information regarding Borrower and its affiliates set
forth in the SBA Form 480, Form 652, and Form 1031 is accurate and complete. The Borrower acknowledges that the Lenders are relying on the representations and warranties made by the Borrower to the SBA in the SBA Form 480 provided to the Lenders.

 7.21 Update of Schedules. Schedules 7.05(b) (in respect of the lists of Patents, Copyrights and Trademarks under
Section 7.05(b)(i) only), 7.05(c), 7.06, 7.12, 7.13(a) and (b), 7.14, 7.16, 7.17 and 7.19 may be updated by Borrower prior to each Borrowing Date to insure the continued accuracy of such
Schedule as of such Borrowing Date, by Borrower providing to the Lenders, in writing (including via electronic means), a revised version of such Schedule in accordance with the provisions of Section 12.02. Each such updated Schedule shall be
effective immediately upon the receipt thereof by the Lenders. 
 SECTION 8 

AFFIRMATIVE COVENANTS 

Each Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than
the Warrant Obligations) have been paid in full indefeasibly in cash: 
 8.01 Financial Statements and Other Information. The Borrower will
furnish to the Lenders: 
 (a) as soon as available and in any event within 5 days following the date the Parent or the Borrower files Form
10-Q with the SEC, the consolidated balance sheets of the Obligors as of the end of such quarter, and the related consolidated statements of income, shareholders’ equity and cash flows of Parent, Borrower and their Subsidiaries for such quarter
and the portion of the fiscal year through the end of such quarter, prepared in accordance with GAAP consistently applied, all in reasonable detail, together with a certificate of a Responsible Officer of Borrower stating that such financial
statements fairly present the financial condition of Parent, Borrower and their Subsidiaries as at such date and the results of operations of Parent, Borrower and their Subsidiaries for the period ended on such date and have been prepared in
accordance with GAAP consistently applied, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes; 

(b) as soon as available and in any event within 5 days following the date the Parent or the Borrower files
Form 10-K with the SEC, the consolidated balance sheets of Parent, Borrower and their Subsidiaries as of the end of such fiscal year, and the related consolidated statements of income, shareholders’
equity and cash flows of Parent, Borrower and their Subsidiaries for such fiscal year, prepared in accordance with GAAP consistently applied, all in reasonable detail, accompanied by a report and opinion thereon of KPMG LLP or another firm of

  
 43 

 
independent certified public accountants of recognized national standing acceptable to the Lenders, which report and opinion shall be prepared in accordance with generally accepted auditing
standards and shall not be subject to any qualification or exception as to the scope of such audit; 
 (c) together with the financial
statements required pursuant to Sections 8.01(a) and (b), a compliance certificate of a Responsible Officer as of the end of the applicable accounting period (which delivery may be by electronic communication including fax or email and
shall be deemed to be an original authentic counterpart thereof for all purposes) in the form of Exhibit E (a “Compliance Certificate”), which Compliance Certificate shall include details of any issues that are
material that are raised by auditors and evidence reasonably satisfactory to the Majority Lenders of compliance with Section 10;

(d) (i) promptly upon receipt thereof copies of all letters of representation signed by an Obligor to its auditors and (ii) copies of all
auditor reports delivered for each fiscal year delivered no more frequently than annually; 
 (e) as soon as available but in any event
within 45 days following the end of each fiscal year, a consolidated financial forecast for Parent, Borrower and their Subsidiaries for the following five fiscal years, including forecasted consolidated balance sheets, consolidated statements of
income, shareholders’ equity and cash flows of Parent, Borrower and their Subsidiaries; 
 (f) promptly after the same are released,
copies of all press releases; 
 (g) promptly, and in any event within five Business Days after receipt thereof by an Obligor thereof,
copies of each notice or other correspondence received from any securities regulator or exchange to the authority of which Borrower may become subject from time to time concerning any investigation or possible investigation or other inquiry by such
agency regarding financial or other operational results of such Obligor except where such investigation, possible investigation or inquiry would not reasonably be expected to have a Material Adverse Effect; 

(h) the information regarding insurance maintained by Parent, Borrower and their Subsidiaries as required under Section 8.05; and 

(i) within 5 days of filing, provide access (via posting and/or links on the Parent’s or the Borrower’s website) to all reports on
Form 10-K and Form 10-Q filed with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC or with any national securities exchange; and within 5 days of filing, provide notice and access (via posting and/or
links on the Parent’s or the Borrower’s website) to all reports on Form 8-K filed with the SEC, and copies of (or access to, via posting and/or links on the Parent’s or the Borrower’s website) all other reports, proxy statements
and other materials filed by the Parent or the Borrower with the SEC, any Governmental Authority succeeding to any of the functions of the SEC or with any national securities exchange. 

Documents required to be delivered pursuant to Section 8.01(a) or (b) or referred to in Section 8.01(h) (to the extent any such documents are
included in materials otherwise filed with the 

  
 44 

 
SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which the Parent or the Borrower posts such documents, or provides a link
thereto on the Parent’s or the Borrower’s website; (ii) on which such documents are posted on the Parent’s or the Borrower’s behalf on an Internet or intranet website, if any, to which each Lender has access (whether a
commercial, third party website or whether sponsored by the Lenders); or (iii) on which the Parent or the Borrower provides notice of filing of such documents with the SEC by electronic mail message to the Lenders in accordance with
Section 12.02. 
 8.02 Notices of Material Events. The Borrower will furnish to the Lenders written notice of the following promptly
after a Responsible Officer first learns of the existence of: 
 (a) the occurrence of any Default; 

(b) notice of the occurrence of any event with respect to its property or assets resulting in a Loss aggregating $500,000 (or the Equivalent
Amount in other currencies) or more; 
 (c) except where a Material Adverse Effect would not reasonably be expected to result in connection
therewith, (A) any proposed acquisition of stock, assets or property by any Obligor that would reasonably be expected to result in environmental liability under Environmental Laws, and (B)(1) spillage, leakage, discharge, disposal, leaching,
migration or release of any Hazardous Material required to be reported to any Governmental Authority under applicable Environmental Laws, and (2) all actions, suits, claims, notices of violation, hearings, investigations or proceedings pending, or
to the best of Borrower’s Knowledge, threatened against or affecting Parent, Borrower or any of their Subsidiaries or with respect to the ownership, use, maintenance and operation of their respective businesses, operations or properties,
relating to Environmental Laws or Hazardous Material; 
 (d) the assertion of any environmental matter by any Person against, or with
respect to the activities of, Parent, Borrower or any of their Subsidiaries and any alleged violation of or non-compliance with any Environmental Laws or any permits, licenses or authorizations which would reasonably be expected to have a Material
Adverse Effect; 
 (e) the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority
against or affecting Parent, Borrower or any of their Affiliates that would reasonably be expected to result in a Material Adverse Effect, including, in any event, any filing or commencement of any action, suit or proceeding by or before any
arbitrator or Governmental Authority against or affecting Parent, Borrower or any of their Affiliates; 
 (f) except where a Material
Adverse Effect would not reasonably be expected to result in connection therewith, (i) on or prior to any filing by any ERISA Affiliate of any notice of intent to terminate any Title IV Plan, a copy of such notice and (ii) promptly, and in any event
within ten days, after any Responsible Officer of any ERISA Affiliate knows or has reason to know that a request for a minimum funding waiver under Section 412 of the Code has been filed with respect to any Title IV Plan or Multiemployer Plan, a
notice (which may be made by 

  
 45 

 
telephone if promptly confirmed in writing) describing such waiver request and any action that any ERISA Affiliate proposes to take with respect thereto, together with a copy of any notice filed
with the PBGC or the IRS pertaining thereto; 
 (g) (i) the termination of any Material Agreement; (ii) the receipt by Parent, Borrower or
any of their Subsidiaries of any material notice under any Material Agreement; (iii) the entering into of any new Material Agreement by an Obligor; or (iv) any material amendment to a Material Agreement; 

(h) the reports and notices as required by the Security Documents; 

(i) within 30 days of the date thereof, or, if earlier, on the date of delivery of any financial statements pursuant to
Section 8.01, notice of any material change in accounting policies or financial reporting practices by the Obligors; 
 (j)
promptly after the occurrence thereof, notice of any labor controversy resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving an Obligor; 

(k) a licensing agreement or arrangement entered into by Parent, Borrower or any Subsidiary in connection with any infringement or alleged
infringement of the Intellectual Property of another Person; 
 (l) any other development that results in, or would reasonably be expected
to result in, a Material Adverse Effect;
 (m) concurrently with the delivery of financial statements under Section 8.01(b), the
creation or other acquisition of any Intellectual Property by Parent, Borrower or any Subsidiary after the date hereof and during such prior fiscal year which is registered or becomes registered or the subject of an application for registration with
the U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable; or 
 (n) such other information respecting the
operations, properties, business or condition (financial or otherwise) of the Obligors (including with respect to the Collateral) as the Majority Lenders may from time to time reasonably request. 

Each notice delivered under this Section 8.02 shall be accompanied by a statement of a financial officer or other executive officer of
Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto.

8.03 Existence; Conduct of Business. Parent and Borrower will, and will cause each of their Subsidiaries to, do or cause to be done all things
necessary to preserve, renew and keep in full force and effect its legal existence and except where failure would not reasonably be expected to have a Material Adverse Effect, the rights, licenses, permits, privileges and franchises material to the
conduct of its business; provided that the foregoing shall not prohibit any merger, amalgamation, consolidation, liquidation or dissolution permitted under Section 9.03 or Section 9.09.

  
 46 

 
Without obtaining the prior written approval of PIOP, Borrower will not change within one (1) year after the first Borrowing Date, Borrower’s business activity to a business activity to
which a licensee under the SBIC Act is prohibited from providing funds by the SBIC Act, as more specifically set forth under Part 107.720 of Title 13 of the United States Code of Federal Regulations. If Borrower’s business activity changes to
such a prohibited business activity or the proceeds are used for ineligible business activities, Borrower will use all commercially reasonable efforts and cooperate in good faith to assist PIOP to sell or transfer its Proportionate Share of the
Loans in a commercially reasonable manner; provided that in no way shall this be considered PIOP’s sole remedy if Borrower’s business activity changes to such a prohibited business activity. 

8.04 Payment of Obligations. Parent and Borrower will, and will cause each of their Subsidiaries to, pay its material obligations, as and when due
and payable after giving effect to any grace periods applicable thereto, but subject to any subordination provisions contained in any instrument or agreement evidencing such obligations, including (i) all material taxes, fees, assessments and
governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which penalties attach thereto, all lawful claims for labor, materials and supplies which, if unpaid, would by law become a Lien upon any properties
or assets of Parent, Borrower or any Subsidiary not constituting a Permitted Lien, except to the extent such material taxes, fees, assessments or governmental charges or levies, or such claims are being contested in good faith by appropriate
proceedings and are adequately reserved against in accordance with GAAP and (ii) all lawful claims which, if unpaid, would by law become a Lien upon its property not constituting a Permitted Lien. Parent and Borrower will, and will cause each
of their Subsidiaries to discharge all Indebtedness other than Permitted Indebtedness. 
 8.05 Insurance. Parent and Borrower will, and will
cause each of their Subsidiaries to maintain, with financially sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses operating
in the same or similar locations. Upon the request of the Majority Lenders, Borrower shall furnish the Lenders from time to time with full information as to the insurance carried by it and, if so requested, copies of all such insurance policies.
Borrower also shall furnish to the Lenders from time to time upon the request of the Majority Lenders a certificate from the Borrower’s insurance broker or other insurance specialist stating that all premiums then due on the policies relating
to insurance on the Collateral have been paid, that such policies are in full force and effect and that such insurance coverage and such policies comply with all the requirements of this Section 8.05. The Borrower shall use commercially
reasonable efforts to ensure, or cause others to ensure, that all insurance policies required under this Section 8.05 shall provide that they shall not be terminated or cancelled nor shall any such policy be materially changed in a manner
adverse to the Borrower without at least 30 days’ prior written notice to the Borrower and the Lenders. Receipt of notice of termination or cancellation of any such insurance policies or reduction of coverages or amounts thereunder shall
entitle the Lenders to renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to the first sentence of this Section 8.05 or otherwise to obtain similar insurance in place of such
policies, in each case at the expense of the Borrower. 

  
 47 

 8.06 Books and Records; Inspection Rights. Parent and Borrower will, and will cause each of their
Subsidiaries to, keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities. Parent and Borrower will, and will cause each of their
Subsidiaries to, permit any representatives designated by the Lender, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition with
its officers and independent accountants, all at such reasonable times (but not more often than once a year unless an Event of Default has occurred and is continuing); provided that such representative shall use its commercially reasonable
efforts to minimize disruptions to the business and affairs of the Borrower as a result of any such visit, inspection, examination or discussion. 
 8.07
Compliance with Laws and Other Obligations. Parent and Borrower will, and will cause each of their Subsidiaries to, (i) comply in all material respects with all laws, rules, regulations and orders of any Governmental Authority
applicable to it or its property (including Environmental Laws) and (ii) comply in all material respects with all terms of Indebtedness and all other Material Agreements, except, in each case, where the failure to do so, individually or in the
aggregate, would not reasonably be expected to result in a Material Adverse Effect. 
 8.08 Maintenance of Properties, Etc. 

(a) Except where the failure to do so would not reasonably be expected to have a Material Adverse Effect, Parent and Borrower shall, and shall
cause each of their Subsidiaries to, maintain and preserve all of its properties necessary or useful in the proper conduct of its business in good working order and condition in accordance with the general practice of other Persons of similar
character and size, ordinary wear and tear and damage from casualty or condemnation excepted. 
 (b) Without limiting the generality of
clause (a) above, Borrower shall comply with each of the following covenants with respect to the Borrower Lease: 
 (i) Borrower shall
diligently perform and timely observe all of the terms, covenants and conditions of the Borrower Lease on the part of Borrower to be performed and observed prior to the expiration of any applicable grace period therein provided and do everything
necessary to preserve and to keep unimpaired and in full force and effect the Borrower Lease except where the failure to do so would not reasonably be expected to have a Material Adverse Effect. 

(ii) Borrower shall promptly notify Lenders of the giving of any written notice by Borrower Landlord to Borrower of any default by Borrower
thereunder that would allow the Borrower Landlord to terminate the Borrower Lease, and promptly deliver to Lenders a true copy of each such notice. If Borrower shall be in default under the Borrower Lease that would allow the Borrower Landlord
to terminate the Borrower Lease, to the extent the Borrower fails to do so within thirty (30) days, following written notice to the Borrower, Lenders shall have the right (but not the obligation) to cause the default or defaults under the Borrower
Lease to be remedied and otherwise exercise any and all rights of Borrower under the Borrower Lease, as may be necessary to prevent or cure any default and Lenders shall have the right to enter all or

  
 48 

 
any portion of the Property, at such times and in such manner as Lenders reasonably deem necessary, to prevent or to cure any such default. Without limiting the foregoing, to the extent Lenders
desire to cure such default or defaults as provided above, Borrower shall promptly execute, acknowledge and deliver to Lenders such instruments as may reasonably be required of Borrower to permit Lenders to cure any default under the Borrower Lease
or permit Lenders to take such other action required to enable Lenders to cure or remedy the matter in default and preserve the security interest of Lenders under the Loan Documents with respect to the Borrower Facility. 

(iii) Borrower shall use commercially reasonable efforts to enforce, in a commercially reasonable manner, each covenant or obligation of the
Borrower Landlord in the Borrower Lease in accordance with its terms. Subject to the terms and requirements of the Borrower Lease, within sixty (60) days after receipt of written request by Lenders, Borrower shall use commercially reasonable efforts
to obtain from the Borrower Landlord under the Borrower Lease and furnish to Lenders an estoppel certificate from Borrower Landlord stating the date through which rent has been paid and whether or not, to Borrower Landlord’s knowledge, there
are any defaults thereunder and specifying the nature of such claimed defaults, if any, and such other matters as Lenders may reasonably request or in the form required pursuant to the terms of the Borrower Lease. Borrower shall furnish to Lenders
all information that Lenders may reasonably request from time to time in the possession of Borrower (or reasonably available to Borrower) concerning the Borrower Lease and Borrower’s compliance with the Borrower Lease. 

(iv) Borrower, promptly upon obtaining Knowledge that Borrower Landlord has failed to perform the material terms and provisions under the
Borrower Lease and immediately upon learning of a rejection or disaffirmance or purported rejection or disaffirmance of the Borrower Lease pursuant to any state or federal bankruptcy law, shall notify Lenders thereof. Borrower shall promptly notify
Lenders of any request to which it has Knowledge that any party to the Borrower Lease makes for arbitration or other dispute resolution procedure pursuant to the Borrower Lease and of the institution of any such arbitration or dispute resolution.
Borrower hereby authorizes Lenders to attend any such arbitration or dispute, and upon the occurrence and during the continuance of an Event of Default participate in any such arbitration or dispute resolution but such participation shall not be to
the exclusion of Borrower; provided, however, that, in any case, Borrower shall consult with Lenders with respect to the matters related thereto. Borrower shall promptly deliver to Lenders a copy of the determination of each such
arbitration or dispute resolution mechanism. 
 (v) Borrower shall promptly, after obtaining Knowledge of such filing notify Lenders orally
of any filing by or against Borrower Landlord under the Borrower Lease of a petition under the Bankruptcy Code or other applicable law. Borrower shall thereafter promptly give written notice of such filing to Lenders, setting forth any
information available to Borrower as to the date of such filing, the court in which such petition was filed, and the relief sought in such filing. Borrower shall promptly deliver to Lenders any and all notices, summonses, pleadings,
applications and other documents received by Borrower in connection with any such petition and any proceedings relating to such petition. 

  
 49 

 8.09 Licenses. Parent and Borrower shall, and shall cause each of their Subsidiaries to, obtain and
maintain all licenses, authorizations, consents, filings, exemptions, registrations and other Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the consummation of the Transactions or
the operation and conduct of its business and ownership of its properties, except where failure to do so would not reasonably be expected to have a Material Adverse Effect. 

8.10 Action under Environmental Laws. Except where failure to do so would not reasonably be expected to have a Material Adverse Effect, Parent and
Borrower shall, and shall cause each of their Subsidiaries to, upon becoming aware of the presence of any Hazardous Materials or the existence of any environmental liability under applicable Environmental Laws with respect to their respective
businesses, operations or properties, take all actions, at their cost and expense, as shall be necessary or advisable to investigate and clean up the condition of their respective businesses, operations or properties, including all required removal,
containment and remedial actions, and restore their respective businesses, operations or properties to a condition in compliance with applicable Environmental Laws. 

8.11 Use of Proceeds. The proceeds of the Loans will be used only as provided in Section 2.05. No part of the proceeds of the
Loans will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board of Governors of the Federal Reserve System, including Regulations T, U and X. 

8.12 Certain Obligations Respecting Subsidiaries and Parent; Further Assurances. 

(a) Subsidiary Guarantors. Subject to the relevant limitations and terms contained in the Security Documents, Borrower will take such
action, and will cause each of its Subsidiaries to take such action, from time to time as shall be necessary to ensure that all Subsidiaries that are Domestic Subsidiaries of Borrower, and such Foreign Subsidiaries as are required under Section
8.12(b), are “Subsidiary Guarantors” hereunder. Without limiting the generality of the foregoing but subject to the relevant limitations and terms contained in the Security Documents, in the event that Borrower or any of its
Subsidiaries shall form or acquire any new Subsidiary that is a Domestic Subsidiary or a Foreign Subsidiary meeting the requirements of Section 8.12(b), Borrower and its Subsidiaries will: 

(i) cause such new Subsidiary to become a “Subsidiary Guarantor” hereunder, and a “Grantor” under the Security Agreement,
pursuant to a Guarantee Assumption Agreement; 
 (ii) take such action or cause such Subsidiary to take such action (including delivering
such shares of stock together with undated transfer powers executed in blank) as shall be necessary to create and perfect valid and enforceable first priority (subject to Permitted Liens permitted under Section 9.02(c)) Liens on substantially
all of the personal property of such new Subsidiary as collateral security for the obligations of such new Subsidiary hereunder; 
 (iii)
cause the parent of such Subsidiary to execute and deliver a pledge agreement in favor of the Lenders in respect of all outstanding issued shares of such Subsidiary; and 

(iv) deliver such proof of corporate action, incumbency of officers and other documents (other than legal opinions of counsel to the Obligors)
as is consistent with those delivered by each Obligor pursuant to Section 6.01 or as the Majority Lenders shall have requested. 

  
 50 

 (b) Foreign Subsidiaries. Subject to the following sentence, in the event that, at
any time, Foreign Subsidiaries have, in the aggregate, (i) total revenues constituting 5% or more of the total revenues of Borrower and its Subsidiaries on a consolidated basis, or (ii) total assets constituting 5% or more of the total assets of
Borrower and its Subsidiaries on a consolidated basis, promptly (and, in any event, within 30 days after such time) the Borrower shall cause one or more of such Foreign Subsidiaries to become Subsidiary Guarantors and to have their Equity Interests
pledged, each in the manner set forth in Section 8.12(a), such that, after such Subsidiaries become Subsidiary Guarantors, the non-guarantor Foreign Subsidiaries in the aggregate shall cease to have revenues or assets, as applicable, that
meet the thresholds set forth in clauses (i) and (ii) above. Notwithstanding the foregoing, no Foreign Subsidiary shall be required to become a Subsidiary Guarantor, grant a lien on any of its assets in favor of the Lenders, or shall
have its Equity Interests pledged to secure the Obligations, to the extent that becoming a Subsidiary Guarantor, granting a lien on any of its assets in favor of the Lenders or providing such pledge would result in adverse tax consequences for
Borrower and its Subsidiaries, taken as a whole; provided that, if a Foreign Subsidiary is precluded from becoming a Subsidiary Guarantor or having all of its Equity Interests pledged as a result of such adverse tax consequences, to the
extent that such Foreign Subsidiary is a “first tier” Foreign Subsidiary, Borrower shall pledge (or cause to be pledged) 65% of the total number of the Equity Interests of such Foreign Subsidiary to the Lenders to secure the Obligations.

 (c) Further Assurances. Borrower will, and will cause each of its Subsidiaries to, take such action from time to time as
shall reasonably be requested by the Majority Lenders to effectuate the purposes and objectives of this Agreement. 
 Without limiting the
generality of the foregoing, the Borrower will, and will cause each Person that is required to be a Subsidiary Guarantor to, take such action from time to time (including executing and delivering such assignments, security agreements, control
agreements and other instruments) as shall be reasonably requested by the Majority Lenders to create, in favor of the Lenders, perfected security interests and Liens in substantially all of the personal property of such Obligor as collateral
security for the Obligations; provided that any such security interest or Lien shall be subject to the relevant limitations and terms contained in the Security Documents, Section 7.18 and Section 8.15. 

(d) Parent. Subject to the relevant limitations and terms contained in the Security Documents, Parent shall take such action from
time to time as shall be necessary to ensure that Parent is a “ Guarantor” hereunder, and will: 
 (i) become a
“Grantor” under the Security Agreement, pursuant to the Parent Security Agreement Joinder Agreement; 
 (ii) take such action
(including delivering such shares of stock together with undated transfer powers executed in blank) as shall be necessary to create and perfect valid and 

  
 51 

 
enforceable first priority (subject to Permitted Liens permitted under Section 9.02(c)) Liens on substantially all of the personal property of Parent as collateral security for the
obligations of Parent hereunder; and 
 (iii) deliver such proof of corporate action, incumbency of officers and other documents (other than
legal opinions of counsel to the Obligors) as is consistent with those delivered by each Obligor pursuant to Section 6.01 or as the Majority Lenders shall have requested. 

8.13 Termination of Non-Permitted Liens. In the event that Parent, Borrower or any of their Subsidiaries shall become aware or be notified by the
Lenders of the existence of any outstanding Lien against any Property of Parent, Borrower or any of their Subsidiaries, which Lien is not a Permitted Lien, the Parent and the Borrower shall use their best efforts to promptly terminate or cause the
termination of such Lien. 
 8.14 Intellectual Property. 

(a) Notwithstanding any provision in this Agreement or any other Loan Document to the contrary, the Lenders are not assuming any liability or
obligation of the Borrower, the Guarantors or their Subsidiaries of whatever nature, whether presently in existence or arising or asserted hereafter, except to the extent required under applicable law in connection with any Intellectual Property
license agreement of the Borrower, the Guarantors or their Subsidiaries in the event that the Lenders foreclose on such Collateral. All such liabilities and obligations shall be retained by and remain obligations and liabilities of the Obligors, the
Guarantors and/or their Affiliates as the case may be, except to the extent required under applicable law in connection with any Intellectual Property license agreement of the Borrower, the Guarantors or their Affiliates in the event that the
Lenders foreclose on such Collateral. Without limiting the foregoing, the Lenders are not assuming and shall not be responsible for any liabilities or Claims of the Borrower, the Guarantors or their Affiliates, whether present or future, absolute or
contingent and whether or not relating to the Obligors, the Obligor Intellectual Property, and/or the Material Agreements, and the Borrower shall indemnify and save harmless the Lenders from and against all such liabilities, Claims and Liens, except
to the extent required under applicable law in connection with any Intellectual Property license agreement of the Borrower, the Guarantors or their Affiliates in the event that the Lenders foreclose on such Collateral. Without limiting the
foregoing, this Agreement shall not constitute an agreement to assign any Contracts of, or Obligor Intellectual Property to, the Lenders, except to the extent required under applicable law in connection with any Intellectual Property license
agreement of the Borrower, the Guarantors or their Affiliates in the event that the Lenders foreclose on such Collateral. 
 (b) In the
event that the Obligors acquire Obligor Intellectual Property during the term of this Agreement, then the provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute part
of the Collateral hereunder, without further action by any party, in each case from and after the date of such acquisition (except that any representations or warranties of any Obligor shall apply to any such Obligor Intellectual Property only from
and after the date, if any, subsequent to such acquisition that such representations and warranties are brought down or made anew as provided herein). 

  
 52 

 (c) Borrower shall use commercially reasonable efforts to execute and deliver to the Lenders such
duly executed Intellectual Property security agreements, following the Majority Lenders’ request therefor, with respect to foreign Intellectual Property, and take such other action as the Lenders may reasonably request to duly record or
otherwise perfect the security interest created thereunder in that portion of the Collateral consisting of Intellectual Property located outside the United States. 

8.15 Post-Closing Items. 
 (a)
Borrower shall, with respect to the location leased by the Borrower pursuant to the Borrower Lease, use commercially reasonable efforts to deliver to the Lenders the Landlord Consent from the Borrower Landlord for such property, in form and
substance reasonably satisfactory to the Lenders. Borrower shall not keep any Collateral with a fair market value in excess of $1,000,000 in the aggregate in any location (other than the location subject to the Borrower Lease) not subject to a Real
Property Security Document. 
 (b) Not later than 5 days following the date hereof, Borrower and Guarantors shall execute and deliver to the
Lenders fully executed control agreements, in form and substance reasonably acceptable to Majority Lenders, as may be required to perfect the security interest created under the Security Agreement in all Deposit Accounts, Securities Accounts and
Commodity Accounts (as each such term is defined in the Security Agreement) (other than Excluded Accounts) owned by the Obligors in the United States. 

8.16 Real Property Security Documents. Parent and Borrower shall promptly from time to time upon the request of the Majority Lenders, use
commercially reasonable efforts to, subject to the receipt of any necessary landlord consents, execute and deliver such Real Property Security Documents with respect to each real Property owned or leased (as tenant) by Parent, Borrower and other
Guarantors in the United States. 
 SECTION 9 

NEGATIVE COVENANTS 
 Each
Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than the Warrant Obligations) have been paid in full indefeasibly in cash: 

9.01 Indebtedness. Parent and Borrower will not, and will not permit any of their Subsidiaries to, create, incur, assume or permit to exist any
Indebtedness, whether directly or indirectly, except: 
 (a) the Obligations; 

(b) Indebtedness existing on the date hereof and set forth on Schedule 7.13(a) and Permitted Refinancings thereof; 

(c) [reserved]; 

  
 53 

 (d) accounts payable to trade creditors for goods and services and current operating liabilities
(not the result of the borrowing of money) incurred in the ordinary course of Borrower’s or its Subsidiary’s business in accordance with customary terms and paid within the specified time, unless contested in good faith by appropriate
proceedings and reserved for in accordance with GAAP; 
 (e) Indebtedness consisting of guarantees resulting from endorsement of negotiable
instruments for collection by Borrower or any Guarantor in the ordinary course of business; 
 (f) Indebtedness (i) of Borrower to any
Guarantor and (ii) of any Guarantor to Borrower or any other Guarantor; 
 (g) Guarantees by Borrower of Indebtedness of any Guarantor and
by any Guarantor of Indebtedness of Borrower or any other Guarantor, in each case, to the extent such Indebtedness is permitted by this Section 9.01; 

(h) normal course of business equipment financing; provided that (i) if secured, the collateral therefor consists solely of the assets
being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal amount of such Indebtedness, when added to the aggregate principal amount of the outstanding Indebtedness permitted
in reliance on Section 9.01(g), does not exceed $1,000,000 (or the Equivalent Amount in other currencies) at any time;
 (i)
Permitted Subordinated Debt;
 (j) [reserved]; 

(k) [reserved]; 
 (l)
Indebtedness approved in advance in writing by the Majority Lenders;
 (m) other Indebtedness in an aggregate outstanding amount not to
exceed $500,000 at any time;
 (n) Investments permitted by Section 9.05; and 

(o) any and all premiums, interest, fees, expenses, charges and additional or contingent interest on obligations described in the foregoing
clauses in this Section 9.01. 
 9.02 Liens. Parent and Borrower will not, and will not permit any of their Subsidiaries to, create,
incur, assume or permit to exist any Lien on any property or asset now owned by it, or assign or sell any income or revenues (including accounts receivable) or rights in respect of any thereof, except: 

(a) Liens securing the Obligations; 

(b) any Lien on any property or asset of Parent, Borrower or any of their Subsidiaries existing on the date hereof and set forth in
Schedule 7.13(b); provided that (i) the scope of the 

  
 54 

 
collateral to which such Lien applies shall not be expanded and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and extensions, renewals and
replacements thereof that do not increase the outstanding principal amount thereof; 
 (c) [reserved]; 

(d) [reserved]; 
 (e) Liens
securing Indebtedness permitted under Section 9.01(h); provided that such Liens are restricted solely to the collateral described in Section 9.01(h); 

(f) Liens imposed by law which were incurred in the ordinary course of business, including (but not limited to) carriers’,
shippers’, landlords’, warehousemen’s, materialmen’s, and mechanics’ liens and other similar liens arising in the ordinary course of business and which (x) do not in the aggregate materially detract from the value of the
Property subject thereto or materially impair the use thereof in the operations of the business of such Person or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or
sale of the Property subject to such liens and for which adequate reserves have been made if required in accordance with GAAP; 
 (g)
pledges or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance or other similar social security legislation; 

(h) deposits to secure the performance of bids, trade contracts, governmental contracts and leases, surety, stay, customs, bid and appeal
bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business; 
 (i) Liens securing taxes,
assessments and other governmental charges, the payment of which is not yet due or is being contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions, if
any, as shall be required by GAAP shall have been made; 
 (j) servitudes, easements, rights of way, restrictions and other similar
encumbrances on real Property imposed by applicable Laws and encumbrances consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor imperfections in title thereto which, in the aggregate, are
not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors; 

(k) with respect to any real Property, (A) such defects or encroachments as might be revealed by an up-to-date survey of such real Property;
(B) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by the original owner of such real Property pursuant to applicable Laws; and (C) rights of expropriation, access or user or
any similar right conferred or reserved by or in applicable Laws, which, in the aggregate for (A), (B) and (C), are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the
ordinary conduct of the business of any of the Obligors;

  
 55 

 (l) Bankers’ liens, rights of setoff and similar Liens incurred on deposits made in the
ordinary course of business; 
 (m) with respect to Patents, Trademarks, Copyrights or other Intellectual Property, licenses and sublicenses
permitted by Section 9.09; 
 (n) [reserved]; 

(o) Liens arising from precautionary UCC financing statement filings regarding leases and consignment arrangements entered into in the
ordinary course of business;
 (p) (i) that certain certificate of deposit in an aggregate amount not to exceed $50,000 plus all interest
accruing thereon maintained with Bank of America, N.A. (and any successor certificate of deposit or account) to secure the Borrower’s obligations to customs authorities and (ii) that certificate of deposit in an aggregate amount not to exceed
$500,000 plus all interest accruing thereon maintained with American Express TRS (and any successor certificate of deposit or account) to secure obligations in connection with the corporate charge card program maintained with American Express; and

 (q) [reserved] 
 provided that, no
Lien otherwise permitted under any of the foregoing Sections 9.02(b) through (p) (other than clauses (i) and (m)) shall apply to any Material Intellectual Property. 

9.03 Fundamental Changes and Acquisitions. Parent and Borrower will not, and will not permit any of their Subsidiaries to, (i) enter into any
transaction of merger, amalgamation or consolidation (ii) liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution) (iii) make any Acquisition or otherwise acquire any business or substantially all the property from, or
capital stock of, or be a party to any acquisition of, any Person. Notwithstanding the foregoing provisions of this Section 9.03: 

(a) Borrower and its Subsidiaries may make Investments permitted under Section 9.05; 

(b) any Subsidiary Guarantor may be merged, amalgamated or consolidated with or into Borrower or any other Subsidiary Guarantor; 

(c) (i) Borrower or any Subsidiary Guarantor may sell, lease, transfer or otherwise dispose of any or all of its property (upon voluntary
liquidation or otherwise) to Borrower or another Subsidiary Guarantor; and 
 (d) the capital stock of any Subsidiary Guarantor may be sold,
transferred or otherwise disposed of to Borrower or another Subsidiary Guarantor; and 
 (e) Borrower may enter into the Reverse Merger
pursuant to which the Borrower shall become a Subsidiary of the Parent. 

  
 56 

 9.04 Lines of Business. Parent and Borrower will not, and will not permit any of their Subsidiaries
to, engage to any material extent in any business other than the business engaged in on the date hereof by Parent, Borrower or any Subsidiary or a business reasonably related thereto. 

9.05 Investments. Parent and Borrower will not, and will not permit any of their Subsidiaries to, make, directly or indirectly, or permit to
remain outstanding any Investments except: 
 (a) Investments outstanding on the date hereof and identified in Schedule 9.05; 

(b) operating deposit accounts with banks; 

(c) extensions of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services in the ordinary
course of business; 
 (d) Permitted Cash Equivalent Investments; 

(e) Investments by Borrower and the Subsidiary Guarantors in Borrower’s wholly-owned Subsidiary Guarantors (for greater certainty,
Borrower shall not be permitted to have any direct or indirect Subsidiaries that are not wholly-owned Subsidiaries); 
 (f) Bona fide
Hedging Agreements and hedging arrangements entered into in the ordinary course of Borrower’s financial planning solely to hedge currency risks (and not for speculative purposes); 

(g) security deposits with utilities and other like Persons made in the ordinary course of business; 

(h) employee loans, travel advances and guarantees in accordance with Borrower’s usual and customary practices with respect thereto (if
permitted by applicable law) which in the aggregate shall not exceed $1,000,000 outstanding at any time (or the Equivalent Amount in other currencies); 

(i) Investments received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and in settlement of
delinquent obligations of, and other disputes with, customers, suppliers or clients; 
 (j) [reserved]; and 

(k) Investments permitted pursuant to Section 9.03. 

9.06 Restricted Payments. Parent and Borrower will not, and will not permit any of their Subsidiaries to, declare or make, or agree to pay or
make, directly or indirectly, any Restricted Payment, except: 
 (a) any Obligor may declare and pay dividends or other distributions with
respect to its Equity Interests payable solely in Equity Interests that are not Disqualified Securities; 

  
 57 

 (b) [reserved]; 

(c) for the payment of dividends by any Subsidiary of an Obligor to any Obligor; 

(d) the Borrower may make Restricted Payments to purchase, redeem or otherwise acquire Equity Interests of Borrower held by officers,
directors and employees or former officers, directors or employees (or their transferees, estates or beneficiaries under their estates) of Borrower so long as no Default or Event of Default shall have occurred and be continuing or would result
therefrom, during any fiscal year, in an amount, when combined with repurchases of Equity Interests permitted under Section 9.06(e), not to exceed $300,000; 

(e) repurchases of Equity Interests deemed to occur upon “cashless” exercise of stock options or warrants if such Equity Interests
represent a portion of the exercise price of such options or warrants plus any amount necessary to pay taxes due and payable in connection therewith, during any fiscal year, in an amount, when combined with purchases, redemptions or acquisitions of
Equity Interests permitted under Section 9.06(d), not to exceed $300,000;
 (f) transactions which are stock for stock exchanges and
other like non-cash transactions which constitute merger consideration in connection with mergers permitted under Section 9.03; and 

(g) [reserved]. 
 9.07 Payments of
Indebtedness. Parent and Borrower will not, and will not permit any of their Subsidiaries to, make any payments in respect of any Indebtedness other than (i) the Obligations and (ii) subject to any applicable terms of subordination, other
Permitted Indebtedness; provided that Parent and Borrower will not, and will not permit any of their Subsidiaries to acquire, repurchase, buy out, retire or prepay in whole or in part any of its outstanding Permitted Subordinated Debt. 

9.08 Change in Fiscal Year. Parent and Borrower will not, and will not permit any of their Subsidiaries to, change the last day of its fiscal year
from that in effect on the date hereof, except to change the fiscal year of a Subsidiary acquired in connection with an Acquisition to conform its fiscal year to the Borrower’s. 

9.09 Sales of Assets, Issuances of Equity, Etc. Unless the Borrower simultaneously makes the prepayment required under
Section 3.03(b)(i), the Parent and the Borrower will not, and will not permit any of its Subsidiaries to, sell, lease, exclusively license in any manner, transfer, or otherwise dispose of any of its Property (including accounts
receivable and capital stock of Subsidiaries) to any Person in one transaction or series of transactions, or issue any additional Equity Interests to Persons who are not holders of Equity Interests in such Person on the date hereof (any thereof, an
“Asset Sale”), except for any of the following: 
 (a) transfers of cash in the ordinary course of its business for
equivalent value; 
 (b) sales of inventory in the ordinary course of its business on ordinary business terms; 

  
 58 

 (c) development and other collaborative arrangements where such arrangements provide for the
licenses or disclosure of Patents, Trademarks, Copyrights or other Intellectual Property rights in the ordinary course of business and consistent with general market practices where such license requires periodic payments based on per unit sales of
a product over a period of time and provided that such licenses must be true licenses as opposed to licenses that are sales transactions in substance; provided, that, such arrangements shall require the prior written consent of the
Lenders;
 (d) transfers of Property by any Obligor to any other Obligor; 

(e) dispositions of any Property that is damaged, obsolete or worn out or no longer used or useful in the Business; 

(f) issuances of Equity Interests in Borrower; 

(g) those transactions permitted by Section 9.03 and 9.06 and Asset Sales consisting of leases and licenses permitted by
Section 9.02;
 (h) the unwinding of any Hedging Agreement permitted by Section 9.05 pursuant to its terms;

(i) other Asset Sales with a fair market value not in excess of $500,000 in the aggregate. 

Lenders acknowledge and agree that the carveout in Section 9.09(e) permits Borrower to make decisions in the ordinary course of
business regarding the registration of any of its Intellectual Property, including without limitation, any decisions regarding application, prosecution, abandonment, or cancellation of any such Intellectual Property, without the consent of any
Lender. 
 9.10 Transactions with Affiliates. Parent and Borrower will not, and will not permit any of their Subsidiaries to, sell, lease,
license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, except for any of the following: 

(a) transactions between or among Obligors; 

(b) [reserved]; 
 (c)
[reserved]; 
 (d) [reserved]; 

(e) customary compensation and indemnification of, and other employment arrangements with, directors, officers and employees of Borrower or
any Subsidiary in the ordinary course of business; 
 (f) [reserved]; 

  
 59 

 (g) issuances of Equity Interests in Borrower; and 

(h) operating leases permitted under Section 9.13(b)(ii). 

9.11 Restrictive Agreements. Except for Permitted Restrictive Agreements, Parent and Borrower will not, and will not permit any of their Subsidiaries
to, directly or indirectly, enter into, incur or permit to exist any agreement or other arrangement that prohibits, restricts or imposes any condition upon (a) the ability of Parent, Borrower or any Subsidiary to create, incur or permit to exist any
Lien upon any of its property or assets, or (b) the ability of any Subsidiary to pay dividends or other distributions with respect to any shares of its capital stock or to make or repay loans or advances to Parent, Borrower or any other Subsidiary
or to Guarantee Indebtedness of Parent, Borrower or any other Subsidiary; provided that: 
 (i) the foregoing shall not apply to (x)
restrictions and conditions imposed by law or by this Agreement and (y) customary restrictions and conditions contained in agreements relating to the sale of a Subsidiary pending such sale, provided such restrictions and conditions apply only to the
Subsidiary that is to be sold and such sale is permitted hereunder; and 
 (ii) the foregoing clause (a) shall not apply to (x)
restrictions or conditions imposed by any agreement relating to secured Permitted Indebtedness if such restrictions or conditions apply only to the property or assets securing such Indebtedness and (y) customary provisions in leases, in-bound
licenses of Intellectual Property and other contracts restricting the assignment thereof. 
 9.12 Amendments to Material Agreements. Parent and
Borrower will not, and will not permit any of their Subsidiaries to, enter into any amendment to or modification of any Material Agreement or terminate any Material Agreement (unless replaced with another agreement that, viewed as a whole, is on
better terms for Parent, Borrower or such Subsidiary or unless such amendment or modification would not be materially adverse to the Lenders) without in each case the prior written consent of the Lender (which consent shall not be unreasonably
withheld or delayed). 
 9.13 Preservation of Borrower Lease; Operating Leases. 

(a) Notwithstanding any provision of this Agreement to the contrary, Borrower shall not: 

(i) Surrender, terminate, forfeit, or suffer or permit the surrender, termination or forfeiture of, or change, modify or amend, the Borrower
Lease, nor transfer, sell, assign, convey, dispose of, mortgage, pledge, hypothecate, assign or encumber any of its interest in, the Borrower Lease;

(ii) Consent to, cause, agree to, or permit to occur any subordination, or consent to the subordination of, the Borrower Lease to any
mortgage, deed of trust or other lien encumbering (or that may in the future encumber) the interest of Borrower Landlord in the Borrower Facility; 

  
 60 

 (iii) Waive, excuse, condone or in any way release or discharge Borrower Landlord of or from its
material obligations, covenants and/or conditions under the Borrower Lease; or 
 (iv) Elect to treat the Borrower Lease as terminated or
rejected under subsection 365 of the Bankruptcy Code or other applicable Law. Any such election made without Majority Lenders’ prior written consent shall be void. If, pursuant to subsection 365 of the Bankruptcy Code or other applicable law,
Borrower seeks to offset, against the rent reserved in the Borrower Lease, the amount of any damages caused by the nonperformance by Borrower Landlord of any of its obligations thereunder after the rejection by Borrower Landlord of the Borrower
Lease under the Bankruptcy Code or other applicable Law, then Borrower shall not effect any offset of any amounts objected to by Lenders. 

(b) Parent and Borrower will not, and will not permit any of their Subsidiaries to, make any expenditures in respect of operating leases,
except for: 
 (i) real estate operating leases; 

(ii) operating leases between any Obligor and any of its wholly-owned Subsidiaries or between any of the Obligor’s wholly-owned
Subsidiaries;
 (iii) to the extent constituting operating leases, leases in respect of computer and information technology equipment that
are now or may hereafter used by the Obligors and their sales representatives in the ordinary course of business; provided that the aggregate payments made by Borrower and its Subsidiaries in connection with such leases shall not exceed $2,000,000
(or the Equivalent Amount in other currencies) in any fiscal year and the value of the leased equipment shall not exceed an average of $10,000 per sales representatives using such equipment on an aggregated basis; and 

(iv) operating leases that would not cause Borrower and its Subsidiaries, on a consolidated basis, to make payments exceeding $2,000,000 (or
the Equivalent Amount in other currencies) in any fiscal year. 
 9.14 Sales and Leasebacks. Except as disclosed on Schedule 9.14, Parent and
Borrower will not, and will not permit any of their Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any property (whether real, personal, or mixed),
whether now owned or hereafter acquired, (i) which Parent, Borrower or such Subsidiary has sold or transferred or is to sell or transfer to any other Person and (ii) which Parent, Borrower or such Subsidiary intends to use for substantially the same
purposes as property which has been or is to be sold or transferred. 
 9.15 Hazardous Material. Parent and Borrower will not, and will not permit
any of their Subsidiaries to, use, generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure to comply would not reasonably be
expected to result in a Material Adverse Change. 

  
 61 

 9.16 Accounting Changes. Parent and Borrower will not, and will not permit any of their Subsidiaries to,
make any significant change in accounting treatment or reporting practices, except as required or permitted by GAAP. 
 9.17 Compliance with ERISA.
No ERISA Affiliate shall cause or suffer to exist (a) any event that could result in the imposition of a Lien with respect to any Title IV Plan or Multiemployer Plan or (b) any other ERISA Event that would, in the aggregate, have a Material Adverse
Effect. No Obligor or Subsidiary thereof shall cause or suffer to exist any event that could result in the imposition of a Lien with respect to any Benefit Plan. 

9.18 Investment Company Act. Parent and Borrower will, and will cause each of their Subsidiaries, not to engage in any activities that will result in
Parent, Borrower or such Subsidiary becoming an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940. 

9.19 Parent. Parent shall not acquire, own, form, or have any interest whatsoever in any direct Subsidiary other than Borrower. 

9.20 Subsidiaries. None of Parent, Borrower or any Subsidiary Guarantor shall have any Subsidiaries that are not also Subsidiary Guarantors. 

SECTION 10 
 FINANCIAL
COVENANTS 
 10.01 Minimum Cash. 

Parent, Borrower and Subsidiaries shall maintain, at all times, a minimum end of day daily balance of cash and Permitted Cash Equivalent
Investments of at least $5,000,000. 
 SECTION 11 

EVENTS OF DEFAULT 
 11.01 Events of
Default. Each of the following events shall constitute an “Event of Default”: 
 (a) Borrower shall fail to pay
any principal of any Loan when and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment thereof or otherwise; 

(b) any Obligor shall fail to pay any Obligation (other than an amount referred to in Section 11.01(a)) when and as the same shall
become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days; 
 (c) any representation or
warranty made or deemed made by or on behalf of Parent, Borrower or any of their Subsidiaries in or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate,
financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to
the extent that such 

  
 62 

 
representation or warranty contains any materiality or Material Adverse Effect qualifier; or (ii) prove to have been incorrect in any material respect when made or deemed made to the extent that
such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier; 
 (d) any Obligor shall
fail to observe or perform any covenant, condition or agreement contained in Section 8.02, 8.03 (with respect to Parent or the Borrower’s existence), 8.11, 8.12 (other than clause (c) therein), 8.14,
9 or 10 or the Borrower; 
 (e) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in
this Agreement or any other Loan Document (other than those specified in Section 11.01(a), (b) or (d)) and such failure shall continue unremedied for a period of 20 or more days; 

(f) Parent, Borrower or any of their Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount)
in respect of any Material Indebtedness, when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such Indebtedness; 

(g) (i) any material breach of, or “event of default” or similar event caused by any Obligor under, any Material Agreement occurs,
(ii) any material breach of, or “event of default” or similar event under, the documentation governing any Material Indebtedness shall occur, or (iii) any event or condition occurs (A) that results in any Material Indebtedness becoming due
prior to its scheduled maturity or (B) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material Indebtedness or any trustee or agent on its or their behalf to cause such
Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that this Section 11.01(g) shall not apply to secured Indebtedness that
becomes due as a result of the voluntary sale or transfer of the property or assets securing such Material Indebtedness. 
 (h) any Obligor:

 (i) becomes insolvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become due, or admits
in writing its inability to pay its debts generally, or declares any general moratorium on its indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors; 

(ii) commits an act of bankruptcy or makes an assignment of its property for the general benefit of its creditors or makes a proposal (or
files a notice of its intention to do so); 
 (iii) institutes any proceeding seeking to adjudicate it an insolvent, or seeking liquidation,
dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), or composition of it or its debts or any other relief, under any
federal, provincial or foreign Law now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity, or files an answer
admitting the material allegations of a petition filed against it in any such proceeding; 

  
 63 

 (iv) applies for the appointment of, or the taking of possession by, a receiver, interim
receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property; or 

(v) takes any action, corporate or otherwise, to approve, effect, consent to or authorize any of the actions described in this Section
11.01(h) or in Section 11.01(i), or otherwise acts in furtherance thereof or fails to act in a timely and appropriate manner in defense thereof; 

(i) any petition is filed, application made or other proceeding instituted against or in respect of Parent, Borrower or any Subsidiary: 

(i) seeking to adjudicate it an insolvent; 

(ii) seeking a receiving order against it; 

(iii) seeking liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay
of proceedings of creditors generally (or any class of creditors), deed of company arrangement or composition of it or its debts or any other relief under any federal, provincial or foreign law now or hereafter in effect relating to bankruptcy,
winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity; or 

(iv) seeking the entry of an order for relief or the appointment of, or the taking of possession by, a receiver, interim receiver,
receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property; and the case of each of Section
11.01(i)(i)-(iv), such petition, application or proceeding continues undismissed, or unstayed and in effect, for a period of thirty (30) days after the institution thereof; provided that if an order, decree or judgment is granted or
entered (whether or not entered or subject to appeal) against Parent, Borrower or such Subsidiary thereunder in the interim, such grace period will cease to apply; provided further that if Parent, Borrower or such Subsidiary files an answer
admitting the material allegations of a petition filed against it in any such proceeding, such grace period will cease to apply; 
 (j) any
other event occurs which, under the laws of any applicable jurisdiction, has an effect equivalent to any of the events referred to in either of Section 11.01(h) or (i); 

(k) one or more judgments for the payment of money shall be rendered against any Obligor or any combination thereof in an aggregate amount in
excess of $250,000 (or the Equivalent Amount in other currencies) and the same shall remain undischarged for a period of 45 consecutive days during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment
creditor to attach or levy upon any assets of any Obligor to enforce any such judgment; 

  
 64 

 (l) a Material Adverse Change shall have occurred; 

(m) (i) any Lien created by the Security Documents shall at any time not constitute a valid and perfected Lien on the collateral intended to
be covered thereby (to the extent perfection by filing, registration, recordation or possession is required herein or therein) in favor of the Lenders, free and clear of all other Liens (other than Permitted Liens), (ii) except for expiration in
accordance with its terms, any of the Security Documents or any Guarantee of any of the Obligations (including that contained in Section 13) shall for whatever reason be terminated or cease to be in full force and effect, or (iii) the
enforceability of any of the Security Documents or any Guarantee of any of the Obligations (including that contained in Section 13) shall be contested by any Obligor; 

(n) any injunction, whether temporary or permanent, shall be rendered against any Obligor that prevents the Obligors from selling or
manufacturing the Product or its commercially available successors, or any of their other material and commercially available products in the entire United States and more than forty-five (45) consecutive calendar days shall have elapsed since such
injunction without such injunction having been stayed, discharged, overturned or vacated. 
 11.02 Remedies. Upon the occurrence of any Event of
Default, then, and in every such event (other than an Event of Default described in Section 11.01(h), (i) or (j)), and at any time thereafter during the continuance of such event, Majority Lenders may, by notice to the Borrower,
take any or all of the following actions, at the same or different times: (i) terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii) declare the Loans then outstanding to be due and payable in whole (or in
part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all
fees and other Obligations, shall become due and payable immediately (in the case of the Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor, and
in case of any Event of Default described in Section 11.01(h), (i) or (j), the Commitment shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon and all fees and
other Obligations, shall automatically become due and payable immediately (in the case of the Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.

 SECTION 12 

MISCELLANEOUS 
 12.01 No Waiver. No
failure on the part of the Lenders to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of
any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided
by law. 

  
 65 

 12.02 Notices. All notices, requests, instructions, directions and other communications provided for
herein (including any modifications of, or waivers, requests or consents under, this Agreement) shall be given or made in writing (including by telecopy) delivered, if to Borrower, another Obligor or the Lenders, to its address specified on the
signature pages hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a notice to the other parties. Except as otherwise provided in this Agreement, all such communications
shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by telecopy shall be confirmed in writing promptly after the delivery of such
communication (it being understood that non-receipt of written confirmation of such communication shall not invalidate such communication). Notwithstanding anything to the contrary in this Agreement, notices, documents, certificates and other
deliverables to the Lenders by any Obligor may be made solely to the Control Agent and the Control Agent shall promptly deliver such notices, documents, certificates and other deliverables to the other Lenders. 

12.03 Expenses, Indemnification, Etc. 

(a) Expenses. Borrower agrees to pay or reimburse (i) the Lenders for all of their reasonable out of pocket costs and expenses
(including the reasonable and documented out-of-pocket fees and expenses of Morrison & Foerster LLP, special counsel to the Lenders, and any sales, goods and services or other similar taxes applicable thereto, and printing, reproduction,
document delivery, communication and travel costs) in connection with (x) the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Loans (exclusive of post-closing costs), (y)
post-closing costs and (z) the negotiation or preparation of any modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not consummated) and (ii) the Lenders for all of their out of
pocket costs and expenses (including the fees and expenses of legal counsel) in connection with any enforcement or collection proceedings resulting from the occurrence of an Event of Default; provided, however, that the Borrower shall not be
required to pay or reimburse any amounts pursuant to Section 12.03(a)(i)(x) in excess of $300,000; provided further that, so long as the conditions precedent in Section 6.01 shall have been satisfied or waived in accordance with
the terms thereof, then such fees shall be fully credited from the fees paid by the Borrower pursuant to Section 2.03 on the Closing Date. 

(b) Indemnification. Borrower hereby indemnifies the Lenders, their Affiliates, and their respective directors, officers, employees,
attorneys, agents, advisors and controlling parties (each, an “Indemnified Party”) from and against, and agrees to hold them harmless against, any and all Claims or Losses of any kind (including reasonable fees and
disbursements of counsel), joint or several, that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or relating to any investigation, litigation or proceeding or the
preparation of any defense with respect thereto arising out of or in connection with or relating to this Agreement or any of the other Loan Documents or the transactions contemplated hereby or thereby or any use made or proposed to be made with the
proceeds of the Loans, whether or not such investigation, litigation or proceeding is brought by Borrower, any of 

  
 66 

 its shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified Party is otherwise a
party thereto, and whether or not any of the conditions precedent set forth in Section 6 are satisfied or the other transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is found in a final,
non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party’s gross negligence or willful misconduct. No Obligor shall assert any claim against any Indemnified Party, on any theory of liability, for
consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the transactions contemplated hereby or thereby or the actual or proposed use of the proceeds of
the Loans. Parent, Borrower, its Subsidiaries and Affiliates and their respective directors, officers, employees, attorneys, agents, advisors and controlling parties are each sometimes referred to in this Agreement as a “Borrower
Party.” No Lender shall assert any claim against any Borrower Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan
Documents or any of the transactions contemplated hereby or thereby or the actual or proposed use of the proceeds of the Loans. 
 12.04 Amendments,
Etc. Except as otherwise expressly provided in this Agreement, any provision of this Agreement may be amended, waived, modified or supplemented only by an instrument in writing signed by the Borrower and the Lenders; provided that any
consent, approval, (including without limitation any approval of or authorization for any amendment, waiver, modification or supplement to any of the Loan Documents), instruction or other expression of the Lenders under any of the Loan Documents may
be obtained by an instrument in writing signed in one or more counterparts by Majority Lenders; provided however, that the consent of all of the Lenders shall be required to: 

(i) amend, modify, discharge, terminate or waive any of the terms of this Agreement if such amendment, modification, discharge, termination or
waiver would increase the amount of the Loans, reduce the fees payable hereunder, reduce interest rates or other amounts payable with respect to the Loans, extend any date fixed for payment of principal, interest or other amounts payable relating to
the Loans or extend the repayment dates of the Loans; 
 (ii) amend the provisions of Section 6; 

(iii) amend, modify, discharge, terminate or waive any Security Document if the effect is to release a material part of the Collateral subject
thereto otherwise than pursuant to the terms hereof or thereof; or 
 (iv) amend this Section 12.04. 

Notwithstanding anything to the contrary herein, a Defaulting Lender shall not have any right to approve or disapprove any amendment, waiver or consent
hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment
of any Defaulting Lender may not be increased or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender
more adversely than other affected Lenders shall require the consent of such Defaulting Lender. 

  
 67 

 12.05 Successors and Assigns. 

(a) General. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and assigns permitted hereby, except that Borrower may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Lenders. Any of the Lenders may assign or otherwise transfer any
of their rights or obligations hereunder to an assignee in accordance with the provisions of Section 12.05(b), (ii) by way of participation in accordance with the provisions of Section 12.05(e) or (iii) by way of pledge or assignment
of a security interest subject to the restrictions of Section 12.05(g). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns
permitted hereby, Participants to the extent provided in Section 12.05(d) and, to the extent expressly contemplated hereby, the Indemnified Parties) any legal or equitable right, remedy or claim under or by reason of this Agreement. 

(b) Assignments by Lenders. Any of the Lenders may at any time assign to one or more transferees all or a portion of their rights and
obligations under this Agreement (including all or a portion of the Commitment and the Loans at the time owing to it) following written notice to the Borrower. Subject to the recording thereof by the Lenders pursuant to Sections 12.05(c) and
12.05(d), from and after the effective date specified in each Assignment and Acceptance, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Acceptance, have the rights
and obligations of the Lenders under this Agreement, and correspondingly the assigning Lender shall, to the extent of the interest assigned by such Assignment and Acceptance, be released from its obligations under this Agreement (and, in the case of
an Assignment and Acceptance covering all of a Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Section 5 and Section 12.03.

 (c) Amendments to Loan Documents. To the extent that the Lender that is the Control Agent has made an assignment pursuant to
Section 12.05(b) or to the extent necessary to reflect new Commitments on Schedule 1, each of the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other
instruments and agreements, in each case in form and substance reasonably acceptable to the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made under this Section 12.05. 

(d) Register. The Lenders, acting solely for this purpose as agents of Borrower, shall maintain at one of its offices, which shall be
the office of the Control Agent, a register for the recordation of the name and address of any assignee of the Lenders and the Commitment and outstanding principal amount of the Loans owing thereto (the “Register”). The
entries in the Register shall be conclusive, absent manifest error, and Borrower may treat each Person whose name is recorded in the Register pursuant to the terms hereof as the “Lender” hereunder for all purposes of this Agreement,
notwithstanding notice to the contrary. The Register shall be available for inspection by Borrower, at any reasonable time and from time to time upon reasonable prior notice. 

  
 68 

 (e) Participations. Any of the Lenders may at any time, without the consent of, or notice
to, Borrower, sell participations to any Person (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of the Commitment and/or the Loans
owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the
Borrower shall continue to deal solely and directly with the Lenders in connection therewith. 
 Any agreement or instrument pursuant to which a Lender
sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or
instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase or extend the term of such Lender’s Commitment, (ii) extend the date fixed for the
payment of principal of or interest on the Loans or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal, or (iv) reduce the rate at which interest is payable thereon to a level below
the rate at which the Participant is entitled to receive such interest. Subject to Section 12.05(f), Borrower agrees that each Participant shall be entitled to the benefits of Section 5 to the same extent as if it were a Lender and had
acquired its interest by assignment pursuant to Section 12.05(b). To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 4.04(a) as though it were the Lender. 

(f) Limitations on Rights of Participants. A Participant shall not be entitled to receive any greater payment under
Section 5.01 or 5.05 than a Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior
written consent. 
 (g) Certain Pledges. The Lenders may at any time pledge or assign a security interest in all or any portion of
its rights under this Agreement and any other Loan Document to secure obligations of the Lenders, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release the
Lenders from any of their obligations hereunder or substitute any such pledgee or assignee for the Lenders as a party hereto. 
 12.06 Survival.
Sections 5.01, 5.03, 5.05, 6.01(g)(iv), 12.03, 12.05, 12.09, 12.10, 12.11, 12.12, 12.13, 12.14 and Section 13 (solely to the extent guaranteeing any of the
obligations under the foregoing Sections) shall survive the repayment of the Loans and the termination of the Commitment and, in the case of the Lenders’ assignment of any interest in the Commitment or the Loans hereunder, shall survive, in the
case of any event or circumstance that occurred prior to the effective date of such assignment, the making of such assignment, notwithstanding that the Lenders may cease to be “Lenders” hereunder. In addition, each representation and
warranty made, or deemed to be made by a notice of the Loans, herein or pursuant hereto shall survive the making of such representation and warranty. 

  
 69 

 12.07 Captions. The table of contents and captions and section headings appearing herein are included
solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement. 
 12.08 Counterparts. This
Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. 

12.09 Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the
law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply. 

12.10 Jurisdiction, Service of Process and Venue. 

(a) Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Agreement or any other
Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the
non-exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment. This Section 12.10(a) is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking
proceedings in any other courts with jurisdiction. To the extent allowed by applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 

(b) Alternative Process. Nothing herein shall in any way be deemed to limit the ability of the Lenders to serve any such process or
summonses in any other manner permitted by applicable law. 
 (c) Waiver of Venue, Etc. Each Obligor irrevocably waives to the
fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document and hereby further irrevocably
waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such
suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such Obligor is or may be subject, by suit upon judgment. 

12.11 Waiver of Jury Trial. EACH OBLIGOR AND EACH LENDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL
RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. 

  
 70 

 12.12 Waiver of Immunity. To the extent that any Obligor may be or become entitled to claim for itself or
its Property or revenues any immunity on the ground of sovereignty or the like from suit, court jurisdiction, attachment prior to judgment, attachment in aid of execution of a judgment or execution of a judgment, and to the extent that in any such
jurisdiction there may be attributed such an immunity (whether or not claimed), such Obligor hereby irrevocably agrees not to claim and hereby irrevocably waives such immunity with respect to its obligations under this Agreement and the other Loan
Documents. 
 12.13 Entire Agreement. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to
the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. EACH OBLIGOR ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS
AGREEMENT AND THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED, AND WILL NOT RELY, ON ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF
OR WITH THE LENDERS OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS. 
 12.14 Severability. If any provision
hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by applicable law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.

 12.15 No Fiduciary Relationship. Borrower acknowledges that the Lenders have no fiduciary relationship with, or fiduciary duty to, Borrower
arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between the Lenders and the Borrower are solely that of creditor and debtor. This Agreement and the other Loan Documents do not create a joint
venture among the parties. 
 12.16 Confidentiality. The Lenders agree to maintain the confidentiality of the Confidential Information (as defined in
the Non-Disclosure Agreement (defined below)) in accordance with the terms of that certain non-disclosure agreement dated March 1, 2013 among Borrower and Capital Royalty, L.P. (the “Non-Disclosure Agreement”). Each new
Lender that becomes party to this Agreement and each Participant hereby agrees to be bound by the terms of the Non-Disclosure Agreement. 
 12.17 USA
PATRIOT Act. The Lenders hereby notify the Borrower that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), they are required to obtain,
verify and record information that identifies Borrower, which information includes the name and address of Borrower and other information that will allow such Lender to identify Borrower in accordance with the Act. 

12.18 Maximum Rate of Interest. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under
the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (in each case, the “Maximum Rate”). If the Lenders shall receive interest in an amount that exceeds the Maximum 

  
 71 

 
Rate, the excess interest shall be applied to the principal of the Loans, and not to the payment of interest, or, if the excessive interest exceeds such unpaid principal, the amount exceeding the
unpaid balance shall be refunded to the applicable Obligor. In determining whether the interest contracted for, charged, or received by the Lenders exceeds the Maximum Rate, the Lenders may, to the extent permitted by applicable Law, (a)
characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of
interest throughout the contemplated term of the Indebtedness and other obligations of any Obligor hereunder, or (d) allocate interest between portions of such Indebtedness and other obligations under the Loan Documents to the end that no such
portion shall bear interest at a rate greater than that permitted by applicable Law. 
 12.19 Certain Waivers. 

(a) Real Property Security Waivers. 

(i) Each Obligor acknowledges that all or any portion of the Obligations may now or hereafter be secured by a Lien or Liens upon real property
evidenced by certain documents including, without limitation, deeds of trust and assignments of rents. Lenders may, pursuant to the terms of said real property security documents and applicable law, foreclose under all or any portion of one or
more of said Liens by means of judicial or nonjudicial sale or sales. Each Obligor agrees that Lenders may exercise whatever rights and remedies they may have with respect to said real property security, all without affecting the liability of
any Obligor under the Loan Documents, except to the extent Lenders realize payment by such action or proceeding. No election to proceed in one form of action or against any party, or on any obligation shall constitute a waiver of Lenders’
rights to proceed in any other form of action or against any Obligor or any other Person, or diminish the liability of any Obligor, or affect the right of Lenders to proceed against any Obligor for any deficiency, except to the extent Lenders
realize payment by such action, notwithstanding the effect of such action upon any Obligor’s rights of subrogation, reimbursement or indemnity, if any, against Obligor or any other Person. 

(ii) To the extent permitted under applicable law, each Obligor hereby waives any rights and defenses that are or may become available to such
Obligor by reason of Sections 2787 to 2855, inclusive, of the California Civil Code. 
 (iii) To the extent permitted under applicable law,
each Obligor hereby waives all rights and defenses that such Obligor may have because the Obligations are or may be secured by real property. This means, among other things: 

(A) Lenders may collect from any Obligor without first foreclosing on any real or personal property collateral pledged by any other
Obligor;
 (B) If Lenders foreclose on any real property collateral pledged by any Obligor: 

(1) The amount of the Loans may be reduced only by the price for which that collateral is sold at the foreclosure sale, even if the
collateral is worth more than the sale price; and 

  
 72 

 (2) Lenders may collect from each Obligor even if Lenders, by foreclosing on the real property
collateral, have destroyed any right that such Obligor may have to collect from any other Obligor. 
 (3) To the extent permitted under
applicable law, this is an unconditional and irrevocable waiver of any rights and defenses each Obligor may have because the Obligations are or may be secured by real property. These rights and defenses include, but are not limited to, any rights or
defenses based upon Section 580a, 580b, 580d or 726 of the California Code of Civil Procedure. 
 (iv) To the extent permitted under
applicable law, each Obligor waives all rights and defenses arising out of an election of remedies by Lenders, even though that election of remedies, such as a nonjudicial foreclosure with respect to security for a guaranteed obligation, has
destroyed such Obligor’s rights of subrogation and reimbursement against the principal by the operation of Section 580d of the California Code of Civil Procedure or otherwise. 

(b) Waiver of Marshaling. WITHOUT LIMITING THE FOREGOING IN
ANY WAY, EACH OBLIGOR HEREBY IRREVOCABLY WAIVES AND RELEASES, TO THE
EXTENT PERMITTED BY LAW, ANY AND ALL RIGHTS IT MAY HAVE AT
ANY TIME (WHETHER ARISING DIRECTLY OR INDIRECTLY, BY OPERATION OF LAW,
CONTRACT OR OTHERWISE) TO REQUIRE THE MARSHALING OF ANY ASSETS OF ANY
OBLIGOR, WHICH RIGHT OF MARSHALING MIGHT OTHERWISE ARISE FROM ANY PAYMENTS
MADE OR OBLIGATIONS PERFORMED. 
 12.20 Acknowledgment of Appointment of Agent. The
Borrower acknowledges that the Lenders have appointed CRG Servicing LLC, a Delaware limited liability company, an Affiliate of the Lenders, as their agent for administrative and collateral matters in respect of this Agreement and to constitute their
Control Agent and Secured Party Representative for purposes of the Loan Documents. 
 SECTION 13 

GUARANTEE 
 13.01 The
Guarantee. The Guarantors hereby jointly and severally guarantee to the Lenders and their successors and assigns the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the principal of and
interest on the Loans and all fees and other amounts from time to time owing to the Lenders by Borrower under this Agreement or under any other Loan Document and by any other Obligor under any of the Loan Documents, in each case strictly in
accordance with the terms thereof (such obligations being herein collectively called the “Guaranteed Obligations”). The Guarantors hereby further jointly and severally agree that if Borrower shall fail to pay in full
when due (whether at stated maturity, by acceleration or otherwise) any of the Guaranteed Obligations, the Guarantors will promptly pay the same, without any demand or notice whatsoever, and that in the case of any extension of time 

  
 73 

 
of payment or renewal of any of the Guaranteed Obligations, the same will be promptly paid in full when due (whether at extended maturity, by acceleration or otherwise) in accordance with the
terms of such extension or renewal. 
 13.02 Obligations Unconditional. The obligations of the Guarantors under Section 13.01 are absolute and
unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of Borrower under this Agreement or any other agreement or instrument referred to herein, or any substitution,
release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by applicable law, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or
equitable discharge or defense of a surety or guarantor, it being the intent of this Section 13.02 that the obligations of the Guarantors hereunder shall be absolute and unconditional, joint and several, under any and all circumstances.
Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or impair the liability of the Guarantors hereunder, which shall remain absolute and unconditional as described
above: 
 (a) at any time or from time to time, without notice to the Guarantors, the time for any performance of or compliance with any of
the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived; 
 (b) any of the acts mentioned in any of
the provisions of this Agreement or any other agreement or instrument referred to herein shall be done or omitted; 
 (c) the maturity of
any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be modified, supplemented or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall
be waived or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with; or 

(d) any lien or security interest granted to, or in favor of, the Lenders as security for any of the Guaranteed Obligations shall fail to be
perfected. 
 The Guarantors hereby expressly waive diligence, presentment, demand of payment, protest and all notices whatsoever, and any
requirement that the Lenders exhaust any right, power or remedy or proceed against Borrower under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other guarantee of, or security for, any
of the Guaranteed Obligations. 
 13.03 Reinstatement. The obligations of the Guarantors under this Section 13 shall be automatically
reinstated if and to the extent that for any reason any payment by or on behalf of Borrower in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by any holder of any of the Guaranteed Obligations, whether as a result
of any proceedings in bankruptcy or reorganization or otherwise, and the Guarantors jointly and severally agree that they will indemnify the Lenders on demand for all reasonable costs and expenses (including fees of counsel) incurred by the Lenders
in connection with such rescission or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy,
insolvency or similar law. 

  
 74 

 13.04 Subrogation. The Guarantors hereby jointly and severally agree that until the payment and
satisfaction in full of all Guaranteed Obligations (other than the Warrant Obligations) and the expiration and termination of the Commitment of the Lenders under this Agreement they shall not exercise any right or remedy arising by reason of any
performance by them of their guarantee in Section 13.01, whether by subrogation or otherwise, against Borrower or any other guarantor of any of the Guaranteed Obligations or any security for any of the Guaranteed Obligations. 

13.05 Remedies. The Guarantors jointly and severally agree that, as between the Guarantors and the Lenders, the obligations of Borrower under this
Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in Section 11 (and shall be deemed to have become automatically due and payable in the circumstances provided in Section 11)
for purposes of Section 13.01 notwithstanding any stay, injunction or other prohibition preventing such declaration (or such obligations from becoming automatically due and payable) as against Borrower and that, in the event of such
declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by Borrower) shall forthwith become due and payable by the Guarantors for purposes of Section 13.01.

 13.06 Instrument for the Payment of Money. Each Guarantor hereby acknowledges that the guarantee in this Section 13 constitutes an
instrument for the payment of money, and consents and agrees that the Lender, at its sole option, in the event of a dispute by such Guarantor in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment
in lieu of complaint pursuant to N.Y. Civ. Prac. L&R § 3213. 
 13.07 Continuing Guarantee. The guarantee in this Section 13 is a
continuing guarantee, and shall apply to all Guaranteed Obligations whenever arising. 
 13.08 Rights of Contribution. The Guarantors hereby agree,
as between themselves, that if any Guarantor shall become an Excess Funding Guarantor (as defined below) by reason of the payment by such Guarantor of any Guaranteed Obligations, each other Guarantor shall, on demand of such Excess Funding Guarantor
(but subject to the next sentence), pay to such Excess Funding Guarantor an amount equal to such Guarantor’s Pro Rata Share (as defined below and determined, for this purpose, without reference to the properties, debts and liabilities of such
Excess Funding Guarantor) of the Excess Payment (as defined below) in respect of such Guaranteed Obligations. The payment obligation of a Guarantor to any Excess Funding Guarantor under this Section 13.08 shall be subordinate and subject in right of
payment to the prior payment in full of the obligations of such Guarantor under the other provisions of this Section 13 and such Excess Funding Guarantor shall not exercise any right or remedy with respect to such excess until payment and
satisfaction in full of all of such obligations. For purposes of this Section 13.08, (i) “Excess Funding Guarantor” means, in respect of any Guaranteed Obligations, a Guarantor that has paid an amount in excess of its Pro
Rata Share of such Guaranteed Obligations, (ii) “Excess Payment” means, in respect of any Guaranteed Obligations, the amount paid by an Excess Funding Guarantor in excess of its Pro Rata Share of 

  
 75 

 
such Guaranteed Obligations and (iii) “Pro Rata Share” means, for any Guarantor, the ratio (expressed as a percentage) of (x) the amount by which the aggregate present fair
saleable value of all properties of such Guarantor (excluding any shares of stock of any other Guarantor) exceeds the amount of all the debts and liabilities of such Guarantor (including contingent, subordinated, unmatured and unliquidated
liabilities, but excluding the obligations of such Guarantor hereunder and any obligations of any other Guarantor that have been Guaranteed by such Guarantor) to (y) the amount by which the aggregate fair saleable value of all properties of all of
the Guarantors exceeds the amount of all the debts and liabilities (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of the Borrower and the Guarantors hereunder and under the other Loan
Documents) of all of the Guarantors, determined (A) with respect to any Guarantor that is a party hereto on the date hereof, as of the date hereof, and (B) with respect to any other Guarantor, as of the date such Guarantor becomes a Guarantor
hereunder. 
 13.09 General Limitation on Guarantee Obligations. In any action or proceeding involving any provincial, territorial or state corporate
law, or any state or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of any Guarantor under Section 13.01 would otherwise, taking into account the provisions of
Section 13.08, be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under Section 13.01, then, notwithstanding any other provision
hereof to the contrary, the amount of such liability shall, without any further action by such Guarantor, the Lenders or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated
to the claims of other creditors as determined in such action or proceeding. 
 13.10 Collateral and Guaranty Matters. Each of the Lenders
(including the Control Agent) agree: 
 (a) to release any Lien on any property granted to or held by the Control Agent or any Lender under
any Loan Document (i) upon the payment in full in cash of all Obligations and the termination or expiration of all Commitments or (ii) that is sold or to be sold as part of or in connection with any sale permitted hereunder or under any other
Loan Document; 
 (b) to release any Subsidiary Guarantor from its obligations under Loan Documents if such Person ceases to be a Subsidiary
as a result of a transaction permitted hereunder; and 
 (c) to subordinate any Lien on any property granted to or held by any Lender or the
Control Agent under any Loan Document to the holder of any Lien on such property that is permitted by Section 9.02(e) solely to the extent the Liens of any Lender or the Control Agent being subordinated encumber the specific assets
financed by such Lien holder. 
 [Signature Pages Follow] 

  
 76 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered as of the day and year first above written. 
  

			
	BORROWER:
	
	VALERITAS, INC.
		
	By	 	 

		 	Name: John Timberlake
		 	Title:   Chief Executive Officer

 
			
	
	Address for Notices:
	750 Route 202 South, Suite 600
	Bridgewater, NJ 08807
	Attn:	 	John Timberlake, Chief Executive Officer
	Tel.:	 	(908) 927-9920
	Fax:	 	(908) 927-9927
	Email:	 	jtimberlake@valeritas.com
	
	With a copy to:
	
	Morgan, Lewis & Bockius LLP
	502 Carnegie Center
	Princeton, New Jersey 08540-6241
	Attn: Steven M. Cohen
	Main: (609) 919-6604
	Facsimile: (609) 919-6701
	Email: steven.cohen@morganlewis.com

  
 [Signature Page to Term
Loan Agreement] 

 
					
	GUARANTORS:
	
	VALERITAS HOLDINGS, INC.
		
	By	 	 

		 	Name:	 	John Timberlake
		 	Title:	 	Chief Executive Officer
	
	Address for Notices:
	750 Route 202 South, Suite 600
	Bridgewater, NJ 08807
	Attn:	 	John Timberlake, Chief Executive Officer
	Tel.:	 	(908) 927-9920
	Fax: 	 	(908) 927-9927
	Email:	 	jtimberlake@valeritas.com
	
	With a copy to:
	Morgan, Lewis & Bockius LLP
	502 Carnegie Center
	Princeton, New Jersey 08540-6241
	Attn: Steven M. Cohen
	Main: (609) 919-6604
	Facsimile: (609) 919-6701
	Email: steven.cohen@morganlewis.com
	
	VALERITAS SECURITY CORPORATION
		
	By	 	 

		 	Name:	 	John Timberlake
		 	Title:	 	President
	
	Address for Notices:
	750 Route 202 South, Suite 600
	Bridgewater, NJ 08807
	Attn: 	 	John Timberlake, President
	Tel.: 	 	(908) 927-9920
	Fax: 	 	(908) 927-9927
	Email:	 	jtimberlake@valeritas.com
	
	With a copy to:
	Morgan, Lewis & Bockius LLP
	502 Carnegie Center
	Princeton, New Jersey 08540-6241
	Attn: Steven M. Cohen
	Main: (609) 919-6604
	Facsimile: (609) 919-6701
	Email: steven.cohen@morganlewis.com

  
 [Signature Page to Term
Loan Agreement] 

									
	 LENDERS: 

	
	CAPITAL ROYALTY PARTNERS II L.P.
		 	By CAPITAL ROYALTY PARTNERS II GP L.P., its General Partner
		 		 	By CAPITAL ROYALTY PARTNERS II GP LLC, its General Partner
				
		 		 	By	 	 

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory

  

									
	PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
		 	 By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP L.P., its General Partner

		 		 	By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP LLC, its General Partner
				
		 		 	 By
	 	 

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory

  

							
	CAPITAL ROYALTY PARTNERS II– PARALLEL FUND “A” L.P.
	By CAPITAL ROYALTY PARTNERS II– PARALLEL FUND “A” GP L.P., its General Partner
		 	By CAPITAL ROYALTY PARTNERS II– PARALLEL FUND “A” GP LLC, its General Partner
			
		 	 By
	 	 

		 		 	 Name:
	 	Nathan Hukill
		 		 	 Title:
	 	Authorized Signatory

  
 [Signature Page to Term
Loan Agreement] 

									
	CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.
		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP L.P., its General Partner
		 		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP LLC, its General Partner
				
		 		 	 By
	 	 

					
		 		 		 	 Name:
	 	Nathan Hukill
		 		 		 	 Title:
	 	Authorized Signatory
					
		 		 		 	 WITNESS:
	 	 

		 		 		 	 Name:
	 	Nicole Nesson
	
	CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “B” (CAYMAN) L.P.
		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP L.P., its General Partner
		 		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP LLC its General Partner
				
		 		 	 By
	 	 

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory

							
			
		 	WITNESS:	 	 

		 	Name:	 	Nicole Nesson

  

					
	Address for Notices:
	1000 Main Street, Suite 2500
	Houston, TX 77002
	Attn: 	 	General Counsel
	Tel.: 	 	713.209.7350
	Fax: 	 	713.209.7351
	Email:	 	adorenbaum@crglp.com

  
 [Signature Page to Term
Loan Agreement] 

 Schedule 1 

to Term Loan Agreement 

COMMITMENT/OUTSTANDING LOANS 
  

									
	 Lender
	  	Commitment/Outstanding
Loans	 	  	Proportionate
Share	 
	 Capital Royalty Partners II L.P.
	  	$	5,450,000	  	  	 	10.9	% 
	 Capital Royalty Partners II – Parallel Fund “A” L.P.
	  	$	6,150,000	  	  	 	12.3	% 
	 Parallel Investment Opportunities Partners II L.P.
	  	$	10,000,000	  	  	 	20	% 
	 Capital Royalty Partners II (Cayman) L.P.
	  	$	1,950,000	  	  	 	3.9	% 
	 Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P.
	  	$	26,450,000	  	  	 	52.9	% 
		  	  
	  
	 	  	  
	  
	 
	 TOTAL
	  	$	50,000,000	  	  	 	100	% 
		  	  
	  
	 	  	  
	  
	 

 Schedule 7.05(b) 

to Term Loan Agreement 

CERTAIN INTELLECTUAL PROPERTY 

PATENTS AND PATENT APPLICATIONS 

Valeritas Security Corporation Patents and Patent Applications: None 

Valeritas, Inc. Patents and Patent Applications: 
  

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-002	 	US	 	Injection Devices	 		 		 	60/112,805	 	18-Dec-98	 	expired	 		 	
	VALT-002-101	 	US	 	Injection Devices	 	60/112,805	 	18-Dec-98	 	09/465,573	 	17-Dec-99	 	granted	 	US 6,406,455 B1	 	18-Jun-02
	VALT-002-102	 	US	 	Injection Devices	 	60/112,805	 	18-Dec-98	 	10/175,541	 	18-Jun-02	 	granted	 	US 6,960,184	 	1-Nov-05
	VALT-002-103	 	US	 	Injection Devices	 	60/112,805	 	18-Dec-98	 	11/063,500	 	22-Feb-05	 	granted	 	US 7,740,607	 	14-Jul-05
	VALT-002-WO1	 	WO	 	Injection Devices	 	60/112,805	 	18-Dec-98	 	PCT/US99/30172	 	17-Dec-99	 	expired	 		 	
	VALT-002-EP1	 	EP	 	Injection Devices	 	60/112,805 & PCT/US99/30172	 	 18-Dec-98

18-Dec-99
	 	99968496.2	 	17-Dec-99	 	granted/validated	 	1144031	 	26-Oct-05
	VALT-002-DE1	 	DE	 	Injection Devices	 	60/112,805 & PCT/US99/30172	 	 18-Dec-98

18-Dec-99
	 	69928012.5	 	17-Dec-99	 	lapsed	 	1144031	 	26-Oct-05
	VALT-003-101	 	US	 	Electroactive Pore	 	60/120,879	 	18-Feb-99	 	09/507,317	 	18-Feb-00	 	granted	 	US 6,314,317 B1	 	6-Nov-01

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-003-102	 	US	 	Electroactive Pore	 	60/120,879	 	18-Feb-99	 	09/878,573	 	11-Jun-01	 	granted	 	US 6.490.483 B2	 	3-Dec-02
	VALT-003-103	 	US	 	Electroactive Pore	 	60/120,879	 	18-Feb-99	 	10/306,767	 	26-Nov-02	 	granted	 	US 7,187,969 B2	 	6-Mar-07
	VALT-003-104	 	US	 	Electroactive Pore	 	60/120,879	 	18-Feb-99	 	11/714,079	 	05-Mar-07	 	abandoned	 		 	
	VALT-003-WO1	 	WO	 	Electroactive Pore	 	60/120,879	 	18-Feb-99	 	PCT/US00/04273	 	18-Feb-00	 	expired	 		 	
	VALT-003-JP1	 	JP	 	Electroactive Pore	 	60/120,879 & PCT/US00/04273	 	 18-Feb-99

18-Feb-00
	 	2000-599456	 	18-Feb-00	 	abandoned	 		 	
	VALT-003-IL1	 	IL	 	Electroactive Pore	 	60/120,879 PCT/US00/04273	 	 18-Feb-99

18-Feb-00
	 	144948	 	18-Feb-00	 	abandoned	 	144948	 	29-May-11
	VALT-003-HK1	 	WO	 	Electroactive Pore	 	60/120,879 PCT/US00/04273 00914640.8	 	 18-Feb-99

18-Feb-00
 18-Feb-00
	 	02102212.6	 	18-Feb-00	 	abandoned	 		 	
	VALT-003-EP1	 	EP	 	Electroactive Pore	 	60/120,879 PCT/US00/04273	 	 18-Feb-99

18-Feb-00
	 	00914640.8	 	18-Feb-00	 	granted	 	1161277	 	11-Oct-06
	VALT-003-DE1	 	DE	 	Electroactive Pore	 	60/120,879 PCT/US00/04273	 	 18-Feb-99

18-Feb-00
	 	00914640.8	 	18-Feb-00	 	validated	 	1161277	 	11-Oct-06
	VALT-003-GB1	 	GB	 	Electroactive Pore	 	60/120,879 PCT/US00/04273	 	 18-Feb-99

18-Feb-00
	 	00194640.8	 	18-Feb-00	 	validated	 	1161277	 	11-Oct-06

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-003-CA1	 	CA	 	Electroactive Pore	 	60/120,879 PCT/US00/04273	 	 18-Feb-99

18-Feb-00
	 	2,362,814	 	18-Feb-00	 	abandoned	 		 	
	VALT-003-AU1	 	AU	 	Electroactive Pore	 	60/120,879 PCT/US00/04273	 	 18-Feb-99

18-Feb-00
	 	36003/00	 	18-Feb-00	 	granted	 	767510	 	26-Feb-04
	VALT-004-001	 	US	 	Needless Injection Syringe	 		 		 	60/174,876	 	7-Jan-00	 	expired	 		 	
	VALT-004-101	 	US	 	Needless Injection Syringe	 	60/174,876	 	7-Jan-00	 	09/755,906	 	5-Jan-01	 	granted	 	US 6,616,627 B2	 	9-Sep-03
	VALT-004-102	 	US	 	Needleless injection Syringe	 	60/174,876	 	7-Jan-00	 	10/658,116	 	8-Sep-03	 	granted	 	US 7,806,867	 	5-Oct-10
	VALT-004-WO1	 	WO	 	Needleless injection Syringe	 	60/174,876	 	7-Jan-00	 	PCT/US01/00346	 	4-Jan-01	 	expired	 		 	
	VALT-004-EP1	 	EP	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	1908589.3	 	4-Jan-01	 	validated/granted	 	1296730	 	16-Mar-11
	VALT-004-DE1	 	DE	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	1908589.3	 	4-Jan-01	 	lapsed	 	60144229.6-08	 	16-Mar-11
	VALT-004-FR1	 	FR	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	1908589.3	 	4-Jan-01	 	lapsed	 	1296730	 	16-Mar-11
	VALT-004-GB1	 	GB	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	1908589.3	 	4-Jan-01	 	lapsed	 	1296730	 	16-Mar-11

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-004-IE1	 	IE	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	1908589.3	 	4-Jan-01	 	lapsed	 	1296730	 	16-Mar-11
	VALT-004-CA1	 	CA	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	2,396,569	 	4-Jan-01	 	lapsed	 	2,396,569	 	23-Mar-10
	VALT-004-AU1	 	AU	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	3644101	 	4-Jan-01	 	lapsed	 	783680	 	9-Mar-06
	VALT-004-AU2	 	AU	 	Needleless injection Syringe	 	60/174,876 PCT/USO1/00346	 	 7-Jan-00
 4-Jan-01
	 	2006200790	 	4-Jan-01	 	lapsed	 	2006200790	 	30-Oct-08
	VALT-007-001	 	US	 	Injection Systems	 		 		 	60/250,537	 	30-Nov-00	 	expired	 		 	
	VALT-007-101	 	US	 	Injection Systems	 	60/250,410 60/250,425 60/250,537 60/250,573	 	30-Nov-00	 	10/001,002	 	14-Nov-02	 	granted	 	US 7,931,614	 	26-Apr-11
	VALT-007-102	 	US	 	Injection Systems	 	same as above	 	same as above	 	09/999,549	 	30-Nov-01	 	abandoned	 		 	
	VALT-007-103	 	US	 	Injection Systems	 	same as above	 	same as above	 	10/007,061	 	30-Nov-01	 	granted	 	US 7,150,409	 	19-Dec-06
	VALT-007-104	 	US	 	Injection Systems	 	same as above	 	same as above	 	13/053,024	 	21-Mar-11	 	granted	 	US 8,500,681	 	06-Aug-2013
	VALT-007-WO1	 	WO	 	Injection Systems	 	same as above	 	same as above	 	PCT/US01/46029	 	30-Nov-01	 	expired	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-007-KR1	 	KR	 	Injection Systems	 	same as above & PCT/US01/46029	 	 30-Nov-00
 30-Nov-01
	 	2003-7007279	 	30-Nov-01	 	abandoned	 		 	
	VALT-007-JP1	 	JP	 	Injection Systems	 	same as above	 	same as above	 	2002-552611	 	30-Nov-01	 	lapsed	 	4434583	 	8-Jan-10
	VALT-007-JP2	 	JP	 	Injection Systems	 	same as above	 	same as above	 	2008-116059	 	30-Nov-01	 	abandoned	 		 	
	VALT-007-JP3	 	JP	 	Injection Systems	 	same as above	 	same as above	 	2009-188071	 	30-Nov-01	 	abandoned	 		 	
	VALT-007-JP4	 	JP	 	Injection Systems	 	same as above	 	same as above	 	2012-207418	 	30-Nov-01	 	granted	 	5525020	 	18-Apr-2014
	VALT-007-EP1	 	EP	 	Injection Systems	 	same as above	 	same as above	 	01994145.9	 	30-Nov-01	 	published	 		 	
	VALT-007-CA1	 	CA	 	Injection Systems	 	same as above	 	same as above	 	2,430,499	 	30-Nov-01	 	granted	 	2,430,499	 	22-May-12
	VALT-007-AU1	 	AU	 	Injection Systems	 	same as above	 	same as above	 	2002246572	 	30-Nov-01	 	abandoned	 		 	
	VALT-007-AU2	 	AU	 	Injection Systems	 	same as above	 	same as above	 	2007202665	 	30-Nov-01	 	lapsed	 	2007202665	 	3-Jun-10
	VALT-013	 	US	 	Sensor System	 		 		 	60/250,295	 	30-Nov-00	 	expired	 		 	
	VALT-020	 	US	 	Injection Devices	 		 		 	60/250,410	 	30-Nov-00	 	expired	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-021	 	US	 	Fluid Delivery Systems and Methods	 		 		 	60/250,413	 	30-Nov-00	 	expired	 		 	
	VALT-019	 	US	 	Injector Safety Lock	 		 		 	60/250,425	 	30-Nov-00	 	expired	 		 	
	VALT-008	 	US	 	Injection Devices	 		 		 	60/250,573	 	30-Nov-00	 	expired	 		 	
	VALT-011-001	 	US	 	Fluid Delivery and Measurement Systems and Methods	 		 		 	60/250,538	 	30-Nov-00	 	expired	 		 	
	VALT-017	 	US	 	Fluid Delivery Device	 		 		 	60/250,403	 	30-Nov-00	 	expired	 		 	
	VALT-016	 	US	 	Fluid Delivery Systems	 		 		 	60/250,408	 	30-Nov-00	 	expired	 		 	
	VALT-014	 	US	 	Electrochemical Cell	 		 		 	60/250,409	 	30-Nov-00	 	expired	 		 	
	VALT-018	 	US	 	Fluid Delivery Systems and Methods	 		 		 	60/250,422	 	30-Nov-00	 	expired	 		 	
	VALT-015	 	US	 	Fluid Delivery Systems and Methods	 		 		 	60/250,927	 	30-Nov-00	 	expired	 		 	
	VALT-011-101	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	60/250,538 60/250,408 60/250/295 60/250,927 60/250,422 60/250,413 60/250,403 60/250,409	 	 30-Nov-00
 24-Sep-01
	 	10/006,526	 	30-Nov-01	 	granted	 	US 6,939,324 B2	 	6-Sep-05

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-011-102	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-00	 	11/219,944	 	6-Sep-05	 	granted	 	US 7,481,792	 	27-Jan-09
	VALT-011-103	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-00	 	12/336,246	 	16-Dec-08	 	granted	 	8,858,511	 	14-Oct-2014
	VALT-011-104	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-00	 	13/743,892	 	17-Jan-2013	 	granted	 	8,992,478	 	31-Mar-2015
	VALT-011- 105US	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-00	 	14/629,801	 	24-Feb-2015	 	Published	 		 	
	VALT-011-WO1	 	WO	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-01	 	PCT/US01/46028	 	30-Nov-01	 	expired	 		 	
	VALT-011-EP1	 	EP	 	Fluid Delivery and Measurement Systems and Methods	 	same as above & PCT/US01/46028	 	 same as above &
 30-Nov-01
	 	01988242.2	 	30-Nov-01	 	granted	 	EP1412017	 	13-Apr-2016
	VALT-011-EP2	 	EP	 	Fluid Delivery and Measurement Systems and Methods	 	same as above & PCT/US01/46028	 	 same as above &
 30-Nov-01
	 	12190927.9	 	30-Nov-01	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-011-EP3	 	EP	 	Fluid Delivery and Measurement Systems and Methods	 	same as above & PCT/US01/46028	 	 same as above &
 30-Nov-01
	 	12190928.7	 	30-Nov-01	 	published	 		 	
	VALT-011-CA1	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,430,590	 	30-Nov-01	 	granted	 	2,430,590	 	14-Aug-2012
	VALT-011-CA2	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,782,501	 	30-Nov-01	 	Granted	 	2,782,501	 	15-Jul-2014
	VALT-011-CA3	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,850,729	 	30-Nov-01	 	pending	 		 	
	VALT-011-CA4	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,850,798	 	30-Nov-01	 	granted	 	2,850,798	 	26-Jan-2016
	VALT-023-001	 	US	 	Microneedle	 		 		 	60/323,417	 	19-Sep-01	 	expired	 		 	
	VALT-023-101	 	US	 	Microneedle, Microneedle arrays, and systems and methods relating to same	 	60/323,417	 	19-Sep-01	 	10/251,480	 	19-Sep-02	 	published	 		 	
	VALT-023-WO1	 	WO	 	Microneedle, Microneedle arrays, and systems and methods relating to same	 	60/323,417	 	19-Sep-01	 	PCT/US02/29913	 	19-Sep-02	 	expired	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-025	 	US	 	Microneedle systems and methods relating to same	 		 		 	60/323,852	 	21-Sep-01	 	expired	 		 	
	VALT-025-101	 	US	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,852	 	21-Sep-01	 	10/252,739	 	23-Sep-02	 	published	 		 	
	VALT-025-WO1	 	WO	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,417	 	19-Sep-01	 	PCT/US02/30117	 	23-Sep-02	 	expired	 		 	
	VALT-025-EP1	 	EP	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,417 & PCT/US02/30117	 	 19-Sep-01
 23-Sep-02
	 	02766341.8	 	23-Sep-02	 	granted	 	1471953	 	16-Feb-11
	VALT-025-CA1	 	CA	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,417 & PCT/US02/30117	 	 19-Sep-01
 23-Sep-02
	 	2,499,838	 	23-Sep-02	 	Granted	 	2,499,838	 	18-Dec-12
	VALT-025-FR1	 	FR	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,417 & PCT/US02/30117	 	 19-Sep-01
 23-Sep-02
	 	02766341.8	 	23-Sep-02	 	Granted	 	1471953	 	16-Feb-11

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-025-DE1	 	DE	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,417 & PCT/US02/30117	 	 19-Sep-01
 23-Sep-02
	 	02766341.8	 	23-Sep-02	 	Granted	 	1471953	 	 16-Feb-11

	VALT-025-IE1	 	IE	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,417 & PCT/US02/30117	 	 19-Sep-01
 23-Sep-02
	 	02766341.8	 	23-Sep-02	 	Granted	 	1471953	 	16-Feb-11
	VALT-025-GB1	 	GB	 	Gas Pressure Actuated Microneedle Arrays, and Systems and methods relating to same	 	60/323,417 & PCT/US02/30117	 	 19-Sep-01
 23-Sep-02
	 	02766341.8	 	23-Sep-02	 	Granted	 	1471953	 	16-Feb-11
	VALT-027-001	 	US	 	Stacked Microneedle Systems	 		 		 	60/174,023	 	30-Dec-99	 	expired	 		 	
	VALT-027-101	 	US	 	Stacked Microneedle Systems	 	60/174,023	 	30-Dec-99	 	09/747,768	 	22-Dec-00	 	abandoned	 		 	
	VALT-027-WO1	 	WO	 	Stacked Microneedle Systems	 	60/174,023	 	30-Dec-99	 	PCT/US00/35144	 	22-Dec-00	 	expired	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-027-EP1	 	EP	 	Stacked Microneedle Systems	 	60/174,023 & PCT/US00/35144	 	 30-Dec-99
 22-Dec-00
	 	00990324.6	 	22-Dec-00	 	Withdrawn/TBA	 		 	
	VALT-027-CA1	 	CA	 	Stacked Microneedle Systems	 	60/174,023 & PCT/US00/35144	 	 30-Dec-99
 22-Dec-00
	 	2,396,767	 	22-Dec-00	 	abandoned	 		 	
	VALT-027-AU1	 	AU	 	Stacked Microneedle Systems	 	60/174,023 & PCT/US00/35144	 	 30-Dec-99
 22-Dec-00
	 	27365/01	 	22-Dec-00	 	abandoned	 		 	
	VALT-027-AU2	 	AU	 	Stacked Microneedle Systems	 	60/174,023 & PCT/US00/35144	 	 30-Dec-99
 22-Dec-00
	 	2005222551	 	22-Dec-00	 	abandoned	 		 	
	VALT-027-AU3	 	AU	 	Stacked Microneedle Systems	 	60/174,023 & PCT/US00/35144	 	 30-Dec-99
 22-Dec-00
	 	2009201331	 	22-Dec-00	 	abandoned	 		 	
	VALT-028-001	 	US	 	Microneedle Adapter	 		 		 	60/247,571	 	9-Nov-00	 	expired	 		 	
	VALT-028-101	 	US	 	Microneedle Adapter	 	60/247,571	 	9-Nov-00	 	09/992,656	 	6-Nov-01	 	abandoned	 		 	
	VALT-028-102	 	US	 	Microneedle Adapter	 	60/247,571	 	9-Nov-00	 	10/412,384	 	11-Apr-03	 	abandoned	 		 	
	VALT-028-103	 	US	 	Microneedle Adapter	 	60/247,571	 	9-Nov-00	 	11/997,158	 	22-Oct-07	 	abandoned	 		 	
	VALT-028-WO1	 	WO	 	Microneedle Adapter	 	60/247,571	 	9-Nov-00	 	PCT/US01/46845	 	8-Nov-01	 	published	 		 	
	VALT-029-001	 	US	 	Microneedle Array System	 		 		 	60/257,757	 	21-Dec-00	 	expired	 		 	
	VALT-029-101	 	US	 	Microneedle Array System	 	60/257,757	 	21-Dec-00	 	10/027,115	 	20-Dec-01	 	granted	 	US 7,027,478 B2	 	11-Apr-06

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-029-0WO1	 	WO	 	Microneedle Array System	 	60/257,757	 	21-Dec-00	 	PCT/US01/49797	 	20-Dec-01	 	expired	 		 	
	VALT-030-001	 	US	 	Microneedle Array with Switch	 		 		 	60/325,522	 	28-Sep-01	 	expired	 		 	
	VALT-030-101	 	US	 	Switchable Microneedle Arrays and Systems and Methods relating to same	 	60/325,522	 	28-Sep-01	 	10/260,711	 	30-Sep-02	 	abandoned	 		 	
	VALT-030-102	 	US	 	Switchable Microneedle Arrays and Systems and Methods relating to same	 	60/325,522	 	28-Sep-01	 	11/975,353	 	18-Oct-07	 	abandoned	 		 	
	VALT-030-WO1	 	WO	 	Switchable Microneedle Arrays and Systems and Methods relating to same	 	60/325,522	 	28-Sep-01	 	PCT/US02/30993	 	30-Sep-02	 	expired	 		 	
	VALT-030-EP1	 	EP	 	Switchable Microneedle Arrays and Systems and Methods relating to same	 	60/325,522	 	28-Sep-01	 	02780401.2	 	30-Sep-02	 	abandoned	 		 	
	VALT-030-CA1	 	CA	 	Switchable Microneedle Arrays and Systems and Methods relating to same	 	60/325,522	 	28-Sep-01	 	2,500,452	 	30-Sep-02	 	abandoned	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-031-001	 	US	 	Fluid Delivery Systems and Methods	 		 		 	60/324,412	 	24-Sep-01	 	expired	 		 	
	VALT-032-001	 	US	 	Microneedle with Membrane	 		 		 	60/325,736	 	28-Sep-01	 	expired	 		 	
	VALT-032-101	 	US	 	Microneedle with Membrane	 	60/325,736	 	28-Sep-01	 	10/261,093	 	30-Sep-02	 	abandoned	 		 	
	VALT-032-102	 	US	 	Microneedle with Membrane	 	60/325,736	 	28-Sep-01	 	10/993,927	 	19-Nov-04	 	abandoned	 		 	
	VALT-032-103	 	US	 	Microneedle with Membrane	 	60/325,736	 	28-Sep-01	 	12/152,138	 	12-May-08	 	pending	 		 	
	VALT-032-WO1	 	WO	 	Microneedle with Membrane	 	60/325,736	 	28-Sep-01	 	PCT/US02/31153	 	30-Sep-02	 	expired	 		 	
	VALT-032-EP1	 	EP	 	Microneedle with Membrane	 	60/325,736 & PCT/US02/31153	 	 28-Sep-01
 30-Sep-02
	 	02773681.8	 	30-Sep-02	 	withdrawn	 		 	
	VALT-032-CA1	 	CA	 	Microneedle with Membrane	 	60/325,736 & PCT/US02/31153	 	 28-Sep-01
 30-Sep-02
	 	2,500,453	 	30-Sep-02	 	abandoned	 		 	
	VALT-034-001	 	US	 	Microneedle Array Patch	 		 		 	60/416,740	 	7-Oct-02	 	expired	 		 	
	VALT-034-101	 	US	 	Microneedle Array Patch	 	60/416,740	 	7-Oct-02	 	10/681,777	 	7-Oct-03	 	abandoned	 		 	
	VALT-034-102	 	US	 	Microneedle Array Patch	 	60/416,740	 	7-Oct-02	 	11/975,717	 	19-Oct-07	 	granted	 	8,162,901	 	24-Apr-12
	VALT-034-EP1	 	EP	 	Microneedle Array Patch	 	60/416,740 & PCT/US03/31847	 	 7-Oct-02
 7-Oct-03
	 	03808167.5	 	7-Oct-03	 	granted	 	1590034	 	14-May-14
	VALT-034-DE1	 	DE	 	Microneedle Array Patch	 	60/416,740 & PCT/US03/31847	 	 7-Oct-02
 7-Oct-03
	 	03808167.5	 	7-Oct-03	 	granted	 	1590034	 	14-May-14

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-034-FR1	 	FR	 	Microneedle Array Patch	 	60/416,740 & PCT/US03/31847	 	 7-Oct-02
 7-Oct-03
	 	03808167.5	 	7-Oct-03	 	granted	 	1590034	 	14-May-14
	VALT-034-WO1	 	WO	 	Microneedle Array Patch	 	60/416,740	 	7-Oct-02	 	PCT/US03/31847	 	7-Oct-03	 	expired	 		 	
	VALT-035-001	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 		 		 	60/465,070	 	23-Apr-03	 	expired	 		 	
	VALT-035-101	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	10/831,354	 	23-Apr-04	 	granted	 	US 7,530,968	 	12-May-09
	VALT-035-102	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	12/336,363	 	16-Dec-08	 	granted	 	8,070,726	 	06-Dec-2011
	VALT-035-103	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	12/336,395	 	16-Dec-08	 	granted	 	9,072,828	 	07-Jul-2015
	VALT-035-104	 	US	 	Hydraulically Actuated Pump For Fluid Administration	 	60/465,070	 	23-Apr-03	 	12/762,307	 	17-Apr-10	 	granted	 	9,125,983	 	08-Sep-2015

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-035-105	 	US	 	Hydraulically Actuated Pump For Fluid Administration	 	60/465,070	 	23-Apr-03	 	14/809,436	 	27-Jul-2015	 	published	 		 	
	VALT-035-WO1	 	WO	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	PCT/US04/12797	 	23-Apr-04	 	expired	 		 	
	VALT-035-EP1	 	EP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	04760179.4	 	23-Apr-04	 	published	 		 	
	VALT-035-JP1	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2006-513327	 	23-Apr-04	 	granted	 	4565193	 	13-Aug-10
	VALT-035-JP2	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2009-44928	 	23-Apr-04	 	abandoned	 		 	
	VALT-035-JP3	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2012-249271	 	23-Apr-04	 	granted	 	5550155	 	30-May-14
	VALT-035-JP2	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2012-249272	 	23-Apr-04	 	abandoned	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-035-JP5	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2014-255376	 	23-Apr-04	 	published	 		 	
	VALT-035-JP6	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2014-255377	 	23-Apr-04	 	published	 		 	
	VALT-035-CA1	 	CA	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2,523,267	 	23-Apr-04	 	granted	 	2,523,267	 	03-Sep-13
	VALT-035-CA2	 	CA	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2,820,537	 	23-Apr-04	 	granted	 	2,820,537	 	20-Oct-2015
	VALT-035-AU1	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2004232858	 	23-Apr-04	 	granted	 	2004232858	 	22-Oct-09
	VALT-035-AU2	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2009202856	 	23-Apr-04	 	granted	 	2009202856	 	21-Jun-12

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-035-AU3	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2012201924	 	23-Apr-04	 	granted	 	2012201924	 	18-Jun-2015
	VALT-035-AU4	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	2015207890	 	23-Apr-04	 	pending	 		 	
	VALT-037-101	 	US	 	Methods and Devices for Delivering Agents Across Biological Barriers	 		 		 	11/198,024	 	5-Aug-05	 	abandoned	 		 	
	VALT-037-102	 	US	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024	 	5-Aug-05	 	12/414,330	 	30-Mar-09	 	published	 		 	
	VALT-037-103	 	US	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024	 	5-Aug-05	 	12/617,566	 	12-Nov-09	 	published	 		 	
	VALT-037-AU1	 	AU	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	2006278258	 	7-Aug-06	 	Granted	 	2006278258	 	28-Jun-12

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-037-CA1	 	CA	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	2,659,785	 	7-Aug-06	 	Granted	 	2,659,785	 	30-Jul-2013
	VALT-037-JP1	 	JP	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	2008-525284	 	7-Aug-06	 	published	 		 	
	VALT-037-EP1	 	EP	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	6801016.4	 	7-Aug-06	 	published	 		 	
	VALT-037-WO1	 	WO	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024	 	5-Aug-05	 	PCT/US06/030981	 	7-Aug-06	 	expired	 		 	
	VALT-037-AU2	 	AU	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	2012203204	 	7-Aug-06	 	Granted	 	2012203204	 	15-May-2014
	VALT-037-CA2	 	CA	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	2,817,035	 	7-Aug-06	 	Pending	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-037-EP2	 	EP	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	12177394.9	 	7-Aug-06	 	published	 		 	
	VALT-037-JP2	 	JP	 	Methods and Devices for Delivering Agents Across Biological Barriers	 	11/198,024 & PCT/US06/030981	 	 5-Aug-05 &
 07-Aug-06
	 	2013-000238	 	7-Aug-06	 	published	 		 	
	VALT-038-001	 	US	 	Methods and Devices for Delivering GLP-1 and Uses Thereof	 		 		 	60/585,330	 	2-Jul-04	 	expired	 		 	
	VALT-038-101	 	US	 	Methods and Devices for Delivering GLP-1 and Uses Thereof	 	60/585,330	 	2-Jul-04	 	11/175,990	 	5-Jul-05	 	granted	 	9,089,636	 	28-Jul-2015
	VALT-038-102	 	US 	 	Methods and Devices for Delivering GLP-1 and Uses Thereof	 	60/585,330	 	2-Jul-04	 	14/739,920	 	15-Jun-2015	 	published	 		 	
	VALT-038-WO1	 	WO	 	Methods and Devices for Delivering GLP-1 and Uses Thereof	 	60/585,330	 	2-Jul-04	 	PCT/US05/023818	 	5-Jul-05	 	expired	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-US1-1000	 	US	 	Multi-Cartridge Fluid Delivery Device	 		 		 	60/787,616	 	30-Mar-06	 	expired	 		 	
	VALT-WO1-1000	 	WO	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616	 	30-Mar-06	 	PCT/US07/065363	 	28-Mar-07	 	Expired/nationalized	 		 	
	VALT-AU1-1000	 	AU	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2007233231	 	28-Mar-07	 	granted	 	2007233231	 	9-Jun-11
	VALT-AU2-1000	 	AU	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2011201473	 	28-Mar-07	 	granted	 	2011201473	 	22-Aug-2013
	VALT-AU3-1000	 	 AU
	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2013231047	 	28-Mar-07	 	granted	 	2013231047	 	25-Jun-2015
	VALT-AU4-1000	 	AU	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2015207984	 	28-Mar-07	 	pending	 		 	
	VALT-CA1-1000	 	CA	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2,646,324	 	28-Mar-07	 	allowed	 		 	
	VALT-CN1-1000	 	CN	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	200780020245.9	 	28-Mar-07	 	granted	 	ZL200780020245.9	 	19-Jun-2013
	VALT-CN2-1000	 	CN	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	201310119427.9	 	28-Mar-07	 	published	 	ZL201310119427.9	 	26-Aug-2015
	VALT-EP1-1000	 	EP	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	07759578.3	 	28-Mar-07	 	granted	 	EP2005309	 	17-Feb-2016

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-EP2-1000	 	EP	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	15182150.1	 	28-Mar-07	 	pending	 		 	
	VALT-HK1-1000	 	HK	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	09105477.2	 	28-Mar-07	 	abandoned	 		 	
	VALT-IL1-1000	 	IL	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	194452	 	28-Mar-07	 	abandoned	 		 	
	VALT-IL2-1000	 	IL	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	232412	 	28-Mar-07	 	pending	 		 	
	VALT-IN1-1000	 	IN	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	8997/DELNP/2008	 	28-Mar-07	 	published	 		 	
	VALT-JP1-1000	 	JP	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2009-503245	 	28-Mar-07	 	abandoned	 		 	
	VALT-JP2-1000	 	JP	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2012-255233	 	28-Mar-2007	 	granted	 	5650709	 	21-Nov-2014
	VALT-KR1-1000	 	KR	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	10-2008-7026677	 	28-Mar-07	 	granted	 	10-1361376	 	04-Feb-2014
	VALT-RU1-1000	 	RU	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	2008143015	 	28-Mar-07	 	granted	 	2438719	 	10-Jan-2012

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-SG1-1000	 	SG	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	200807302-5	 	28-Mar-07	 	abandoned	 	146773	 	31-Aug-2011
	VALT-SG2-1000	 	SG	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616 & PCT/US07/065363	 	 30-Mar-06
 28-Mar-07
	 	201104696-8	 	28-Mar-2007	 	granted	 	173319	 	06-May-2015
	VALT-US1-1000	 	US	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616	 	30-Mar-06	 	12/295,173	 	29-Sep-08	 	granted	 	US 7,914,499	 	29-Mar-11
	VALT-102-1000	 	US	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616	 	30-Mar-06	 	13/013,379	 	25-Jan-11	 	granted	 	US 8,361,053	 	29-Jan-2013
	VALT-US3-1000	 	US	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616	 	30-Mar-06	 	13/719,481	 	19-Dec-2012	 	granted	 	US 8,821,443	 	02-Sep-2014
	VALT-US4-1000	 	US	 	Multi-Cartridge Fluid Delivery Device	 	60/787,616	 	30-Mar-06	 	14/341,879	 	28-Jul-2014	 	published	 		 	
	VALT-110-001	 	US	 	Microneedle Patch Applicator	 		 		 	61/426,199	 	22-Dec-10	 	expired	 		 	
	VALT-110-101	 	US	 	Microneedle Patch Applicator	 	61/426,199	 	22-Dec-10	 	13/332,065	 	20-Dec-11	 	Granted	 	8,540,672	 	24-Sep-2013
	VALT-110-102	 	US	 	Microneedle Patch Applicator	 	61/426,199 & 13/332,065	 	 22-Dec-10 &
 20-Dec-11
	 	13/972,442	 	21-Aug-13	 	Granted	 	8,734,395	 	27-May-2014
	VALT-110-103	 	US	 	Microneedle Patch Applicator	 	61/426,199 & 13/332,065	 	 22-Dec-10 &
 20-Dec-11
	 	13/972,460	 	21-Aug-13	 	Published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-110-WO1	 	PCT	 	Microneedle Patch Applicator	 	61/426,199	 	22-Dec-10	 	PCT/US2011/066248	 	20-Dec-11	 	Expired	 		 	
	VALT-110-AU1	 	AU	 	Microneedle Patch Applicator	 	61/426,199 & PCT/US2011/066248	 	 22-Dec-10 &
 20-Dec-11
	 	2011349277	 	20-Dec-11	 	pending	 		 	
	VALT-110-CA1	 	CA	 	Microneedle Patch Applicator	 	61/426,199 & PCT/US2011/066248	 	 22-Dec-10 &
 20-Dec-11
	 	2,822,428	 	20-Dec-11	 	pending	 		 	
	VALT-110-EP1	 	EP	 	Microneedle Patch Applicator	 	61/426,199 & PCT/US2011/066248	 	 22-Dec-10 &
 20-Dec-11
	 	11850496.8	 	20-Dec-11	 	Published	 		 	
	VALT-110-JP1	 	JP	 	Microneedle Patch Applicator	 	61/426,199 & PCT/US2011/066248	 	 22-Dec-10 &
 20-Dec-11
	 	2013-546336	 	20-Dec-11	 	pending	 		 	
	VALT-1001-100	 	US	 	Fluid Transfer Device and Method of Use	 		 		 	61/175,329	 	4-May-09	 	expired	 		 	
	VALT-1001-101	 	US	 	Fluid Transfer Device	 	61/175,329	 	04-May-09	 	12/773,679	 	4-May-10	 	granted	 	US 8,667,996	 	11-Mar-2014
	VALT-1001-102	 	US	 	Fluid Transfer Device	 	61/175,329	 	04-May-09	 	14/156,514	 	16-Jan-2014	 	allowed	 		 	
	VALT-1001-201	 	US	 	Fluid Transfer Device-Design	 		 		 	29/361,753	 	14-May-10	 	granted	 	D667946	 	25-Sep-2012
	VALT-1001-202	 	US	 	Fluid Transfer Device-Design	 	29/361,753	 	14-May-10	 	29/428,565	 	01-Aug-2012	 	granted	 	D687948	 	13-Aug-2013
	VALT-1001-203	 	US	 	Fluid Transfer Device-Design	 	29/361,753	 	14-May-10	 	29/458,166	 	17-Jun-2013	 	granted	 	D706415	 	03-Jun-2014

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1001-CN1	 	CN	 	Fluid Transfer Device-Design	 	29/361,753	 	14-May-10	 	201030616664.3	 	12-Nov-10	 	granted	 	ZL201030616664.3	 	19-Oct-2011
	VALT-1001-CA1	 	CA	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	2,760,641	 	4-May-10	 	pending	 		 	
	VALT-1001-CN1	 	CN	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	201080029611.9	 	4-May-10	 	granted	 	ZL201080029611.9	 	25-Jun-14
	VALT-1001-CN2	 	CN	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	201410204112.9	 	4-May-10	 	published	 		 	
	VALT-1001-EP1	 	EP	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	10772721.6	 	4-May-10	 	published	 		 	
	VALT-1001-HK1	 	HK	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	12108444.1	 	4-May-10	 	published	 		 	
	VALT-1001-IN1	 	IN	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	8394/DELNP/2011	 	4-May-10	 	published	 		 	
	VALT-1001-JP1	 	JP	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	2012-508830	 	4-May-10	 	granted	 	5645278	 	14-Nov-2014
	VALT-1001-JP2	 	JP	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	2014-87852	 	4-May-10	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1001-KR1	 	KR	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	10-2011-7028818	 	4-May-10	 	published	 		 	
	VALT-1001-101	 	US	 	Fluid Transfer Device	 	61/175,329	 	04-May-09	 	12/773,679	 	4-May-10	 	granted	 	8,667,996	 	11-Mar-2014
	VALT-1001-102	 	US	 	Fluid Transfer Device	 	61/175,329	 	04-May-09	 	14/156,514	 	16-Jan-2014	 	published	 		 	
	VALT-1001-WO1	 	WO	 	Fluid Transfer Device	 	61/175,329	 	04-May-09	 	PCT/US10/33590	 	4-May-10	 	Expired/nationalized	 		 	
	 VALT-107-001
	 	 US
	 	 Fluid Delivery Device
	 		 		 	 61/251,236
	 	 13-Oct-09
	 	 expired
	 		 	
	VALT-107-002	 	US	 	Fluid Delivery Device	 		 		 	61/325,136	 	16-Apr-10	 	expired	 		 	
	VALT-107-AU	 	AU	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	2010307002	 	12-Oct-2010	 	granted	 	2010307002	 	21-Aug-2014
	VALT-107-AU2	 	AU	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	2014202952	 	12-Oct-2010	 	granted	 	2014202952	 	27-Aug-2015
	VALT-107-AU3	 	AU	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	2015202656	 	12-Oct-2010	 	pending	 		 	
	VALT-107-CA	 	CA	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	2,776,397	 	12-Oct-2010	 	allowed	 		 	
	VALT-107-CN	 	CN	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	201080046063.0	 	12-Oct-2010	 	granted	 	ZL201080046063.0	 	17-Dec-2014

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-107-CN2	 	CN	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	201410634901.6	 	12-Oct-2010	 	published	 		 	
	VALT-107-CN3	 	CN	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	201410635389.7	 	12-Oct-2010	 	published	 		 	
	VALT-107-CN4	 	CN	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	201410634903.5	 	12-Oct-2010	 	published	 		 	
	VALT-107-EP	 	EP	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	10823957.5	 	12-Oct-2010	 	published	 		 	
	VALT-107-HK	 	HK	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	13102796.7	 	12-Oct-2010	 	granted	 	HK1175725B	 	23-Oct-2015
	VALT-107-IL	 	IL	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	218554	 	12-Oct-2010	 	allowed	 		 	
	VALT-107-IN	 	IN	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	2600/DELNP/2012	 	12-Oct-2010	 	pending	 		 	
	VALT-107-JP	 	JP	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	2012-534285	 	12-Oct-2010	 	granted	 	5748299	 	22-May-2015
	VALT-107-JP1	 	JP	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	2015-20930	 	12-Oct-2010	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-107-KR	 	KR	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	10-2012-7008581	 	12-Oct-2010	 	published	 		 	
	VALT-107-SG	 	SG	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	201201782-8	 	12-Oct-2010	 	granted	 	179126	 	28-Nov-2014
	VALT-107-101	 	US	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	13/500,136	 	04-Apr-2012	 	granted	 	9,101,706	 	11-Aug-2015
	VALT-107-102	 	US	 	Fluid Delivery Device	 	61/251,236 PCT/US10/52352	 	 13-Oct-09
 12-Oct-10
	 	14/790,044	 	02-Jul-2015	 	published	 		 	
	VALT-107-WO1	 	WO	 	Fluid Delivery Device	 	61/251,236	 	13-Oct-09	 	PCT/US10/52352	 	12-Oct-10	 	Expired/nationalized	 		 	
	VALT-025-CA1	 	CA	 	Gas Pressure Actuated Microneedle Arrays, and Systems and Methods Relating to Same	 		 		 	2,499,838	 	23-Sep-02	 	abandoned	 		 	
	VALT-1002-AU1	 	AU	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	2011264825	 	09-Jun-2011	 	granted	 	2011264825	 	19-Feb-2015

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1002-AU2	 	AU	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	2014277752	 	09-Jun-2011	 	pending	 		 	
	VALT-1002CA1	 	CA	 	same as above	 	61/353,004	 	09-Jun-10	 	2,799,784	 	09-Jun-2011	 	pending	 		 	
	VALT-1002CN1	 	CN	 	same as above	 	61/353,004	 	09-Jun-10	 	201180028239.4	 	09-Jun-2011	 	granted	 	ZL201180028239.4	 	19-Aug-2015
	VALT-1002CN2	 	CN	 	same as above	 	61/353,004	 	09-Jun-10	 	201510422211.9	 	09-Jun-2011	 	published	 		 	
	VALT-1002CN3	 	CN	 	same as above	 	61/353,004	 	09-Jun-10	 	201510422237.3	 	09-Jun-2011	 	published	 		 	
	VALT-1002EP1	 	EP	 	same as above	 	61/353,004	 	09-Jun-10	 	11793149.3	 	09-Jun-2011	 	published	 		 	
	VALT-1002IL1	 	IL	 	same as above	 	61/353,004	 	09-Jun-10	 	222801	 	09-Jun-2011	 	allowed	 		 	
	VALT-1002IN1	 	IN	 	same as above	 	61/353,004	 	09-Jun-10	 	11298/DELNP/2012	 	09-Jun-2011	 	published	 		 	
	VALT-1002JP1	 	JP	 	same as above	 	61/353,004	 	09-Jun-10	 	2013-514364	 	09-Jun-2011	 	granted	 	5809258	 	18-Sep-2015
	VALT-1002JP2	 	JP	 	same as above	 	61/353,004	 	09-Jun-10	 	2015-178414	 	09-Jun-2011	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1002KR1	 	KR	 	same as above	 	61/353,004	 	09-Jun-10	 	10-2013-7000391	 	09-Jun-2011	 	pending	 		 	
	VALT-1002SG1	 	SG	 	same as above	 	61/353,004	 	09-Jun-10	 	201208331-7	 	09-Jun-2011	 	granted	 	185534	 	07-Jul-2015
	VALT-1002-001	 	US	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 		 		 	61/353,004	 	9-Jun-10	 	Expired/converted	 		 	
	VALT-1002-101	 	US	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	13/156,839	 	9-Jun-11	 	granted	 	8,740,847	 	03-Jun-2014
	VALT-1002-102	 	US	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	14/259,897	 	23-Apr-2014	 	published	 		 	
	VALT-1002WO1	 	WO	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	PCT/US11/39771	 	9-Jun-11	 	Expired/nationalized	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1003-001	 	US	 	Vented Needle	 		 		 	61/569,642	 	12-Dec-2011	 	Expired/converted	 		 	
	VALT-1003-WO1	 	WO	 	Vented Needle	 	61/569,642	 	12-Dec-2011	 	PCT/US12/69054	 	12-Dec-2012	 	Expired/nationalized	 		 	
	VALT-1003-AU1	 	AU	 	Vented Needle	 	61/569,642 PCT/US12/69054	 	 12-Dec-2011
 12-Dec-2012
	 	2012352470	 	12-Dec-2012	 	pending	 		 	
	VALT-1003-CA1	 	CA	 	Vented Needle	 	61/569,642 PCT/US12/69054	 	 12-Dec-2011
 12-Dec-2012
	 	2,858,722	 	12-Dec-2012	 	abandoned	 		 	
	VALT-1003-CN1	 	CN	 	Vented Needle	 	61/569,642 PCT/US12/69054	 	 12-Dec-2011
 12-Dec-2012
	 	201280060538.0	 	12-Dec-2012	 	abandoned	 		 	
	VALT-1003-EP1	 	EP	 	Vented Needle	 	61/569,642 PCT/US12/69054	 	 12-Dec-2011
 12-Dec-2012
	 	12858115.4	 	12-Dec-2012	 	abandoned	 		 	
	VALT-1003-IN1	 	IN	 	Vented Needle	 	61/569,642 PCT/US12/69054	 	 12-Dec-2011
 12-Dec-2012
	 	4148/DELNP/2014	 	12-Dec-2012	 	published	 		 	
	VALT-1003-JP1	 	JP	 	Vented Needle	 	61/569,642 PCT/US12/69054	 	 12-Dec-2011
 12-Dec-2012
	 	2014-546188	 	12-Dec-2012	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1003-US1	 	US	 	Vented Needle	 	61/569,642 PCT/US12/69054	 	 12-Dec-2011
 12-Dec-2012
	 	14/363,981	 	09-Jun-14	 	published	 		 	
	VALT-1004-001	 	US	 	Infusion Needle Mechanism For A Fluid Delivery Device	 		 		 	61/829,325	 	31-May-2013	 	expired/converted	 		 	
	VALT-1004-WO1	 	WO	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	PCT/US2014/040205	 	30-May-2014	 	published	 		 	
	VALT-1004-AU1	 	AU	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	2014274061	 	30-May-2014	 	pending	 		 	
	VALT-1004-CA1	 	CA	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	2,911,250	 	30-May-2014	 	pending	 		 	
	VALT-1004-CN1	 	CN	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	201480030789.3	 	30-May-2014	 	published	 		 	
	VALT-1004-EP1	 	EP	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	14803383.0	 	30-May-2014	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1004-IN1	 	IN	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	10708/DELNP/2015	 	30-May-2014	 	pending	 		 	
	VALT-1004-JP1	 	JP	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	2016-517035	 	30-May-2014	 	pending	 		 	
	VALT-1005-001	 	US	 	Cartridge Insertion Mechanism For A Fluid Delivery Device	 		 		 	61/857,415	 	23-Jul-2013	 	expired/unconverted	 		 	
	VALT-1005-002	 	US	 	Cartridge Insertion Mechanism For A Fluid Delivery Device	 		 		 	61/918,746	 	20-Dec-2013	 	expired/unconverted	 		 	
	VALT-1004-US1	 	US	 	A Fluid Delivery Device Having An Insertable Prefilled Cartridge	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-2013	 	14/786,009	 	21-Oct-2015	 	published	 		 	
	VALT-1006-001	 	US	 	Infusion Needle For A Fluid Delivery Device	 		 		 	61/923,957	 	06-Jan-2014	 	expired/unconverted	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing

Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1007-001	 	US	 	Piston	 		 		 	61/925,286	 	09-Jan-2014	 	Expired/converted	 		 	
	VALT-1007-002	 	WO	 	Piston	 	61/925,286	 	09-Jan-2014	 	PCT/US2015/010564	 	08-Jan-2015	 	published	 		 	
	VALT-1008-001	 	US	 	Moving Basal Engine For A Fluid Delivery Device	 		 		 	61/934,259	 	31-Jan-2014	 	Expired/converted	 		 	
	VALT-1008-002	 	WO	 	Moving Basal Engine For A Fluid Delivery Device	 	61/934,259	 	31-Jan-2014	 	PCT/US2015/013283	 	28-Jan-2015	 	pending	 		 	
	VALT-1009-001	 	US	 	Cartridge Insertion Mechanism For A Fluid Delivery Device	 		 		 	62/063,979	 	15-Oct-2014	 	Expired/converted	 		 	
	VALT-1009-WO1	 	WO 	 	Cartridge Insertion Mechanism For A Fluid Delivery Device 	 	62/063,979	 	15-Oct-2014	 	 PCT/US2015/055117
	 	 12-Oct-2015
	 	 pending
	 		 	
		 	US	 	NEEDLE Control And Drug Mixing Systems For A Fluid Delivery Device	 		 		 	62/188,464	 	02-Jul-2015	 	pending	 		 	
		 	US	 	Fluid Delivery Monitoring System	 		 		 	62/182,115	 	 19-Jun-2015
	 	pending	 		 	

 TRADEMARKS 

Valeritas Security Corporation Trademarks and Trademark Applications: None 

Valeritas, Inc. Trademarks and Trademark Applications: 
  

																	
	 Mark
	 	 Type
	 	 Serial No.
	 	 Filing Date
	 	 Country
	 	 Status
	 	 Reg. Date
	 	 Reg. No.
	 	 Class

	VALERITAS	 	Standard Character Mark	 	77/752,916	 	5-Jun-2009	 	United States of America	 	Registered	 	21-Feb-2012	 	4,102,741	 	10 Int.
	V-GO DISPOSABLE INSULIN DELIVERY	 	Design Plus Words, Letters, and/or Numbers	 	77/752,697	 	4-Jun-2009	 	United States of America	 	Registered	 	28-Feb-2012	 	4,105,936	 	10 Int. 
	VALERITAS	 	Design Plus Words, Letters, and/or Numbers	 	77/752,695	 	4-Jun-2009	 	United States of America	 	Registered	 	 6-Mar-2012
	 	4,109,207	 	10 Int.
	V-GO	 	Standard Character Mark	 	77/752,694	 	4-Jun-2009	 	United States of America	 	Registered	 	10-Apr-2012	 	4,125,819	 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Australia	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.
	V-GO	 	Standard Character Mark	 	840260458	 	11-Sep-2012	 	Brazil	 	Published	 		 		 	10 Int.
	V-GO	 	Standard Character Mark	 	1,587,483	 	25-Jul-2012	 	Canada	 	Registered	 	02-Mar-2015	 	TMA897,669	 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	China (People’s Republic)	 	Pending	 		 		 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	European Community	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.
	V-GO	 	Standard Character Mark	 	302324475	 	24-Jul-2012	 	Hong Kong	 	Registered	 	24-Jul-2012	 	302324475	 	10 Int.
	V-GO	 	Standard Character Mark	 	2370294	 	26-Jul-2012	 	India	 	Pending	 		 		 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Israel	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Japan	 	Abandoned	 		 		 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Korea, Republic of	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.

																	
	V-GO	 	Standard Character Mark	 	1,294,519	 	25-Jul-2012	 	Mexico	 	Abandoned	 		 		 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Russian Federation	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Singapore	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.
	V-GO	 	Standard Character Mark	 	2012/21399	 	08-Aug-2012	 	South Africa	 	Registered	 	28-Nov-2014	 	2012/21399	 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Switzerland	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.
	V-GO	 	Standard Character Mark	 	101041558	 	24-Jul-2012	 	Taiwan	 	Registered	 	16-Mar-2013	 	01570123	 	10 Int.
	V-GO	 	Standard Character Mark	 	1130842	 	20-Jul-2012	 	Turkey	 	Registered	 	20-Jul-2012	 	1130842	 	10 Int.
	V-GO (Stylized and/or design)	 	Design Plus Words, Letters, and/or Numbers	 	53700/2013	 	10-Jul-2013	 	Japan	 	Registered	 	07-Mar-2014	 	5654250	 	10 Int.
	V-GO LIFE	 	Standard Character Mark	 	85/666,487	 	02-Jul-2012	 	United States of America	 	Registered	 	04-Mar-2014	 	4,491,871	 	44 Int.
	V-GO	 	Standard Character Mark	 	1,547,240	 	10-Nov-2014	 	Mexico	 	Pending	 		 		 	10 Int.

	
	 U.S. COMMON LAW USE
  

Name/Picture
  

 REGISTERED DOMAIN NAMES 
  

			
	 Domain Name
	  	 Renewal Date

	 clickvgo.com
	  	2/2/2017
	 getyourvgoon.com
	  	1/7/2018
	 go-vgo.com
	  	10/3/2016
	 insulin2go.com
	  	6/27/2016
	 managemytype2.com
	  	6/27/2016
	 simplebasalbolus.com
	  	6/27/2016
	 simpleinsulin.com
	  	6/27/2016
	 v-golife.com
	  	2/2/2017
	 v-gonow.com
	  	2/2/2017
	 vgo-life.com
	  	2/2/2017
	 vgoclick.com
	  	2/2/2017
	 vgoclickit.com
	  	1/11/2018
	 vgoclicks.com
	  	1/11/2018
	 vgolife.com
	  	2/2/2016
	 vgostart.com
	  	1/14/2016
	 vgotraining.com
	  	12/9/2018
	 wearableinsulin.com
	  	3/24/2017
	 valeritas.com
	  	7/21/2015
	 valeritas.net
	  	7/21/2015
	 valeritas.org
	  	1/5/2016
	 vgo-insulin.com
	  	10/3/2015
	 vgo-insulin.net
	  	10/3/2015

 TWITTER ACCOUNTS 

@Valeritas _US 
 @Valeritas _VGo

 @VGo_Insulin 
 @Go_VGo 

 Borrower has been unable to locate the assignments to BioValve Technologies, Inc. for the
following expired provisional patent applications, although all inventor assignments have been obtained with respect to all issued patents: 
  

			
	 Application Number
	  	 Inventor Name

	60/250,409	  	Peter F. Marshall
	60/250,927	  	Peter F. Marshall
	60/250,408	  	Peter F. Marshall
	60/250,403	  	Peter F. Marshall
	60/250,422	  	Peter F. Marshall
	60/250,413	  	Peter F. Marshall

 OPPOSITION PROCEEDINGS 

Valeritas instituted Opposition Proceeding No. 92054171 against VGo Communication’s pending App. Ser. No. 77948481 for the VGO mark in
standard characters. The proceeding is pending. 
 THIRD PARTY PATENTS 

Borrower is aware of U.S. Patent No. 6,629,954, U.S. Patent No. 6,736,795, U.S. Patent 7,938,801 and U.S. Patent No. 5,858,001 and have
obtained written non-infringement and/or invalidity opinions for each of these patents. 

 Schedule 7.05(c) 

to Term Loan Agreement 

MATERIAL INTELLECTUAL PROPERTY 
  

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-011-101	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	60/250,538 60/250,408 60/250/295 60/250,927 60/250,422 60/250,413 60/250,403 60/250,409	 	 30-Nov-00
 24-Sep-01
	 	10/006,526	 	30-Nov-01	 	granted	 	US 6,939,324 B2	 	6-Sep-05
	VALT-011-102	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-00	 	11/219,944	 	6-Sep-05	 	granted	 	US 7,481,792	 	27-Jan-09
	VALT-011-103	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-00	 	12/336,246	 	16-Dec-08	 	granted	 	US 8,858,511	 	14-Oct-14
	VALT-011-104	 	US	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	30-Nov-00	 	13/743,892	 	17-Jan-2013	 	granted	 	US 8,992,478	 	31-Mar-15
	VALT-011-EP1	 	EP	 	Fluid Delivery and Measurement Systems and Methods	 	same as above & PCT/US01/46028	 	 30-Nov-00
 30-Nov-01
	 	01988242.2	 	30-Nov-01	 	allowed	 		 	
	VALT-011-EP2	 	EP	 	Fluid Delivery and Measurement Systems and Methods	 	same as above & PCT/US01/46028	 	 30-Nov-00
 30-Nov-01
	 	12190927.9	 	30-Nov-01	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-011-EP3	 	EP	 	Fluid Delivery and Measurement Systems and Methods	 	same as above & PCT/US01/46028	 	 30-Nov-00
 30-Nov-01
	 	12190928.7	 	30-Nov-01	 	published	 		 	
	VALT- 011-CA1	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,430,590	 	30-Nov- 01	 	granted	 	2,430,590	 	14-Aug-12
	VALT-011-CA2	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,782,501	 	30-Nov-01	 	allowed	 	2,782,501	 	15-July-14
	VALT-011-CA3	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,850,729	 	30-Nov-01	 	pending	 		 	
	VALT-011-CA4	 	CA	 	Fluid Delivery and Measurement Systems and Methods	 	same as above	 	same as above	 	2,850,798	 	30-Nov-01	 	granted	 	2,850,798	 	26-Jan-16
	VALT-035-101	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	10/831,354	 	23-Apr-04	 	granted	 	US 7,530,968	 	12-May-09
	VALT-035-102	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	12/336,363	 	16-Dec-08	 	Granted	 	US 8,070,726	 	06-Dec-11

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-035-103	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	12/336,395	 	16-Dec-08	 	granted	 	US 9,072,828	 	7-Jul-15
	VALT-035-104	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	12/762,307	 	17-Apr-10	 	granted	 	US 9,125,983	 	8-Sep-15
	VALT-035-105	 	US	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070	 	23-Apr-03	 	14/809,436	 	27-Jul-15	 	published	 		 	
	VALT-035-EP1	 	EP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	60/465,070 & PCT/US04/12797	 	 23-Apr-03
 23-Apr-04
	 	04760179.4	 	23-Apr-04	 	pending	 		 	
	VALT-035-JP1	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2006-513327	 	23-Apr-04	 	granted	 	4565193	 	13-Aug-10
	VALT-035-JP2	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2009-44928	 	23-Apr-04	 	abandoned	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-035-JP3	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2012-249271	 	23-Apr-04	 	granted	 	5550155	 	30-May-14
	VALT-035-JP4	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2012-249272	 	23-Apr-04	 	abandoned	 		 	
	VALT-035-JP5	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2014-255376	 	23-Apr-04	 	published	 		 	
	VALT-035-JP6	 	JP	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2014-255377	 	23-Apr-04	 	published	 		 	
	VALT-035-CA1	 	CA	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2,523,267	 	23-Apr-04	 	granted	 	2523267	 	3-Sept-13
	VALT-035-AU1	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2004232858	 	23-Apr-04	 	granted	 	2004232858	 	22-Oct-09

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-035-AU2	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2009202856	 	15-Jul-09	 	granted	 	2009202856	 	5-Jul-12
	VALT-035-AU3	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2012201924	 	02-Apr-12	 	granted	 	2012201924	 	15-Oct-15
	VALT-035-AU4	 	AU	 	Hydraulically Actuated Pump for Long Duration Medicament Administration	 	same as above	 	same as above	 	2015207890	 	24-Jul-09	 	pending	 		 	
	VALT-1001-101	 	US	 	Fluid Transfer Device	 	61/175,329	 	04-May-09	 	12/773,679	 	4-May-10	 	granted	 	8,667,996	 	11-Mar-2014
	VALT-1001-102	 	US	 	Fluid Transfer Device	 	61/175,329	 	04-May-09	 	14/156,514	 	16-Jan-2014	 	allowed	 		 	
	VALT-1001-201	 	US	 	Fluid Transfer Device-Design	 		 		 	29/361,753	 	14-May-10	 	granted	 	D667946	 	25-Sep-2012
	VALT-1001-202	 	US	 	Fluid Transfer Device-Design	 	29/361,753	 	01-Aug-12	 	29/428,565	 	01-Aug-12	 	granted	 	D687948	 	13-Aug-2013
	VALT-1001-203	 	US	 	Fluid Transfer Device-Design	 	29/361,753	 	01-Aug-12	 	29/458,166	 	17-Jun-2013	 	granted	 	D706415	 	03-Jun-2014

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1001-CA1	 	CA	 	Fluid Transfer Device	 	61/175,329 PCT/US10/33590	 	 04-May-09
 04-May-10
	 	2,760,641	 	04-May-10	 	pending	 		 	
	VALT-1001-CN1	 	CN	 	Fluid Transfer Device	 	same as above	 	same as above	 	201080029611.9	 	04-May-10	 	granted	 	ZL201030616664.3	 	19-Oct-11
	VALT-1001-CN2	 	CN	 	Fluid Transfer Device	 	same as above	 	same as above	 	201410204112.9	 	04-May-10	 	granted	 	ZL201080029611.9	 	25-Jun-14
	VALT-1001-EP1	 	EP	 	Fluid Transfer Device	 	same as above	 	same as above	 	10772721.6	 	04-May-10	 	published	 		 	
	VALT-1001-HK1	 	HK	 	Fluid Transfer Device	 	same as above	 	same as above	 	12108444.1	 	04-May-10	 	published	 		 	
	VALT-1001-IN1	 	IN	 	Fluid Transfer Device	 	same as above	 	same as above	 	8394/DELNP/2011	 	04-May-10	 	published	 		 	
	VALT-1001-JP1	 	JP	 	Fluid Transfer Device	 	same as above	 	same as above	 	2012-508830	 	04-May-10	 	granted	 	5645278	 	14-Nov-14
	VALT-1001-JP2	 	JP	 	Fluid Transfer Device	 	same as above	 	same as above	 	2014-87852	 	04-May-10	 	pending	 		 	
	VALT-1001-KR1	 	KR	 	Fluid Transfer Device	 	same as above	 	same as above	 	10-2011-7028818	 	04-May-10	 	published	 		 	
	VALT-107-AU1	 	AU	 	Fluid Delivery Device	 	61/251,236 61/325,136 PCT/US10/52352	 	 13-Oct-09
 16- Apr-10

12-Oct-10
	 	2010307002	 	12-Oct-10	 	granted	 	2010307002	 	21-Aug-14
	VALT-107-AU2	 	AU	 	Fluid Delivery Device	 	61/251,236 61/325,136 PCT/US10/52352	 	 13-Oct-09
 16- Apr-10

12-Oct-10
	 	2014202952	 	12-Oct-10	 	granted	 	2014202952	 	27-Aug-15

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-107-CA	 	CA	 	Fluid Delivery Device	 	same as above	 	same as above	 	2,776,397	 	12-Oct-10	 	allowed	 		 	
	VALT-107-CN1	 	CN	 	Fluid Delivery Device	 	same as above	 	same as above	 	201080046063.0	 	12-Oct-10	 	published	 		 	
	VALT-107-CN2	 	CN	 	Fluid Delivery Device	 	same as above	 	same as above	 	201410634901.6	 	12-Oct-10	 	published	 		 	
	VALT-107-CN3	 	CN	 	Fluid Delivery Device	 	same as above	 	same as above	 	201410635389.7	 	12-Oct-10	 	published	 		 	
	VALT-107-CN4	 	CN	 	Fluid Delivery Device	 	same as above	 	same as above	 	201410634903.5	 	12-Oct-10	 	published	 		 	
	VALT-107-EP	 	EP	 	Fluid Delivery Device	 	same as above	 	same as above	 	10823957.5	 	12-Oct-10	 	published	 		 	
	VALT-107-HK	 	HK	 	Fluid Delivery Device	 	same as above	 	same as above	 	13102796.7	 	12-Oct-10	 	granted	 	HK1175725B	 	23-Oct-15
	VALT-107-IL	 	IL	 	Fluid Delivery Device	 	same as above	 	same as above	 	218554	 	12-Oct-10	 	pending	 		 	
	VALT-107-IN	 	IN	 	Fluid Delivery Device	 	same as above	 	same as above	 	2600/DELNP/2012	 	12-Oct-10	 	pending	 		 	
	VALT-107-JP1	 	JP	 	Fluid Delivery Device	 	same as above	 	same as above	 	2012-534285	 	12-Oct-10	 	published granted	 	5748299	 	22-May-15
	VALT-107-JP2	 	JP	 	Fluid Delivery Device	 	same as above	 	same as above	 	2015-20930	 	12-Oct-10	 		 		 	
	VALT-107-KR	 	KR	 	Fluid Delivery Device	 	same as above	 	same as above	 	10-2012-7008581	 	12-Oct-10	 	published	 		 	
	VALT-107-SG	 	SG	 	Fluid Delivery Device	 	same as above	 	same as above	 	201201782-8	 	12-Oct-10	 	granted	 	179126	 	28-Nov-14

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-107-101	 	US	 	Fluid Delivery Device	 	same as above	 	same as above	 	13/500,136	 	04-Apr-12	 	granted	 	US 9,101,706	 	11-Aug-15
	VALT-1002-101	 	US	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	13/156,839	 	9-Jun-11	 	granted	 	8,740,847	 	03-Jun-2014
	VALT-1002-102	 	US	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	14/259,897	 	23-Apr-2014	 	published	 		 	
	VALT-1002-AU1	 	AU	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	2011264825	 	9-Jun-11	 	granted	 	2011264825	 	25-Feb-15
	VALT-1002-CA1	 	CA	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	2,799,784	 	9-Jun-11	 	pending	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1002-CN1	 	CN	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	201180028239.4	 	9-Jun-11	 	granted	 	ZL201180028239.4	 	19-Aug-15
	VALT-1002-EP1	 	EP	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	11793149.3	 	9-Jun-11	 	published	 		 	
	VALT-1002-IL1	 	IL	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	222801	 	9-Jun-11	 	pending	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1002-IN1	 	IN	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	11298/DELNP/2012	 	9-Jun-11	 	pending	 		 	
	VALT-1002-JP1	 	JP	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	2013-514364	 	9-Jun-11	 	granted	 	5809258	 	18-Sept-15
	VALT-1002-JP2	 	JP	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	2015-178414	 	9-Jun-11	 	published	 		 	
	VALT-1002-KR1	 	10-2013-7000391	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	10-2013-7000391	 	9-Jun-11	 	pending	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1002-SG1	 	SG	 	Fluid Delivery Device Cartridges, Needle Retraction Mechanisms and Expandable Hydraulic Fluid Seals	 	61/353,004	 	09-Jun-10	 	201208331-7	 	9-Jun-11	 	granted	 	185534	 	7-Jul-15
	VALT-1004-001	 	US	 	INFUSION NEEDLE MECHANISM FOR A FLUID DELIVERY DEVICE	 	“61/829,325 61/857,415 61/918,746 61/923,957”	 	31-May-14	 	14/786,009	 	21-Oct-15	 	pending	 		 	
	VALT-1004-AU1	 		 	INFUSION NEEDLE MECHANISM FOR A FLUID DELIVER	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-14	 	2014274061	 	30-May-14	 	pending	 		 	
	VALT-1004-CA1	 	CA	 	INFUSION NEEDLE MECHANISM FOR A FLUID DELIVER	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-14	 		 	30-May-14	 	pending	 		 	
	VALT-1004-CN1	 	CN	 	INFUSION NEEDLE MECHANISM FOR A FLUID DELIVER	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-14	 		 	30-May-14	 	published	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1004-EP1	 	EU	 	INFUSION NEEDLE MECHANISM FOR A FLUID DELIVER	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-14	 	14803383.0	 	30-May-14	 	pending	 		 	
	VALT-1004-IN1	 	IN	 	INFUSION NEEDLE MECHANISM FOR A FLUID DELIVER	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-14	 	10708/DELNP/2015	 	30-May-14	 	pending	 		 	
	VALT-1004-JP1	 	JP	 	INFUSION NEEDLE MECHANISM FOR A FLUID DELIVER	 	61/829,325 61/857,415 61/918,746 61/923,957	 	31-May-14	 	not yet assigned	 	30-May-14	 	pending	 		 	
	VALT-1005-001	 	US	 	Cartridge Insertion Mechanism For A Fluid Delivery Device	 	61/857,415	 	23-Jul-13	 	PCT/US14/40205	 	30-May-14	 	Pending	 		 	
	VALT-1005-002	 	WO	 	Same as above	 	61/857,415	 	20-Dec-13	 	PCT/US14/40205	 	30-May-14	 	pending	 		 	
	VALT-1009-WO1	 	WO	 	Cartridge Insertion Mechanism for a Fluid Delivery Device	 	62/063,979	 	15-Oct-14	 	PCT/US15/55117	 	12-Oct-15	 	pending	 		 	

																			
	 VALT Ref. No.
	 	 Territory
	 	 Invention
	 	 Priority
Application
	 	 Priority Appln.
Filing Date
	 	 Application No.
	 	 Appln. Filing
Date
	 	 Status
	 	 Patent No.
	 	 Issue Date

	VALT-1010-001	 	US	 	Needle Control and Drug Mixing Mechanisms for a Fluid Delivery Device	 	62/188,464	 	2-Jul-15	 		 		 	pending	 		 	
	VALT-1011-001	 	US	 	Fluid Delivery Monitoring System	 	62/182,115	 	19-Jun-15	 		 		 	Pending	 		 	

 Schedule 7.06 

to Term Loan Agreement 

CERTAIN LITIGATION 
 None 

 Schedule 7.12 

to Term Loan Agreement 

INFORMATION REGARDING PARENT SUBSIDIARIES 
  

									
	 Subsidiary
	  	 Jurisdiction of

Organization
	  	 Direct Equity

Holder
	  	Percentage of
Subsidiary held by
Direct Equity Holder	 
	 Valeritas, Inc.
	  	Delaware	  	Valeritas Holdings, Inc.	  	 	100	% 

 INFORMATION REGARDING BORROWER SUBSIDIARIES 

 

									
	 Subsidiary
	  	 Jurisdiction of

Organization
	  	 Direct Equity

Holder
	  	Percentage of
Subsidiary held by
Direct Equity Holder	 
	 Valeritas Security Corporation
	  	Delaware	  	Valeritas, Inc.	  	 	99.99000099990001	% 

 Schedule 7.13(a) 

to Term Loan Agreement 

EXISTING INDEBTEDNESS OF BORROWER AND ITS SUBSIDIARIES 
  

	1.	Amended and Restated Promissory Note, dated May 3, 2015, issued by Valeritas, Inc. to WCAS Capital Partners IV, L.P., in the original principal amount of $5,000,000. 

 Schedule 7.13(b) 

to Term Loan Agreement 

LIENS GRANTED BY THE OBLIGORS 
 None. 

 Schedule 7.14 

to Term Loan Agreement 

MATERIAL AGREEMENTS OF EACH OBLIGOR 
  

	A.	Agreements evidencing or creating any Material Indebtedness: See Schedule 7.13(a). 

  

	B.	Material Agreements: 

 Agreements between the Company and any stockholders, officers, directors and
affiliates. 
  

	 	1.	Employment Agreement, dated February 18, 2016, by and between Valeritas, Inc. and John Timberlake. 

  

	 	2.	Employment Agreement, dated March 23, 2015, by and between Valeritas, Inc. and Matthew Nguyen. 

  

	 	3.	Employment Agreement, dated March 4, 2015, by and between Valeritas, Inc. and Geoffrey Jenkins. 

  

	 	4.	Employment Agreement, dated February 19, 2016, by and between Valeritas, Inc. and Mark Conley 

 Material
Manufacturing and Distribution Agreements: 
  

	 	1.	Manufacturing Services Agreement dated March 22, 2012 by and between the Company and Asia Invest Limited. 

  

	 	•	 	Quality Agreement dated March 23, 2012 

  

	 	•	 	Amendment to Manufacturing Services Agreement dated August 15, 2013. 

  

	 	•	 	Settlement Agreement dated November 1, 2013. 

  

	 	2.	Distribution Services Agreement, dated November 5, 2009, by and between the Company and AmerisourceBergen Drug Corporation and Bellco Drug Corp. 

 

	 	•	 	Amendment to Distribution services Agreement dated February 1, 2014. 

  

	 	3.	Strategic Redistribution Center and Core Distribution Agreement, dated November 6, 2009, by and between the Company and McKesson Corporation. 

 

	 	•	 	Amendment No. 1 to Strategic Redistribution Center and Core Distribution Agreement, dated January 31, 2010, by and between the Company and McKesson Corporation. 

 

	 	•	 	Amendment No. 2 to Strategic Redistribution Center and Core Distribution Agreement, dated November 1, 2011. 

  

	 	4.	Developing Suppliers Program Distribution Services Agreement, dated November 11, 2009, by and between the Company and Cardinal Health. 

 

	 	•	 	Amendment to Developing Suppliers Program Distribution Services Agreement, dated January 1, 2013. 

	 	5.	Distribution Agreement by and between the Company and McKesson Corporation dated January 31, 2010. 

  

	 	6.	Agreement, dated February 4, 2010, by and between the Company and Cardinal Health re: National Logistics Center. 

  

	 	7.	Amendment to Distribution Services Agreement, dated December 1, 2010, by and between the Company and AmerisourceBergen Drug Corporation and Bellco Drug Corp. 

Other Material Agreements 
  

	 	8.	Note, dated September 8, 2011, by and between the Company and WCAS Capital Partners IV, L.P. 

  

	 	9.	Amendment No. 1 to Note, dated May 24, 2013, by and between the Company and WCAS Capital Partners IV, L.P. 

  

	 	10.	Amended and Restated Subordination Agreement, dated as of May 18, 2015, among Capital Royalty Partners II L.P., Parallel Investment Opportunities Partners II, L.P., Capital Royalty Partners II—Parallel Fund
“A” L.P., Capital Royalty Partners II (Cayman) L.P. and Capital Royalty Partners II—Parallel Fund “B” (Cayman) L.P. and WCAS Capital Partners IV, L.P. 

 

	 	11.	Amendment No. 1 to Amended and Restated Subordination Agreement, dated as of September 28, 2015. 

  

	 	12.	Lease, dated October 20, 2009, by and between the Company and BTCT Associates, L.L.C., as amended on January 17, 2013, in respect of the building located at 750 Route 202, Bridgewater, New Jersey 08807.

  

	 	13.	Lease, dated December 22, 2006, by and among Valeritas, LLC, The Taming of the Shrewsbury, LLC, O’Neill Partners, LLC and Chanski, LLC, as amended on April 24, 2009, in respect of the building located at 800 Boston
Turnpike, Shrewsbury, Massachusetts 01545. 

  

	 	14.	Valeritas, Inc. 2014 Incentive Compensation Plan, as amended or restated from time to time. 

  

	 	15.	Agreement and Plan of Merger and Reorganization, dated June 9, 2014, by and among the Company, Valeritas Holdings, LLC and Valeritas Merger Sub, Inc. 

 

	 	16.	Series AB Preferred Stock Purchase Agreement, dated as of September 28, 2015. 

  

	 	17.	First Amendment to the Series AB Preferred Stock Purchase Agreement, dated as of January 29, 2016. 

  

	 	18.	Second Amended and Restated Investors’ Rights Agreement, dated September 28, 2015, by and among the Company, the Investors and the Holdings Investor. 

 

	 	19.	Third Amended and Restated Voting Agreement, dated January 29, 2016, by and among the Company and the stockholder signatories thereto. 

	 	20.	Series D Preferred Stock Purchase Agreement, dated June 23, 2014, as amended. 

  

	 	21.	Series D Preferred Stock Purchase Agreement, dated February 27, 2014. 

  

	 	22.	Letter Agreement, dated June 23, 2014, by and between the Company and Full Succeed International Limited. 

  

	 	23.	Series AA Preferred Stock Purchase Agreement, dated May 18, 2015. 

  

	 	24.	Common Stock Purchase Warrant No. 2014-1, dated August 5, 2014, issued to Capital Royalty Partners II L.P., exercisable for 21,655 shares of common stock. 

 

	 	25.	Common Stock Purchase Warrant No. 2014-2, dated August 5, 2014, issued to Capital Royalty Partners II – Parallel Fund “A” L.P., exercisable for 24,436 shares of common stock. 

 

	 	26.	Common Stock Purchase Warrant No. 2014-3, dated August 5, 2014, issued to Parallel Investment Opportunities Partners II L.P., exercisable for 39,733 shares of common stock. 

 

	 	27.	Common Stock Purchase Warrant No. 2014-4, dated August 5, 2014, issued to Capital Royalty Partners II (Cayman) L.P., exercisable for 7,748 shares of common stock. 

 

	 	28.	Common Stock Purchase Warrant No. 2014-5, dated August 5, 2014, issued to Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P., exercisable for 105,095 shares of common stock. 

 

	 	29.	Common Stock Purchase Warrant No. 2015-1, dated January 2, 2015, issued to Capital Royalty Partners II L.P., exercisable for 3,490 shares of common stock. 

 

	 	30.	Common Stock Purchase Warrant No. 2015-2, dated January 2, 2015, issued to Capital Royalty Partners II – Parallel Fund “A” L.P., exercisable for 3,908 shares of common stock. 

 

	 	31.	Common Stock Purchase Warrant No. 2015-3, dated January 2, 2015, issued to Parallel Investment Opportunities Partners II L.P., exercisable for 6,380 shares of common stock. 

 

	 	32.	Common Stock Purchase Warrant No. 2015-4, dated January 2, 2015, issued to Capital Royalty Partners II (Cayman) L.P., exercisable for 1,233 shares of common stock. 

 

	 	33.	Common Stock Purchase Warrant No. 2015-5, dated January 2, 2015, issued to Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P., exercisable for 16,873 shares of common stock. 

 

	 	34.	Common Stock Purchase Warrant No. 2015-6, dated February 27, 2015, issued to Capital Royalty Partners II L.P., exercisable for 256 shares of common stock. 

 

	 	35.	Common Stock Purchase Warrant No. 2015-7, dated February 27, 2015, issued to Capital Royalty Partners II – Parallel Fund “A” L.P., exercisable for 287 shares of common stock. 

	 	36.	Common Stock Purchase Warrant No. 2015-8, dated February 27, 2015, issued to Parallel Investment Opportunities Partners II L.P., exercisable for 469 shares of common stock. 

 

	 	37.	Common Stock Purchase Warrant No. 2015-9, dated February 27, 2015, issued to Capital Royalty Partners II (Cayman) L.P., exercisable for 91 shares of common stock. 

 

	 	38.	Common Stock Purchase Warrant No. 2015-10, dated February 27, 2015, issued to Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P., exercisable for 1,240 shares of common stock.

  

	 	39.	Series D Preferred Stock Purchase Warrant, dated February 27, 2015, issued to Tabaris Capital, exercisable for 3,750 shares of Series D preferred stock. 

 

	 	40.	Series AB Preferred Stock Purchase Warrant No. 2016-1, dated January 29, 2016, issued to Capital Royalty Partners II (Cayman) L.P., exercisable for 688,000 shares of Series AB preferred stock, of which 435,481 remain
unexercised. 

  

	 	41.	Series AB Preferred Stock Purchase Warrant No. 2016-2, dated January 29, 2016, issued to Capital Royalty Partners II L.P., exercisable for 1,808,000 shares of Series AB preferred stock, of which 1,140,710 remain
unexercised. 

  

	 	42.	Series AB Preferred Stock Purchase Warrant No. 2016-3, dated January 29, 2016, issued to Capital Royalty Partners II – Parallel Fund “A” L.P., exercisable for 2,016,000 shares of Series AB preferred
stock, of which 1,271,420 remain unexercised. 

  

	 	43.	Series AB Preferred Stock Purchase Warrant No. 2016-4, dated January 29, 2016, issued to Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P., exercisable for 8,176,000 shares of Series AB
preferred stock, of which 5,159,330 remain unexercised. 

  

	 	44.	Series AB Preferred Stock Purchase Warrant No. 2016-5, dated January 29, 2016, issued to Parallel Investment Opportunities Partners II L.P., exercisable for 3,312,000 shares of Series AB preferred stock, of which
2,093,059 remain unexercised. 

  

	 	45.	Series AB Preferred Stock Purchase Warrant No. 2016-6, dated February 29, 2016, issued to Tullis Opportunity Fund, L.P., exercisable for 99,261 shares of Series AB preferred stock. 

 

	 	46.	Series AB Preferred Stock Purchase Warrant No. 2016-7, dated February 29, 2016, issued to Tullis Opportunity Fund II, L.P., exercisable for 99,261 shares of Series AB preferred stock. 

 

	 	47.	Series AB Preferred Stock Purchase Warrant No. 2016-8, dated February 29, 2016, issued to Evan Norton, exercisable for 9,553 shares of Series AB preferred stock. 

 

	 	48.	Series AB Preferred Stock Purchase Warrant No. 2016-9, dated February 29, 2016, issued to Elizabeth Gordon, exercisable for 720,762 shares of Series AB preferred stock. 

 Schedule 7.15 

to Term Loan Agreement 

PERMITTED RESTRICTIVE AGREEMENTS 
  

	1.	Amended and Restated Promissory Note, dated May 3, 2015, issued by Valeritas, Inc. to WCAS Capital Partners IV, L.P., in the original principal amount of $5,000,000. 

 Schedule 7.16 

to Term Loan Agreement 
 REAL
PROPERTY OWNED OR LEASED BY BORROWER AND SUBSIDIARIES 
 Leased Real Property 

 

	1.	800 Boston Turnpike, Shrewsbury, Massachusetts. 

  

	2.	750 Route 202 South, Suite 600, Bridgewater, NJ. 

 Schedule 7.17 

to Term Loan Agreement 

PENSION MATTERS 
  

	(a)	Title IV Plans 

  

	 	i.	Valeritas Inc. 401(k) Profit Sharing Plan, as amended. 

  

	 	ii.	Valeritas, Inc. 2014 Incentive Compensation Plan, as amended or restated from time to time. 

  

	(b)	Multiemployer Plans 

 None. 

 

	(c)	Material Benefit Plans 

  

	 	i.	Medical – PPO Plan through Blue Cross & Blue Shield of Massachusetts, Policy No. 2305332 

  

	 	ii.	Medical – HMO Plan through Blue Cross & Blue Shield of Massachusetts, Policy No. 4050078 

  

	 	iii.	Medical – PPO/HSA Plan through Blue Cross & Blue Shield of Massachusetts, Policy No. 2350252 

  

	 	iv.	Dental – Met Life, Policy No. TM-05913564-G 

  

	 	v.	Short Term Disability – Sun Life Insurance Company, Policy No. 211641 

  

	 	vi.	Long Term Disability – Sun Life Insurance Company, Policy No. 211641 

  

	 	vii.	Life (Basic Term and AD&D) - SunLife Insurance Company, Policy No. 211641 

  

	 	viii.	Disability Plan for employees based in New York state – Sun life Insurance Company, Policy No. 820083 

  

	 	ix.	Vision – Vision Service Plan Insurance Company – Policy No. 30043929 

  

	 	x.	Ameriflex Flexible Spending Account Plan 

 Schedule 7.19 

to Term Loan Agreement 

REGULATORY APPROVALS 
 None. 

 Schedule 9.05 

to Term Loan Agreement 

EXISTING INVESTMENTS 
 None. 

 Schedule 9.14 

to Term Loan Agreement 

PERMITTED SALES AND LEASEBACKS 
 None. 

 Exhibit A 

to Term Loan Agreement 
 FORM
OF GUARANTEE ASSUMPTION AGREEMENT 
 GUARANTEE ASSUMPTION AGREEMENT dated as of
[                    ] by [NAME OF ADDITIONAL GUARANTOR], a
                     [corporation][limited liability company] (the “Additional Guarantor”), in favor of Capital Royalty
Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P., Paralleled Investment Opportunities Partners II L.P., Capital Royalty Partners II (Cayman) L.P., and Capital Royalty Partners II – Parallel Fund
“B” (Cayman) L.P., as Lenders (the “Lenders”) under that certain Second Amended and Restated Term Loan Agreement, dated as of May 3, 2016 (as amended, restated, supplemented or otherwise modified, renewed,
refinanced or replaced, the “Loan Agreement”), among Valeritas, Inc., a Delaware corporation (“Borrower”), the lenders party thereto and the Guarantors party thereto. 

Pursuant to Section 8.12(a) of the Loan Agreement, the Additional Guarantor hereby agrees to become a “Guarantor” for all
purposes of the Loan Agreement, and a “Grantor” for all purposes of the Security Agreement. Without limiting the foregoing, the Additional Guarantor hereby, jointly and severally with the other Guarantors, guarantees to the Lenders
and their successors and assigns the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of all Guaranteed Obligations (as defined in Section 13.01 of the Loan Agreement) in the same manner and to the
same extent as is provided in Section 13 of the Loan Agreement. In addition, as of the date hereof, the Additional Guarantor hereby makes the representations and warranties set forth in Sections 7.01, 7.02, 7.03,
7.05(a), 7.06, 7.07, 7.08 and 7.18 of the Loan Agreement, and in Section 2 of the Security Agreement, with respect to itself and its obligations under this Agreement and the other Loan Documents, as if each
reference in such Sections to the Loan Documents included reference to this Agreement, such representations and warranties to be made as of the date hereof. 

IN WITNESS WHEREOF, the Additional Guarantor has caused this Guarantee Assumption Agreement to be duly executed and delivered as of the day
and year first above written.
  

			
	[ADDITIONAL GUARANTOR]
		
	By	 	  

		 	Name:
		 	Title:

  
 Exhibit A-1 

 Exhibit B 

to Term Loan Agreement 

[Reserved] 

  
 Exhibit B-1 

 Exhibit C 

to Term Loan Agreement 
 FORM
OF TERM LOAN NOTE 
 [DATE] 
 U.S.
$[        ] plus all compounded interest calculated pursuant to Section 3.02(d)(ii) of the Loan Agreement 

FOR VALUE RECEIVED, the undersigned, Valeritas, Inc., a Delaware corporation (“Borrower”), hereby promises to pay to
[Capital Royalty Partners II L.P., Capital Royalty/ Partners II – Parallel Fund “A” L.P./ Paralleled Investment Opportunities Partners II L.P./ Capital Royalty Partners II (Cayman) L.P./ Capital Royalty Partners II – Parallel
Fund “B” (Cayman) L.P.] or its assigns (the “Lender”) at the Lender’s principal office in 1000 Main Street, Suite 2500, Houston, TX 77002, in immediately available funds, the aggregate principal sum set forth
above, or, if less, the aggregate unpaid principal amount of all Loans made by the Lender pursuant to Section 2.01 of the Second Amended and Restated Term Loan Agreement, dated as of May 3, 2016 (as amended, restated, supplemented or
otherwise modified, renewed, refinanced or replaced, the “Loan Agreement”), among the Borrower, the Lender, the other lenders party thereto and the Guarantors party thereto, on the date or dates specified in the Loan
Agreement, together with interest on the principal amount of such Loans from time to time outstanding thereunder at the rates, and payable in the manner and on the dates, specified in the Loan Agreement. 

This Note is a Note issued pursuant to the terms of Section 2.04 of the Loan Agreement and Section 3.02(d)(ii) of the Loan
Agreement to the extent the Borrower has elected to pay interest on the outstanding principal amount of this Note in kind pursuant to Section 3.02(d)(ii) of the Loan Agreement, and this Note and the holder hereof are entitled to all the
benefits and security provided for thereby or referred to therein, to which Loan Agreement reference is hereby made for a statement thereof. All defined terms used in this Note, except terms otherwise defined herein, shall have the same meaning
as in the Loan Agreement. 
 THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION; PROVIDED THAT SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS
LAW SHALL APPLY. 
 The Borrower hereby waives demand, presentment, protest or notice of any kind hereunder, other than notices provided for
in the Loan Documents. The non-exercise by the holder hereof of any of its rights hereunder in any particular instance shall not constitute a waiver thereof in such particular or any subsequent instance. 

THIS NOTE MAY NOT BE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS OF THE LOAN AGREEMENT. 

  
 Exhibit C-1 

 THIS NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT. TO OBTAIN (I) THE ISSUE PRICE OF THIS
NOTE, (II) THE AMOUNT OF ORIGINAL ISSUE DISCOUNT, (III) THE ISSUE DATE, OR (IV) THE YIELD TO MATURITY; CONTACT [CONTACT AT ISSUER] AT [ADDRESS], OR BY PHONE AT [NUMBER]. 

 

			
	VALERITAS, INC.
		
	By	 	  

		 	Name:
		 	Title:

  
 Exhibit C-2 

 Exhibit D 

to Term Loan Agreement 
 FORM
OF U.S. TAX COMPLIANCE CERTIFICATE 
 Reference is made to the Second Amended and Restated Term Loan Agreement, dated as of May 3, 2016 (as
the same may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), among Valeritas, Inc., a Delaware corporation (“Borrower”), Capital Royalty Partners II
L.P., Capital Royalty Partners II – Parallel Fund “A” L.P., Paralleled Investment Opportunities Partners II L.P., Capital Royalty Partners II (Cayman) L.P., and Capital Royalty Partners II – Parallel Fund “B” (Cayman)
L.P., and other parties from time to time party thereto as lenders (“Lenders”), and the Guarantors from time to time party thereto.
[                                        ] (the
“Foreign Lender”) is providing this certificate pursuant to Section 5.05(e)(ii)(B) of the Loan Agreement. The Foreign Lender hereby represents and warrants that: 

1. The Foreign Lender is the sole record owner of the Loans as well as any obligations evidenced by any Note(s) in respect of which it is
providing this certificate; 
 2. The Foreign Lender’s direct or indirect partners/members are the sole beneficial owners of the Loans
as well as any obligations evidenced by any Note(s) in respect of which it is providing this certificate; 
 3. Neither the Foreign Lender
nor its direct or indirect partners/members is a “bank” for purposes of Section 881(c)(3)(A) of the Internal Revenue Code of 1986, as amended (the “Code”). In this regard, the Foreign Lender further represents
and warrants that: 
 (a) neither the Foreign Lender nor its direct or indirect partners/members is subject to regulatory or other legal
requirements as a bank in any jurisdiction; and 
 (b) neither the Foreign Lender nor its direct or indirect partners/members has been
treated as a bank for purposes of any tax, securities law or other filing or submission made to any Governmental Authority, any application made to a rating agency or qualification for any exemption from tax, securities law or other legal
requirements; 
 3. Neither the Foreign Lender nor its direct or indirect partners/members is a 10-percent shareholder of Borrower within
the meaning of Section 881(c)(3)(B) of the Code; and 
 4. Neither the Foreign Lender nor its direct or indirect partners/members is a
controlled foreign corporation receiving interest from a related person within the meaning of Section 881(c)(3)(C) of the Code. 
 [Signature
follows] 

  
 Exhibit D-1 

 IN WITNESS WHEREOF, the undersigned has caused this certificate to be duly executed and delivered
as of the date indicated below. 
  

			
	[NAME OF NON-U.S. LENDER]
		
	By	 	  

		 	Name:
		 	Title:
		
	Date:	 	  

  
 Exhibit D-2 

 Exhibit E 

to Term Loan Agreement 
 FORM
OF COMPLIANCE CERTIFICATE 
 [Date] 

This certificate is delivered pursuant to Section 8.01(c) of, and in connection with the consummation of the transactions contemplated
in, the Second Amended and Restated Term Loan Agreement, dated as of May 3, 2016 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), among Valeritas, Inc., a
Delaware corporation (“Borrower”), Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P., Paralleled Investment Opportunities Partners II L.P., Capital Royalty Partners II
(Cayman) L.P., and Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P., and other parties from time to time party thereto as lenders (“Lenders”), and the Guarantors from time to time party
thereto. Capitalized terms used herein and not otherwise defined herein are used herein as defined in the Loan Agreement. 
 The
undersigned, a duly authorized Responsible Officer of Borrower having the name and title set forth below under his signature, hereby certifies, on behalf of the Borrower for the benefit of the Lenders and pursuant to Section 8.01(c) of the
Loan Agreement that such Responsible Officer of the Borrower is familiar with the Loan Agreement and that, in accordance with each of the following sections of the Loan Agreement, each of the following is true on the date hereof, both before and
after giving effect to any Loan to be made on or before the date hereof: 
 In accordance with Section 8.01[(a)/(b)] of the
Loan Agreement, attached hereto as Annex A are the financial statements for the [fiscal quarter/fiscal year] ended [                    ]
required to be delivered pursuant to Section 8.01[(a)/(b)] of the Loan Agreement. Such financial statements fairly present in all material respects the consolidated financial position, results of operations and cash flow of the Parent,
Borrower and its Subsidiaries as at the dates indicated therein and for the periods indicated therein in accordance with GAAP [(subject to the absence of footnote disclosure and normal year-end audit adjustments)]1 [without qualification as to the scope of the audit.]2 

Attached hereto as Annex B are the calculations used to determine compliance with each financial covenant contained in
Section 10 of the Loan Agreement. 
 No Default is continuing as of the date hereof[, except as provided for on Annex C
attached hereto, with respect to each of which Borrower proposes to take the actions set forth on Annex C]. 
 IN WITNESS WHEREOF,
the undersigned has executed this certificate on the date first written above. 
  

	1 	Insert language in brackets only for quarterly certifications. 

	2 	Insert language in brackets only for annual certifications. 

  
 Exhibit E-1 

 
			
	VALERITAS, INC.
		
	By	 	  

		 	Name:
		 	Title:

  
 Exhibit E-2 

 Annex A to Compliance Certificate 

FINANCIAL STATEMENTS 
 [see
attached] 

  
 Exhibit E-3 

 Annex B to Compliance Certificate 

CALCULATIONS OF FINANCIAL COVENANT COMPLIANCE 
  

							
	I.	  		  	Section 10.01: Minimum Cash	  	
		  	A.	  	Minimum daily balance of cash and Permitted Cash Equivalent Investments of Borrower and its Subsidiaries during the most recently ended fiscal quarter of Borrower:	  	$            
		  	B.	  	Minimum end of day daily cash balance required by Section 10.01: $5,000,000	  	
		  		  	Is line I.A greater than $5,000,000?	  	
		  		  		  	Yes: In compliance;
		  		  		  	No: Not in compliance

  
 Exhibit E-4 

 Exhibit F 

to Term Loan Agreement 
 FORM
OPINION FROM CORPORATE COUNSEL 

 May 3, 2016 
 To:

 Capital Royalty Partners II L.P., as a Lender
 Capital
Royalty Partners II – Parallel Fund “A” L.P., as a Lender 
 Parallel Investment Opportunities Partners II L.P., as a Lender 

Capital Royalty Partners II (Cayman) L.P., as a Lender 
 Capital
Royalty Partners II – Parallel Fund “B” (Cayman) L.P., as a Lender 
 1000 Main Street, Suite 2500 

Houston, TX 77002 
  

	Re:	Valeritas, Inc. 

 Ladies and Gentlemen: 

We have acted as special counsel for Valeritas, Inc., a Delaware corporation (the “Borrower” or the “Company”), Valeritas
Holdings, Inc., a Delaware corporation (the “Parent”), and Valeritas Security Corporation, a Delaware corporation (“Valeritas Security” or “VSC”; together with the Parent, the
“Guarantors”; the Company and Guarantors together being referred to, collectively, herein as the “Opinion Parties”) in connection with the Second Amended and Restated Term Loan Agreement dated as of May 3, 2016 (the
“Term Loan Agreement”) among the Company, as Borrower, and Capital Royalty Partners II L.P. (“CRP II”), Capital Royalty Partners II –Parallel Fund “A” L.P. (“CRP IIA”), Parallel
Investment Opportunities Partners II L.P., (“PIOP” and, together with CRP II and CPR IIA, collectively, “Original Lenders”), Capital Royalty Partners II (Cayman) L.P. (“CRP II Cayman”), and Capital
Royalty Partners II – Parallel Fund “B” (Cayman) L.P. (“CRP IIB”, and, together with CRP II Cayman, collectively, the “Additional Lenders” and, together with the Original Lenders, collectively, the
“Lenders”) as Lenders. Terms defined in the Term Loan Agreement are used as therein defined, unless otherwise defined herein. This opinion letter is being delivered to you pursuant to Section 6.01(e)(viii) of the Term Loan
Agreement. 
 References in this opinion letter to the “DE UCC” are to the Uniform Commercial Code as currently in effect in the State of
Delaware. References in this opinion letter to the “NY UCC” are to the Uniform Commercial Code as currently in effect in the State of New York. The terms in paragraph 10 that are defined in the DE UCC and that are not capitalized have the
respective meanings given to them in the DE UCC. The terms in paragraphs 9 and 11 that are defined in the NY UCC and that are not capitalized have the respective meanings given to them in the NY UCC. 

 May     , 2016 

Page 2 
  

 In connection with this opinion letter, we have examined originals, or copies certified or otherwise
identified to our satisfaction, of (i) Certificate of Incorporation of each of the Opinion Parties, as amended (the “Charters”), (ii) the Bylaws of each of the Opinion Parties, as amended (the “Bylaws”), and (iii)
such other documents and records, and other instruments as we have deemed appropriate for purposes of the opinions set forth herein, including the following documents (the documents referred to in clauses (a) through (e) below are referred to herein
as the “Loan Documents”): 
  

	 	(a)	the Term Loan Agreement; 

  

	 	(b)	the Security Agreement dated as of May 24, 2013 among the Opinion Parties and the Original Lenders (the “Initial Security Agreement”); 

 

	 	(c)	the Assignment and Assumption dated as of November 12, 2013 by and among CRP II and CRP IIA as assignors, and the Additional Lenders as assignees (the “Assignment and Assumption”); 

 

	 	(d)	the previous Joinder Agreement dated as of April 16, 2015, entered into by VSC, relating to the Initial Security Agreement (the “VSC Joinder”); the Initial Security Agreement as modified by the VSC
Joinder being referred to as the “Existing Security Agreement”); 

  

	 	(e)	the Joinder Agreement dated as of May 3, 2016, entered into by and among the Opinion Parties and the Lenders, relating to the Initial Security Agreement (the “Parent Joinder”; the Existing Security
Agreement as modified by the Parent Joinder being referred to as the “Security Agreement”); 

  

	 	(f)	Good standing certificates, dated as of a recent date, (i) with respect to the valid existence and good standing of each of the Opinion Parties, in each case, in the State of Delaware (the “DE Good Standing
Certificates”), (ii) in the case of the Company and VSC, foreign qualified certificates in the Commonwealth of Massachusetts (“MA Foreign Qualified Certificates”), and (iii) in the case of the Company, a foreign qualified
certificate in the State of New Jersey (the “NJ Foreign Qualified Certificate” and, together with the DE Good Standing Certificates and MA Foreign Qualified Certificates, collectively, the “Good Standing
Certificates”); 

  

	 	(g)	a copy of a Uniform Commercial Code financing statement (the “Parent Financing Statement”) naming the Parent as debtor and the Lenders as secured parties, to be filed in the Office of the Secretary of
State of the State of Delaware (the “DE Filing Office”), a copy of which is attached hereto as part of Schedule 1; 

  

	 	(h)	a copy of a Uniform Commercial Code financing statement (the “Company Financing Statement”) naming the Company as debtor and the Original Lenders as secured parties, filed in the DE Filing Office on May
24, 2013, a copy of which is attached hereto as part of Schedule 1;

 May     , 2016 

Page 3 
  

	 	(i)	a copy of a Uniform Commercial Code financing statement amendment (the “Additional Lenders Financing Statement”) naming the Company as debtor and the Additional Lenders as secured parties to be filed in
the DE Filing Office, a copy of which is attached hereto as part of Schedule 1; 

  

	 	(j)	a copy of a Uniform Commercial Code financing statement (the “VSC Financing Statement”) naming VSC as debtor and the Lenders as secured parties, filed in the DE Filing Office on April 20, 2015, a copy
of which is attached hereto as part of Schedule 1 (the Company Financing Statement, and the VSC Financing Statement being referred to herein, collectively, as the “Existing Financing Statements”; and, together with the Parent
Financing Statement and Additional Lenders Financing Statement, collectively, the “Financing Statements”). 

 We have assumed
the genuineness of all signatures, the legal capacity of natural persons, the authenticity of the documents submitted to us as originals, the conformity to the original documents of all documents submitted to us as certified, facsimile or
photostatic copies, and the authenticity of the originals of all documents submitted to us as copies. We have also assumed that the Loan Documents constitute valid and binding obligations of each party thereto other than the Opinion Parties party
thereto. The Term Loan Agreement, and the Parent Joinder are referred to herein, collectively, as the “New Loan Documents”; the Term Loan Agreement and the Security Agreement are referred to herein, collectively, as the
“Operative Loan Documents”. We have assumed that, immediately prior to giving effect to the New Loan Documents, the Existing Security Agreement has not been amended, modified or supplemented (other than by the VSC Joinder and
Assignment and Assumption as applicable), has not been terminated or discharged, and is in full force and effect as the enforceable agreement of the parties thereto, and that no circumstances exist or events have taken place which constitute a
defense, waiver, or excuse with respect to the obligations of any party under the Existing Security Agreement.
 As to any facts that are material to the
opinions hereinafter expressed that we did not independently establish or verify, we have relied without investigation upon the representations of the Opinion Parties contained in the Loan Documents and upon certificates of officers of the Opinion
Parties. 
 We express no opinion as to the enforceability of any obligations purportedly guarantied or secured by (or incorporated by reference into) the
Operative Loan Documents that are not evidenced by the Operative Loan Documents (such as, but not limited to, obligations arising under other contracts or arrangements) and we assume such obligations are valid, binding and enforceable obligations of
the applicable obligors. 
 In rendering the opinions set forth herein, whenever a statement or opinion set forth therein is qualified by “to our
knowledge,” “known to us” or by words of similar import, it is intended to indicate that, during the course of our representation of the Opinion Parties in the subject 

 May     , 2016 

Page 4 
  

 
transaction, no information has come to the attention of those lawyers in our firm who have rendered legal services in connection with such transaction that gives us actual knowledge of the
inaccuracy of such statement or opinion. We have not undertaken any independent investigation to determine the accuracy of facts material to any such statement or opinion, and no inference as to such statement or opinion should be drawn from the
fact of our representation of the Opinion Parties. 
 We have relied upon a certificate of an officer of each of the Opinion Parties dated the date hereof,
certifying that the items listed in such certificate are (i) all of the indentures, loan or credit agreements, leases, guarantees, mortgages, security agreements, bonds, notes, other agreements or instruments (the “Other Material
Agreements”) which affect or purport to affect any Opinion Party’s right to borrow money or guarantee debt or enter into the Loan Documents; and (ii) all of the judicial or administrative orders, writs, judgments, awards, injunctions
and decrees (the “Orders”), which affect or purport to affect any Opinion Party’s right to borrow money or guarantee debt or enter into the Loan Documents. We have relied upon a certificate of an officer of each of the
Opinion Parties as to certain matters relevant to our opinions in paragraph 8 below relating to the 1940 Act (as defined below). 
 Based upon and subject
to the foregoing, and to the limitations and qualifications described below, we are of the opinion that: 
 1. The Company and VSC are each
duly qualified to do business as a foreign corporation in the Commonwealth of Massachusetts. The Company is duly qualified to do business as a foreign corporation in the State of New Jersey. Each Opinion Party is a corporation duly
incorporated, validly existing and in good standing under the laws of the State of Delaware.
 2. Each Opinion Party has the corporate power
and authority to enter into the New Loan Documents and perform the Operative Loan Documents to which it is a party, has taken all necessary corporate action to authorize the execution, delivery and performance of such New Loan Documents and the
performance of such Operative Loan Documents, and has duly executed and delivered such New Loan Documents to which it is a party.
 3. Each
Operative Loan Document to which each Opinion Party is a party is the valid and binding obligation of such Opinion Party enforceable against such Opinion Party in accordance with its terms. 

4. The execution and delivery by each Opinion Party of the New Loan Documents to which it is a party do not, and the performance by such
Opinion Party of its obligations under the Operative Loan Documents to which it is a party will not, result in a violation of the Charter or Bylaws of such Opinion Party. 

5. The execution and delivery by each Opinion Party of the New Loan Documents to which it is a party does not, and the performance of such
Opinion Party of its obligations under the Operative Loan Documents to which it is party will not, require any approval from or filing with any governmental authority of the United States under federal law, the State of New York under New York law
or the State of Delaware under any provision of the Delaware General Corporation Law. 

 May     , 2016 

Page 5 
  

 6. The execution and delivery by each Opinion Party of the New Loan Documents to which it is
a party does not, and the performance by such Opinion Party of its obligations under the Operative Loan Documents to which it is a party will not, result in any violation of any federal law of the United States or any law of the State of New York or
any provision of the Delaware General Corporation Law. 
 7. The extension of credit made on the date hereof and the use of the proceeds
thereof in accordance with the provisions of the Term Loan Agreement do not violate the provisions of Regulations T, U or X of the Board of Governors of the Federal Reserve System. For purposes of this paragraph, we have assumed that none of
the assets of any Opinion Party or its subsidiaries constitutes “margin stock” as such term is used in such Regulations; that none of the Lenders falls within the definition of “Creditor” as such term is used in Regulation T of
such Board of Governors; and that the proceeds of the loans made under the Term Loan Agreement are used in accordance with the provisions thereof. 

8. No Opinion Party is required to register as an “investment company” within the meaning of the Investment Company Act of 1940, as
amended (the “1940 Act”).
 9. The Security Agreement is effective to create in favor of the Lenders, as security for the
Secured Obligations, as defined in the Security Agreement, a security interest (the “Article 9 Security Interest”) in the collateral of the applicable Opinion Parties described in the Security Agreement in which a security interest
may be created under Article 9 of the NY UCC (the “Article 9 Collateral”). 
 10. As a result of the previous filing of the
Existing Financing Statements with the DE Filing Office, the Article 9 Security Interest in that portion of the Article 9 Collateral of the Company and VSC in which a security interest may be perfected by the filing of a financing statement under
the DE UCC has been perfected. Upon the filing of the Parent Financing Statement with the DE Filing Office, the Article 9 Security Interest in that portion of the Article 9 Collateral of the Parent in which a security interest may be perfected by
the filing of a financing statement under the DE UCC will be perfected. 
 11. The Article 9 Security Interest in that portion of the
Article 9 Collateral consisting of the certificated securities constituting the capital stock of the Company, the applicable security certificates for which are being delivered by the Parent to the Control Agent pursuant to the Security Agreement in
connection with the Parent Joinder, will be perfected upon delivery of such security certificates to the Control Agent, together with duly executed stock powers or other signed transfer powers in blank, within the State of New York.

 May     , 2016 

Page 6 
  

 The opinions expressed above are subject to the following limitations, exceptions, qualifications and
assumptions:
 A. The opinions expressed herein are subject to bankruptcy, insolvency, fraudulent transfer and other similar laws affecting
the rights and remedies of creditors generally and general principles of equity, including concepts of materiality, reasonableness, good faith and fair dealing, and (as to collateral security) the duty to act in a commercially reasonable
manner. We express no opinion as to the effect of suretyship defenses, or defenses in the nature thereof, with respect to the obligations of any Guarantor. 

B. Provisions of the Loan Documents relating to indemnification or exculpation may be limited by public policy or by law. 

C. The opinions expressed in this opinion letter are limited to the laws of the State of New York, (including the NY UCC), the General
Corporation Law of the State of Delaware, the DE UCC, and the Federal laws of the United States of America, and we express no opinion with respect to any other laws of any state or jurisdiction. With respect to the DE UCC, we have, with your
permission, confined our investigation thereof to an examination of the relevant provisions of the Uniform Commercial Code as in effect in the State of Delaware as set forth in the CCH Secured Transactions Guide (as updated through a recent date),
without regard to any case law decided thereunder or other laws or regulations related thereto. 
 D. For purposes of our opinions herein as
to the valid existence and good standing of the Opinion Parties, we have relied solely upon the Good Standing Certificates. 
 E. We have
considered only such laws and regulations that in our experience are typically applicable to a transaction of the nature contemplated by the Loan Documents. 

F. Certain waivers by the Opinion Parties in the Loan Documents may relate to matters that cannot, as a matter of law, be effectively
waived. Without limiting the foregoing, you should be aware that under applicable law guarantors may be entitled to certain rights or protections which as a matter of statutory or common law may not be waived or altered. We express no
opinion herein as to the enforceability of any provision of any Loan Document which purport to waive or alter such rights or protections, except to the extent permitted by law. 

G. The enforceability of the Loan Documents may be limited by the unenforceability under certain circumstances of provisions imposing
penalties, forfeitures, late payment charges or an increase in interest rate upon delinquency in payment or an occurrence of default. 
 H.
In connection with the opinions set forth in paragraphs 9-11, we have assumed that each applicable Opinion Party has, or has the power to transfer, rights (to the extent necessary to grant a security interest) in the Article 9 Collateral existing on
the date hereof and will have, or will have the power to transfer, rights (to such extent) in property which becomes Article 9 Collateral after the date hereof. We assume that the Control Agent (as defined in the Security Agreement) is validly
acting as agent for and “representative” (as defined in the applicable Uniform Commercial Code (the “UCC”) of each relevant jurisdiction) of each holder of Secured Obligations (as defined in the Security Agreement) or
holder of any applicable obligation purported to be secured or benefitted by a security interest granted in favor of the Control Agent or in favor of any Lender by any Opinion Party. 

 May     , 2016 

Page 7 
  

 I. We express no opinion as to the creation, attachment or perfection of any security
interest except as expressly stated herein. We express no opinion as to (i) the perfection of any security interest in any Collateral consisting of timber to be cut or as-extracted collateral or goods which are or are to become fixtures or (ii)
the priority of any security interest or lien. We assume the Collateral does not include any “commercial tort claims” (as defined in the NY UCC or the DE UCC) or “cooperative interests” (as defined in the NY UCC). We express
no opinion as to the enforceability of any provision of the Loan Documents to the extent such enforceability is limited by Sections 1-302, 9-602, 9-603, 9-406, 9-407, 9-408, or other applicable provisions of the NY UCC or the DE UCC. 

J. In connection with the opinions set forth in paragraphs 9-11, the perfection of a security interest in any collateral consisting of
“proceeds” (as defined in the Uniform Commercial Code of the applicable jurisdiction) is subject to limitations set forth in Section 9-315 of the Uniform Commercial Code of the applicable
jurisdiction. 
 K. We call to your attention the requirement to file appropriate periodic Uniform Commercial Code continuation statements
on a timely basis under the DE UCC with respect to each Financing Statement. We also point out that certain actions may be required if any applicable debtor changes its name or its “location” for purposes of Article 9 of the
applicable Uniform Commercial Code, or if a “new debtor” (as defined in the applicable Uniform Commercial Code) becomes bound by the applicable security agreement.

L. We assume that none of the Existing Financing Statements has been amended, modified, assigned, released or terminated in any manner, and
each Existing Financing Statement is in full force and effect and on file as of record in the DE Filing Office.
 M. For purposes of Section
122 (13) of the Delaware General Corporation Law, we assume that each of the Company and VSC is a direct or indirect wholly-owned subsidiary of the Parent.

N. Except to the extent that any provision in the Loan Documents providing for the choice of New York law to govern the Loan Documents is made
enforceable by New York General Obligations Law Section 5-1401, as applied by a New York state court or a federal court sitting in New York and applying New York choice of law principles, no opinion is given herein as to any contractual choice of
law clause or otherwise as to any choice of law matters. 
 O. We express no opinion as to: 

(i) The enforceability of any provision of the Loan Documents insofar as it provides that any Person purchasing a participation from any
Lender or any other Person may exercise set-off or similar rights with respect to such participation or that a Lender or other Person may exercise set-off or similar rights other than in accordance with applicable law. 

(ii) The enforceability of any provision of the Loan Documents permitting modification thereof only by means of an agreement in writing signed
by the parties thereto.

 May     , 2016 

Page 8 
  

 (iii) The enforceability of any provision of the Loan Documents purporting to waive the right
to trial by jury, or any provisions in the Loan Documents relating to jurisdiction, venue, choice of forum, service of process, or choice of law (except to the extent made enforceable by New York General Obligations Law Sections 5-1401 and
5-1402).
 (iv) The enforceability of any provision of the Loan Documents purporting to grant the right to confess judgment against the
Opinion Parties. 
 (v) The enforceability of the provisions contained in the last sentence of Section 2.01 of the Term Loan Agreement. 

This opinion letter is effective only as of the date hereof. We do not assume responsibility for updating this opinion letter as of any date subsequent
to its date, and we assume no responsibility for advising you of any changes with respect to any matters described in this opinion letter that may occur subsequent to the date of this opinion letter or from the discovery, subsequent to the date of
this opinion letter, of information not previously known to us pertaining to the events occurring prior to such date. 

 May     , 2016 

Page 9 
  

 This opinion letter is furnished by us solely for the benefit of the Lenders and their respective successors
and permitted assigns and participants pursuant to the Term Loan Agreement, and this opinion letter may not be relied upon by such parties for any other purpose or by any other person or entity for any purpose whatsoever. This opinion letter is not
to be quoted in whole or in part or otherwise referred to or used or furnished to any other person, except as may be required by any governmental authority or pursuant to law or legal process, without our express written consent. 

 

	
	Very truly yours,

 May     , 2016 

Page 10 
  

 Schedule 1 

[Attach Financing Statements] 

 Exhibit G 

to Term Loan Agreement 
 FORM
OF LANDLORD CONSENT 

  
 Exhibit G-1 

 LANDLORD CONSENT 

WHEREAS, CAPITAL ROYALTY PARTNERS II L.P., as Collateral Agent (“CRPII”, and in such capacity, “Collateral
Agent”) and the lenders party thereto from time to time including CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P. and PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P., each in its capacity as a Lender (“each a
“Lender” and collectively, the “Lenders”), has entered into a term loan agreement and a security agreement, each dated as of May 24, 2013, with VALERITAS, INC. (“Debtor”) pursuant to which
Lenders have been granted, with certain exceptions, a security interest in all of Debtor’s personal property, including, but not limited to, inventory, equipment and trade fixtures (hereinafter “Personal Property”); and 

WHEREAS, THE TAMING OF THE SHREWSBURY, LLC, O’NEILL PARTNERS, LLC, and CHANSKI, LLC as tenants in common (collectively, the
“Landlord”) are the owners of the real property located at 800 Boston Turnpike, Shrewsbury, Massachusetts (the “Premises”); and 

WHEREAS, Landlord has entered into that certain Lease Agreement dated December 22, 2007 with Debtor, as tenant (collectively, the
“Lease”); and 
 WHEREAS, certain of the Personal Property has or may become affixed to or be located on, wholly or in
part, the Premises. 
 NOW, THEREFORE, in consideration of any loans or other financial accommodation extended by Lenders to Debtor at any
time, and other good and valuable consideration, the parties agree as follows: 
 (a) Landlord subordinates to Lenders all rights of
security interest or other interest Landlord may now or hereafter have in any of the Personal Property whether for rent or otherwise while Debtor is indebted to Lenders; 

(b) That the Personal Property may be installed in or located on the Premises and is not and shall not be deemed a fixture or part of the real
estate and shall at all times be considered personal property; 
 (c) That Collateral Agent or its representatives may enter upon the
Premises during normal business hours, and upon not less than 24-hours advance notice, to inspect the Personal Property; 
 (d) That
Collateral Agent, at its option, upon written notice delivered to Landlord not less than ten (10) business days in advance, may enter the Premises during normal business hours for the purpose of repossessing, removing or otherwise dealing with said
Personal Property; provided that neither Collateral Agent nor Lenders shall be permitted to operate the business of Debtor on the Premises or sell, auction or otherwise dispose of any Personal Property at the Premises or advertise any of the
foregoing; and such license shall continue, subject to paragraph (g) below, from the date Collateral Agent enters the Premises for as long as Collateral Agent reasonably deems necessary but not to exceed a period of ten (10) days. During the
period Collateral Agent occupies the Premises, it shall pay to Landlord the Rent and Additional Rent provided under the Lease relating to the Premises, prorated on a per diem basis to be determined on a thirty (30) day month, without incurring any
other obligations of Debtor; 
 (e) Collateral Agent shall pay to Landlord any costs for damage to the Premises or the building in which the
Premises is located in removing or otherwise dealing with said Personal Property and shall indemnify and hold harmless Landlord from and against (i) all claims, disputes and expenses, including reasonable attorneys’ fees, suffered or incurred
by Landlord arising from Collateral Agent’s exercise of any of its rights hereunder, and (ii) any injury to third persons, caused by actions of Collateral Agent pursuant to this consent; 

  
 - 1 - 

 (f) Landlord agrees to give notice to Collateral Agent in writing by certified mail or facsimile
of Landlord’s intent to exercise its remedies in response to any default by Debtor of any of the provisions of the Lease, to: 
 Capital
Royalty Partners II L.P. 
 1000 Main Street, Suite 2500 

Houston, TX 77002 
 Attention:
General Counsel 
 Fax: 713.209.7351 

(g) If Landlord acquires possession of the Premises after a default by Debtor, it may require that the Personal Property be removed by
Collateral Agent within sixty (60) days following written notice in accordance with paragraph (f) above.
 (h) If Collateral Agent fails to
exercise its right to remove the Personal Property strictly in accordance with the requirements and conditions of this consent, Landlord may proceed with any remedies available to it by reason of Debtor’s default under the Lease and may remove
all Personal Property from the Premises and dispose of same, without regard to this consent or Collateral Agent’s security interest in the Personal Property. 

(i) Landlord shall have no obligation to preserve or protect the Personal Property or take any action in connection therewith, and Lenders
waive all claims they may now or hereafter have against Landlord in connection with the Personal Property. 
 (j) Upon payment and
performance of all indebtedness secured by the Personal Property to Lenders, Lenders shall, upon Landlord’s or Debtor’s request, execute and/or file any release or termination statement reasonably necessary to evidence Lenders’
release of the subordination herein provided by it. In no event shall this consent remain in force or effect after the date that the Lease is terminated or expires. 

(k) Nothing contained herein shall be construed to amend the Lease, and the Lease remains unchanged and in full force and effect. 

This consent shall be construed and interpreted in accordance with and governed by the laws of the Commonwealth of Massachusetts. 

This consent may not be changed or terminated orally and is binding upon and shall inure to the benefit of Landlord, Collateral Agent, Lenders
and Debtor and the heirs, personal representatives, successors and assigns of Landlord, Collateral Agent, Lenders and Debtor. 
 [Signature
Page follows] 

  
 - 2 - 

			
	Dated this      day of         , 2013.
	
	LANDLORD:
	
	THE TAMING OF THE SHREWSBURY, LLC
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	O’NEILL PARTNERS, LLC
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	CHANSKI, LLC
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 [Signature Page to
Landlord Consent] 

									
	LENDERS:
	
	CAPITAL ROYALTY PARTNERS II L.P.
		 	By CAPITAL ROYALTY PARTNERS II GP L.P., its General Partner
		 		 	By CAPITAL ROYALTY PARTNERS II GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Charles Tate
		 		 		 	Title:	 	Sole Member
	
	CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P.
		 	 By CAPITAL ROYALTY PARTNERS II –

PARALLEL FUND “A” GP L.P., its General Partner

		 		 	By CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Charles Tate
		 		 		 	Title:	 	Sole Member
	
	PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
		 	By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP L.P., its General Partner
		 		 	By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Charles Tate
		 		 		 	Title:	 	Sole Member

  
 [Signature Page to
Landlord Consent] 

			
	DEBTOR:
	
	VALERITAS, INC.
		
	By:	 	  

	Name:	 	James Dentzer
	Title:	 	Chief Financial Officer

  
 [Signature Page to
Landlord Consent] 

 Exhibit H 

to Term Loan Agreement 
 FORM
OF SUBORDINATION AGREEMENT 

  
 Exhibit H-1 

 EXECUTION VERSION 

SECOND AMENDED AND RESTATED SUBORDINATION AGREEMENT 

This Second Amended and Restated Subordination Agreement (this “Agreement”) is made as of May 3, 2016, among Capital
Royalty Partners II L.P., a Delaware limited partnership (“CRII”), Capital Royalty Partners II – Parallel Fund “A” L.P., a Delaware limited partnership (“CRII Parallel”), Parallel
Investment Opportunities Partners II L.P., a Delaware limited partnership (“Parallel Investment”), Capital Royalty Partners II (Cayman) L.P., a Cayman Islands exempted limited partnership (“Cayman”)
and Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P., a Cayman Islands exempted limited partnership (“Parallel B” and, collectively with CRII, CRII Parallel, Parallel Investment and Cayman, and
their successors and assigns, the “Lenders”), and WCAS Capital Partners IV, L.P., a Delaware limited partnership (“WCAS”). 

Recitals 
  

	A.	Valeritas, Inc., a Delaware corporation (“Borrower”), has issued in favor of WCAS the Subordinated Note (as defined below). 

 

	B.	Lenders and Borrower have entered into the Senior Term Loan Agreement (as defined below) and the Senior Term Loan Security Agreement (as defined below) to grant a security interest in the Collateral (as defined below)
in favor of Lenders as security for the payment of Borrower’s obligations under the Senior Term Loan Agreement. 

  

	C.	To induce Lenders to make and maintain the credit extensions to Borrower under the Senior Term Loan Agreement, on May 24, 2013, WCAS and Lenders entered into a Subordination Agreement (the “Subordination
Agreement”) to (i) subordinate in right and time of payment, the Subordinated Debt (as defined below) to payment in full of the Senior Debt (as defined below) on the terms and conditions set forth therein and (ii) prohibit WCAS from
obtaining any security interests in the Collateral to secure the Subordinated Debt. 

  

	D.	Lenders and Borrower are entering into the second amendment and restatement of the Senior Term Loan Agreement on the date hereof. To induce Lenders to enter into such second amendment and restatement of the Senior Term
Loan Agreement, WCAS agrees to amend and restate the Subordination Agreement as set forth below. 

 NOW, THEREFORE, THE
PARTIES AGREE AS FOLLOWS: 
 1. Definitions. As used herein, the following terms have the following meanings: 

“Bankruptcy Code” means title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. 

“Collateral” means “Collateral” as defined in the Senior Term Loan Security Agreement. 

“Enforcement Action” means, with respect to any indebtedness or obligation (contingent or otherwise) or Collateral at
any time held by any Lender or holder of the Subordinated Note: commencing by judicial or non-judicial means the enforcement with respect to such 

 
indebtedness, obligation or Collateral of any of the default remedies under any of the applicable agreements or documents of such Lender or holder, the UCC or other applicable law (other than the
mere issuance of a notice of default and the right by the holder of the Subordinated Note to seek specific performance with respect to any covenants in favor of the holder thereunder); repossessing, selling, leasing or otherwise disposing of all or
any part of such Collateral, or exercising account debtor or obligor notification or collection rights with respect to all or any portion thereof, or attempting or agreeing to do so; or appropriating, setting off or applying to such Lender or
holder’s claim any part or all of such Collateral or other property in the possession of, or coming into the possession of, such Lender or holder or its agent, trustee or bailee. 

“Insolvency Event” means that Borrower and/or any of its subsidiaries shall have applied for, consented to or
acquiesced in the appointment of a trustee, receiver or other custodian for it or any of its property, or made a general assignment for the benefit of creditors and, in the absence of such application, consented or acquiesced, permitted or suffer to
exist the appointment of a trustee, receiver or other custodian for it or for a substantial part of its property, and such trustee, receiver or other custodian shall not have been discharged within sixty days; or permitted or suffered to exist the
commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency law, or any dissolution, winding up or liquidation proceeding, in respect of it, and if any such case or proceeding was
not commenced by it, such case or proceeding shall have been consented to or acquiesced in by it or shall have resulted in the entry of an order for relief or shall have remained for sixty (60) days undismissed. 

“Management Incentive Fee Payments” means cash payments approved by the Borrower’s board of directors on
April 23, 2015, which payments are to be paid to Borrower’s management as part of an incentive fee program. 

“Permitted Subordinated Debt Payment” means any payment or distribution in respect of the Subordinated Debt which
consists solely of (i) conversion into the Borrower’s Series AB preferred stock of all interest and fees accrued on the Subordinated Debt outstanding as of April 29, 2016, and (ii) non-cash PIK Interest (as defined in the Subordinated Note on
May 24, 2013). 
 “Person” means “Person” as defined in the Senior Term Loan Agreement. 

“Required Lenders” means, as of the date of any determination, Lenders having more than 50% of the sum of the (a)
outstanding principal amount of Loans (as defined in the Senior Term Loan Agreement) and (b) aggregate unused Commitments (as defined in the Senior Term Loan Agreement). 

“Senior Debt” means the Obligations (as defined in the Senior Term Loan Agreement). 

“Senior Discharge Date” has the meaning set forth in Section 2. 

“Senior Term Loan Agreement” means that certain Term Loan Agreement, dated as of May 24, 2013 between Borrower and the
Lenders, as amended, restated, supplemented or otherwise modified from time to time, but without giving effect to any amendment and/or restatement, supplement, renewal or other modification prohibited by this Agreement. 

  
 2 

 “Senior Term Loan Documents” means, collectively, the Loan Documents (as
defined in the Senior Term Loan Agreement), in each case as amended, restated, supplemented or otherwise modified from time to time, but without giving effect to any amendment and/or restatement, supplement, renewal or other modification prohibited
by this Agreement. 
 “Senior Term Loan Security Agreement” means that certain Security Agreement, dated as of
May 24, 2013, between Borrower and the Secured Parties (as defined therein), as amended, restated, supplemented or otherwise modified from time to time, but without giving effect to any amendment and/or restatement, supplement, renewal or other
modification prohibited by this Agreement. 
 “Subordinated Debt” means and includes all obligations, liabilities
and indebtedness of Borrower owed to WCAS under the Subordinated Debt Documents, whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, which may arise under, out of, or in connection with
the Subordinated Debt Documents, including without limitation, principal, premium (if any), interest, fees, charges, expenses, costs, professional fees and expenses, and reimbursement obligations, in each case to the extent payable under the
Subordinated Debt Documents. 
 “Subordinated Debt Documents” means, collectively, the Subordinated Note and any
other loan document or agreement entered into by Borrower in connection with the Subordinated Note, as amended, restated, supplemented or otherwise modified from time to time, but without giving effect to any amendment and/or restatement,
supplement, renewal or other modification prohibited by this Agreement. 
 “Subordinated Note” means the Note issued
by Borrower to WCAS, dated September 8, 2011, as amended by that certain Amendment No. 1 to Note, dated as of May 24, 2013, as such note is amended, restated, supplemented or otherwise modified from time to time, but without giving effect to any
amendment and/or restatement, supplement, renewal or other modification prohibited by this Agreement. 
 “Subsidiary
Guarantor” means any subsidiary guarantor party to the Senior Term Loan Agreement. 
 “UCC” means the
Uniform Commercial Code of any applicable jurisdiction and, if the applicable jurisdiction shall not have any Uniform Commercial Code, the Uniform Commercial Code as in effect in the State of New York. 

2. Payment Subordination. Notwithstanding the terms of the Subordinated Debt Documents, until all of the Senior Debt is indefeasibly paid in full
(other than contingent indemnification obligations and the Warrant Obligations (as defined in the Senior Term Loan Agreement)) and all commitments of Lenders under the Senior Term Loan Documents have been terminated (such date, the
“Senior Discharge Date”), (a) all payments and distributions of any kind or character, whether in cash, property or securities, in respect of the Subordinated Debt are (i) subordinated in right and time of payment to all
payments in respect of the Management Incentive Fee Payments and (ii) except with respect to Permitted Subordinated Debt Payments, subordinated in right and time of payment to all payments in respect of the Senior Debt, and (b)

  
 3 

 
WCAS will not demand, sue for or receive from Borrower (and Borrower will not pay) any part of the Subordinated Debt, whether by payment, prepayment, distribution, setoff, or otherwise, or
accelerate the Subordinated Debt, except as permitted pursuant to this Agreement. 
 3. Subordination of Remedies. Until the Senior Discharge
Date, WCAS will not accelerate the maturity of all or any portion of the Subordinated Debt, exercise any remedy with respect to the Collateral, or take any other Enforcement Action with respect to the Subordinated Debt.

4. Insolvency Proceedings. These provisions remain in full force and effect until the Senior Discharge Date, despite an Insolvency Event. In
furtherance thereof: 
  

	 	a)	All payments and distributions of any kind, whether in cash, property or securities, in respect of the Subordinated Debt to which WCAS would be entitled if the Subordinated Debt were not subordinated pursuant to this
Agreement, shall be paid to Lender and applied in payment of the Senior Debt, regardless of whether such Senior Debt, or any portion thereof, is reduced, expunged, disallowed, subordinated or recharacterized; 

 

	 	b)	Notwithstanding the foregoing, if any payment or distribution of any kind, whether in cash, property or securities, shall be received by WCAS on account of the Subordinated Debt before all of the Senior Debt has been
paid, then such payment or distribution shall be received by WCAS in trust for, and shall be promptly paid over to, Lenders and applied in payment of the Senior Debt, regardless of whether such Senior Debt, or any portion thereof, is reduced,
expunged, disallowed, subordinated or recharacterized; 

  

	 	c)	The immediately preceding subsections (a) and (b) shall be enforceable even if Lenders’ liens on the Collateral are declared fraudulent, preferential or otherwise avoided, set aside, recharacterized or equitably
subordinated; 

  

	 	d)	WCAS will not, and hereby waives any right to bring, join in, or otherwise support any action to (i) contest the validity, legality, enforceability, perfection, priority or avoidability of any of the Senior Debt, any of
the Senior Term Loan Documents or any security interests and/or liens of Lenders on or in any property or assets of Borrower or any Subsidiary Guarantor with respect to the Senior Debt, including without limitation, the Collateral; (ii) request or
require the marshaling of any assets of Borrower or any Subsidiary Guarantor with respect to the Senior Debt; (iii) provide a priming debtor-in-possession facility to the Borrower or any Subsidiary Guarantor without the consent, in their sole
discretion, of the Required Lenders; or (iv) exercise any rights against the Lenders or the Collateral under Section 506(c) of the Bankruptcy Code; 

  

	 	e)	 WCAS will not, and hereby waives any right to object to, join in, or otherwise support any objection with respect
to, (i) any request or motion of the Required Lenders seeking the modification, lifting or vacating of the automatic stay with respect to the Collateral or seeking adequate protection of Lenders’ interests in the Collateral or with respect to
the Senior Debt; (ii) any debtor-in-possession financing or use of cash collateral arrangement if the Required Lenders, in their sole discretion, consent to such debtor-in-possession financing or cash collateral arrangement; (iii) any sale of the
Collateral or substantially 

  
 4 

	 	
all of the assets of the Borrower and/or any Subsidiary Guarantor under Section 363 of the Bankruptcy Code if the Required Lenders, in their sole discretion, consent to such sale; (vii)
Lenders’ right to make an election under Section 1111(b) of the Bankruptcy Code; (viii) Lenders’ right to credit bid any or all of its debt claims against the Borrower or any Subsidiary Guarantor, including, without limitation, the
Senior Debt; or (ix) any plan of reorganization or liquidation if the Required Lenders, in their sole discretion, consent to such plan of reorganization or liquidation, and, in furtherance thereof, WCAS hereby grants to the Lenders the right to vote
WCAS’s claim on account of the Subordinated Debt with respect to any plan of reorganization or liquidation to which WCAS may be entitled in any bankruptcy or liquidation proceeding of the Borrower and/or any Subsidiary Guarantor.

 5. Distributions of Proceeds of Collateral. All realizations upon any Collateral pursuant to an Enforcement Action, an
Insolvency Event or otherwise shall be paid or delivered to Lenders and applied first to the Senior Debt until the Senior Debt is indefeasibly paid in full before any payment may be made to WCAS. 

6. Attorney-In-Fact. Until the Senior Discharge Date, WCAS irrevocably appoints the Control Agent as its attorney-in-fact, with power of attorney
with power of substitution, in WCAS’s name or in Lenders’ name, for Lenders’ use and benefit, to do the following during an Insolvency Event: 
  

	 	a)	file appropriate claims in respect of the Subordinated Debt on behalf of WCAS if WCAS does not do so at least 30 days before the time to file claims expires (provided that the Lenders shall use good faith diligent
efforts promptly to give WCAS copies of such claims or notice of such action, as the case may be, but failure by Lenders to do so shall not impair the rights of the Lenders under this Agreement or otherwise result in the imposition of any liability
on the Lenders hereunder) if Lenders elect, in their sole discretion, to file such claim or claims and (b) vote WCAS’s claim on account of the Subordinated Debt with respect to any plan of reorganization or liquidation to which WCAS may be
entitled in any bankruptcy or liquidation proceeding of the Borrower and/or any Subsidiary Guarantor; 

 Such power of attorney
is irrevocable and coupled with an interest. 
 7. Legend; Amendment of Debt. 

(a) WCAS will cause Borrower to immediately put a legend on or otherwise indicate on the Subordinated Note that the Subordinated Note is
subject to this Agreement. 
 (b) Until the Senior Discharge Date, WCAS shall not, without prior written consent of the Required Lenders,
agree to any amendment, modification or supplement to the Subordinated Debt Documents, if the effect of such amendment, modification or supplement is to: (i) terminate or impair the subordination of the Subordinated Debt in favor of the
Lenders, (ii) increase the interest rate in respect of the Subordinated Debt or change (to earlier dates) the dates upon which principal, interest and other sums are due under the Subordinated Note; (iii) alter the redemption, prepayment or
subordination provisions of the Subordinated Note in a 

  
 5 

 
manner that individually or in the aggregate would be adverse to Borrower of the Subordinated Debt or Lenders; (iv) impose on Borrower any new or additional prepayment charges, premiums,
reimbursement obligations, reimbursable costs or expenses, fees or other payment obligations; (v) alter the representations, warranties, covenants, events of default, remedies and other provisions in a manner which would make such provisions
materially more onerous, restrictive or burdensome to Borrower; (vi) grant a lien or security interest in favor of any holder of the Subordinated Debt on any asset or Collateral to secure all or any portion of the Subordinated Debt, or (vii)
otherwise increase the obligations, liabilities and indebtedness in respect of the Subordinated Debt or confer additional rights upon WCAS, which individually or in the aggregate would be materially adverse to Borrower or Lenders, provided,
however, that WCAS shall be permitted to amend or modify the Subordinated Debt Documents to modify or add covenants or defaults to the extent the corresponding provisions of the Senior Term Loan Documents have been added, amended or modified.

 (c) Until the Senior Discharge Date, Lenders may take such action with respect to the Senior Debt as Lenders, in their sole discretion,
may deem appropriate, provided, however, that unless and until the Subordinated Note is paid in full in cash, Lenders may not, without prior written consent of WCAS, agree to any amendment, modification or supplement to the Senior Term
Loan Documents, if the effect of such amendment, modification or supplement is to: (i) increase the maximum principal amount of the Senior Debt other than (a) in a principal amount not to exceed $20,000,000 (which, for the avoidance of doubt, may be
provided under a second lien term loan agreement) and (b) as such principal amount of Senior Debt may be increased by the accrual of PIK interest; (ii) increase the interest rates applied to the unpaid principal balance of the Senior Debt; or (iii)
impose any restrictions on the making of payments with respect to the Subordinated Debt that do not already exist in the Senior Term Loan Documents as in effect on the date hereof. No action or inaction will impair or otherwise affect
Lenders’ rights under this Agreement. For the further avoidance of doubt, notwithstanding anything to the contrary set forth herein, Lenders shall not require the consent of WCAS to impose default interest on the Senior Debt under the terms of
the Senior Term Loan Documents. 
 8. WCAS Acknowledgement of Lien Subordination. WCAS acknowledges and agrees that the Lenders have been
granted liens upon the Collateral, and WCAS hereby consents thereto and to the incurrence of the Senior Debt. WCAS represents and warrants to the Lenders that as at the date of this Agreement, the Subordinated Debt is unsecured. WCAS
agrees that it shall not obtain a lien or security interest on any asset or Collateral to secure all or any portion of the Subordinated Debt; provided further that should WCAS obtain a lien or security interest on any asset or Collateral to secure
all or any portion of the Subordinated Debt for any reason, notwithstanding the respective dates of attachment and perfection of the security interests in the Collateral in favor of the Lenders or WCAS, or any contrary provision of the UCC, or any
applicable law or decision to the contrary, or the provisions of the Senior Term Loan Documents or the Subordinated Debt Documents, and irrespective of whether WCAS or the Lenders hold possession of any or all part of the Collateral, all now
existing or hereafter arising security interests in the Collateral in favor of WCAS in respect of the Subordinated Debt Documents shall at all times be subordinate to the security interest in such Collateral in favor of the Lenders in respect of the
Senior Term Loan Documents. Additionally, WCAS shall not accept or take any guaranty of the Subordinated Debt. 

  
 6 

 Until the Senior Discharge Date, in the event of any private or public sale or other disposition
of all or any portion of the Collateral, WCAS agrees that such Collateral shall be sold or otherwise disposed of free and clear of any liens in favor of WCAS in respect of the Subordinated Debt Documents. WCAS agrees that any such sale or
disposition of Collateral shall not require any consent from WCAS, and WCAS hereby waives any right it may have to object to such sale or disposition. 
 9.
Representations and Warranties. Each party hereto represents and warrants to each other party hereto that: 
 (a) all action on
the part of such party, its officers, directors, partners, members and shareholders, as applicable, necessary for the authorization of this Agreement and the performance of all obligations of such party hereunder has been taken; 

(b) this Agreement constitutes the legal, valid and binding obligation of such party, enforceable against such party in accordance with its
terms; 
 (c) the execution, delivery and performance of and compliance with this Agreement by such party will not (i) result in any
material violation or default of any term of any of such party’s charter, formation or other organizational documents (such as Articles or Certificate of Incorporation, bylaws, partnership agreement, operating agreement, etc.) or (ii) violate
any material applicable law, rule or regulation. 
 10. Term; Reinstatement. This Agreement shall remain effective until the Senior Discharge
Date. If, after the Senior Discharge Date, Lenders must disgorge any payments made on the Senior Debt for any reason (including, without limitation, the bankruptcy of Borrower), this Agreement and the relative rights and priorities provided in
it, will be reinstated as to all disgorged payments as though such payments had not been made, and WCAS will immediately pay Lenders all payments received in respect of the Subordinated Debt to the extent such payments or retention thereof would
have been prohibited under this Agreement. 
 11. Successors and Assigns. This Agreement shall be binding upon, inure to the benefit of and be
enforceable by each Lender and WCAS and in each case their respective successors or assigns. WCAS shall not sell, assign, pledge, dispose of or otherwise transfer all or any portion of the Subordinated Debt or any related document or any
interest in any Collateral therefor unless prior to the consummation of any such action, the transferee thereto shall execute and deliver to Lenders an agreement of such transferee to be bound hereby, or an agreement substantially identical to this
Agreement providing for the continued subjection of the Subordinated Debt, any interests of the transferee in the Collateral and the remedies of the transferee with respect thereto as provided herein with respect to WCAS and for the continued
effectiveness of all of the other rights of Lenders arising under this Agreement, in each case in form satisfactory to Lenders. 
 12. Further
Assurances. WCAS hereby agrees to execute such documents and/or take such further action as Lenders may at any time or times reasonably request in order to carry out the provisions and intent of this Agreement, including, without
limitation, ratifications and confirmations of this Agreement from time to time hereafter. 

  
 7 

 13. Reliance. For the avoidance of doubt, in connection with any payment or distribution by WCAS to
any Lender, WCAS shall be entitled to rely for the purpose of ascertaining the Persons entitled to participate in such payment or distribution, the holders of the Senior Debt and other indebtedness or obligations of Borrower, the amount thereof or
payable thereon, the amount or amounts paid or distributed thereon and all other facts pertinent thereto or to this Agreement and for purposes of determining whether the provisions of this Agreement have been fully effectuated and carried out, and
the rights and obligations of the parties hereto given effect, (i) upon any order, judgment or decree of a court of competent jurisdiction in which (x) any bankruptcy, reorganization, insolvency, receivership or similar proceeding relating to
Borrower or its property is pending or (y) any other proceeding to which the Lenders have been properly joined as parties is pending, (ii) upon a certificate of the liquidating trustee or agent or other Person making such payment or distribution to
WCAS or (iii) upon any trustee, agent or other representative for the holder of the applicable Senior Debt. In the event that WCAS determines, in good faith (and with a reasonable basis for so concluding), that evidence is required with respect to
the right of any Person as a holder of Senior Debt to participate in any payment or distribution pursuant to this Agreement, WCAS may request such Person to furnish reasonable evidence as to the amount of such Senior Debt held by such Person, the
extent to which such Person is entitled to participate in such payment or distribution and other facts pertinent to the rights of such Person under this Agreement, and, if such evidence is not furnished, WCAS may defer any payment to such Person
pending judicial determination as to the right of such Person to receive such payment. 
 14. Counterparts. This Agreement may be executed in
two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. Executed counterparts may be delivered by facsimile. 

15. Governing Law; Waiver of Jury Trial. 

(a) This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of
the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply. 

(b) EACH PARTY HERETO WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OF
THE TRANSACTIONS CONTEMPLATED HEREIN. 
 16. Entire Agreement; Waivers and Amendments. This Agreement represents the entire agreement with
respect to the subject matter hereof, and supersedes all prior negotiations, agreements and commitments. Lenders and WCAS are not relying on any representations by the other creditor party or Borrower in entering into this Agreement. No
amendment, modification, supplement, termination, consent or waiver of or to any provision of this Agreement, nor any consent to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the Required
Lenders and WCAS. Any waiver of any provision of this Agreement, or any consent to any departure from the terms of any provision of this Agreement, shall be effective only in the specific instance and for the specific purpose for which
given. No failure or delay on the part of any Lender or WCAS in the exercise of any power, right, remedy 

  
 8 

 
or privilege under this Agreement shall impair such power, right, remedy or privilege or shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or
privilege preclude any other or further exercise of any other power, right or privilege. The waiver of any such right, power, remedy or privilege with respect to particular facts and circumstances shall not be deemed to be a waiver with respect
to other facts and circumstances. 
 17. Legal Fees. In the event of any legal action to enforce the rights of a party under this Agreement, the
party prevailing in such action shall be entitled, in addition to such other relief as may be granted, all reasonable, invoiced and out-of-pocket costs and expenses, including reasonable attorneys’ fees, incurred in such action. 

18. Severability. Any provision of this Agreement which is illegal, invalid, prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent such illegality, invalidity, prohibition or unenforceability without invalidating or impairing the remaining provisions hereof or affecting the validity or enforceability of such provision in any other
jurisdiction. 
 19. Notices. All notices, demands, instructions and other communications required or permitted to be given to or made upon any
party hereto shall be in writing and shall be delivered or sent by first-class mail, postage prepaid, or by overnight courier or messenger service or by facsimile, message confirmed, and shall be deemed to be effective for purposes of this Agreement
on the day that delivery is made or refused. Unless otherwise specified in a notice mailed or delivered in accordance with the foregoing sentence, notices, demands, instructions and other communications in writing shall be given to or made upon
the respective parties hereto at their respective addresses and facsimile numbers indicated on the signature pages hereto. 
 20. Loan
Document. Notwithstanding anything to the contrary in the Senior Term Loan Agreement, the parties agree that this Agreement shall be a “Loan Document” under the Senior Term Loan Agreement. 

[Signature pages follow.] 

  
 9 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above
written. 
  

			
	WCAS:
	
	WCAS CAPITAL PARTNERS IV, L.P.
	
	By WCAS CP IV Associates LLC, its General Partner
		
	By	 	  

		 	Name:
		 	Title:
	
	Address for Notices:
	
	  

	  

	Attn:
	Tel:
	Fax:

  
 [Signature Page to
Second Amended and Restated Subordination Agreement] 

									
	LENDERS:
	
	CAPITAL ROYALTY PARTNERS II L.P.
		 	By CAPITAL ROYALTY PARTNERS II GP L.P., its General Partner
		 		 	By CAPITAL ROYALTY PARTNERS II GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory
	
	CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P.
		 	 By CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” GP L.P., its General

Partner

		 		 	By CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory
	
	PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
		 	By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP L.P., its General Partner
		 		 	By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory

  
 [Signature Page to
Second Amended and Restated Subordination Agreement] 

									
	CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.
		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP L.P., its General Partner
		 		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory
				
		 		 		 	WITNESS:
		 		 		 	Name:	 	
	
	CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “B” (CAYMAN) L.P.
		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP L.P., its General Partner
		 		 	By CAPITAL ROYALTY PARTNERS II (CAYMAN) GP LLC, its General Partner
				
		 		 	By	 	  

		 		 		 	Name:	 	Nathan Hukill
		 		 		 	Title:	 	Authorized Signatory
				
		 		 		 	WITNESS:
		 		 		 	Name:	 	
	
	Address for Notices:
	
	1000 Main Street, Suite 2500
	Houston, TX 77002
	Attn: General Counsel
	Tel: 713.209.7350
	Fax: 713.209.7351

  
 [Signature Page to
Second Amended and Restated Subordination Agreement] 

			
	Acknowledged and Agreed to:
	
	BORROWER:
	
	VALERITAS, INC.
		
	By	 	  

		 	Name:
		 	Title:
	
	Address for Notices:
	750 Route 202 South, Suite 100
	Attn: Chief Financial Officer
	Bridgewater, NJ 08807
	Tel: 908.927.9920
	Fax: 908.927.9927

  
 [Signature Page to
Second Amended and Restated Subordination Agreement]EX-10.24

 Exhibit 10.24 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”), effective as of May 3, 2016 (the “Effective Date”), is entered into by and
between Valeritas, Inc., a Delaware corporation (the “Company”), and John Timberlake (the “Executive”). The Company and the Executive are referred to each individually as a “party” and collectively as the
“parties.” 
 RECITALS: 

WHEREAS, the Company and the Executive previously executed an Employment Agreement, dated February 18, 2016 (the “Original
Agreement”); and 
 WHEREAS, the Executive and the Company desire to amend and restate the terms and conditions of the Original
Agreement and to continue the Executive’s employment with the Company upon the amended and restated terms and conditions as set forth herein in this Agreement. 

NOW, THEREFORE, in consideration of the mutual agreements herein set forth, the parties agree as follows: 

1. Term. Subject to termination under Section 4, this Agreement shall be effective for the period beginning on the
Effective Date and continuing until the third anniversary of the Effective Date. The term of this Agreement shall automatically renew for periods of one-year, unless either party gives written notice to the other party at least 30 days prior to the
end of the then existing term or any one-year renewal period, that the term of the Agreement shall not be further extended. The period commencing on the Effective Date and ending on the date on which the term of the Agreement terminates in
accordance with this Section 1 or upon termination of employment in accordance with Section 4 is referred to hereinafter as the “Term.” Nothing in this Agreement shall be construed as giving the Executive any right to be retained
in the employ of the Company, and the Executive specifically acknowledges that the Executive shall be an employee-at-will of the Company, and thus subject to discharge at any time by the Company with or without Cause (as defined in Section 4)
and without compensation of any nature except as provided in Section 5 below. 
 2. Duties. During the Term, the
Executive shall serve as the Chief Executive Officer, Chief Commercial Officer, President and Secretary of the Company, and shall perform the executive and administrative duties, functions and privileges incumbent with such positions and such other
duties as reasonably determined and assigned by the Board of Directors of the Company (the “Board”), from time to time. In addition, the Executive shall serve as the Chief Executive Officer, Chief Commercial Officer and President of
Valeritas Holdings, Inc., the parent of the Company. The Executive shall devote substantially all of his time, attention and skill to such duties, except for paid vacation and other excused absence periods, and shall serve the Company and its
affiliates faithfully and to the best of his ability, and shall use his best efforts to promote the success of the business of the Company. The Executive’s employment is subject to compliance with the Company’s policies, including any code
of conduct, all as may be amended from time to time. 
 Notwithstanding the foregoing, nothing in this Section 2 will prevent the
Executive from 

 
engaging in additional activities in connection with personal investments and community affairs that are not materially inconsistent with the Executive’s duties under this Agreement and that
do not violate Section 6. 
 3. Compensation. 

a. Base Salary. During the Term, the Company shall pay to the Executive an annual base salary (“Base Salary”) of at least
$392,141, less applicable and authorized deductions, subject to review annually for appropriate increases by the Board pursuant to the normal performance review policy for senior level executives. The Base Salary shall be payable in accordance with
the Company’s payroll schedule. 
 b. Annual Bonus. For each calendar year during the Term, the Executive shall be eligible to
earn an annual discretionary bonus (“Annual Bonus”) based upon the level of attainment of performance goals established by the Board. The target level of the Annual Bonus during the period he is serving as Chief Executive Officer, Chief
Commercial Officer, President and Secretary of the Company is 50% of the Executive’s Base Salary (the “Target Bonus”). The Executive’s actual Annual Bonus, if any, will be awarded in the Company’s discretion, and shall be
paid in accordance with the terms and conditions of the Company’s Annual Bonus program. Except as provided in Section 5, in no event will the Executive be eligible to be awarded an Annual Bonus if the Executive is not actively employed by the
Company on, or has given or received notice of termination or resignation prior to, the date on which bonuses for the applicable year are paid to similarly situated employees. In no event will any Annual Bonus be paid later than March 15 of the
calendar year following the calendar year for which the Annual Bonus is earned. The Executive’s receipt of an Annual Bonus in one year does not guarantee receipt of any bonus in any subsequent year. 

c. Equity Compensation. The Executive currently holds outstanding equity awards that remain subject to the terms of the applicable
award agreement evidencing the equity award. The Executive will be eligible to receive equity awards pursuant to the terms of the Valeritas Holdings, Inc. 2016 Incentive Compensation Plan, or successor equity compensation plan, as each may be
amended from time to time (the “Equity Plan”) as determined by the Company in its discretion. All determinations as to eligibility to receive equity awards, as well as the amount of any such equity grants made under the Equity Plan, shall
be made in the Company’s sole discretion, subject to final approval by the Board or its designee. All equity awards shall be subject to the terms of the award agreement evidencing the equity award and the Equity Plan, or other equity plan
pursuant to which the equity award was granted. 
 d. Other Benefits. During the Term, the Executive shall be eligible to participate
in such employee benefit plans, programs or arrangements as are generally made available from time to time to other Company senior executives, to the extent the Executive is eligible under the terms of the plans, programs or arrangements pursuant to
which such benefits are provided. Nothing in this Agreement shall prevent the Company from amending or terminating any Company employee benefit plan, program or arrangement from time to time as the Company deems appropriate. 

e. Paid Time Off. During the Term, the Executive shall accrue a minimum of four (4) weeks paid time off each year, subject to the terms
of the Company’s paid time off policy as in effect from time to time. 

  
 2 

 4. Termination Events. This Agreement, the Executive’s employment with the
Company and its affiliates, and any and all rights of the Executive under this Agreement will terminate (except as otherwise provided in Section 5): 

a. Upon the death of the Executive; 

b. If the Company terminates the Executive due to the Disability (as hereinafter defined) of the Executive, immediately upon notice from the
Company to the Executive; 
 c. For Cause (as hereinafter defined), immediately upon notice from the Company to the Executive, or such later
time as such notice may specify; 
 d. If the Company terminates the Executive without Cause or the Executive resigns for Good Reason (as
hereinafter defined); and 
 e. If the Executive resigns other than for Good Reason. 

The Executive agrees to resign from all officer and director positions with the Company and its affiliates effective upon the Executive’s
termination of employment. 
 For purposes of this Agreement, the Executive will be deemed to have a “Disability” if he is
disabled within the meaning of such term under the Company’s long-term disability plan. 
 For purposes of this Agreement,
“Cause” shall mean the Executive’s (i) misappropriation of funds with respect to the Company or its affiliates, (ii) a material violation of this Agreement or of the employment policies of the Company or an affiliate, as in effect
from time to time, (iii) a breach of any written confidentiality, nonsolicitation or noncompetition covenant with the Company or an affiliate, including but not limited to those set forth in this Agreement, (iv) conviction of a felony, or (v)
misconduct that has a material adverse effect on the business, operations, assets, properties, or financial condition of the Company or an affiliate; provided, however, that to the extent the Board determines to terminate the Executive for
Cause based on violation under clause (ii) or a breach under (iii), the Board shall provide the Executive with ten(10) days’ written notice prior to such a termination for Cause and the Executive shall have an opportunity to cure the applicable
violation or breach, but only to the extent such violation or breach, as applicable, is capable of being cured, as determined by the Board in its sole discretion. 

For purposes of this Agreement, the Executive shall have “Good Reason” if he provides the Company with written notice of his intent to resign within
sixty (60) days after the occurrence of any of the following without the Executive’s written consent: (i) a material diminution in the Executive’s duties, authority or responsibilities relative to the duties, authority or responsibilities
in effect immediately prior to the change such that Executive no longer has the title of, or serves or functions as, Chief Executive Officer of the Company; (ii) the Company requires that the 

  
 3 

 
Executive’s principal office location be moved to a location more than fifty (50) miles from the Executive’s principal office location immediately before the change; (iii) a material
diminution by the Company of the Executive’s Base Salary or Target Bonus; (iv) the Company fails to renew the Agreement, in accordance with Section 1; or (v) any material breach by the Company of this Agreement; provided, however, that the
occurrence of an event described in clauses (i) through (v) of this definition shall not constitute Good Reason if such event is fully corrected in all material respects by the Company within thirty (30) days following the receipt of the
Executive’s written notice of his intent to resign. If the Company fails to cure the event described in clauses (i) through (v) the Executive must actually resign within thirty (30) days following the expiration of the cure period. 

5. Obligations Upon Termination. 

a. By the Company or the Executive for any Reason. If the Executive’s employment is terminated by the Company or the Executive for
any reason, with or without Cause (as defined below), the Executive will have no further rights against the Company or an affiliate hereunder, except as set forth in subsection (b) or (c) below to the extent applicable, and except for the right to
receive any unpaid Base Salary attributable to employment before the termination date and any other payments that have accrued or fully vested but which have not yet been paid prior to such termination. Other than the payments set forth in this
subsection (a) and subsections (b) and (c) below, as applicable, the Executive will not be entitled to receive any other compensation for the calendar year during which the Executive’s termination of employment occurs or any subsequent calendar
period. 
 b. By the Company without Cause or the Executive for Good Reason. If the Executive’s employment is terminated by the
Company without Cause (other than due to death or Disability), or the Executive resigns for Good Reason, and in either case the Executive executes and does not revoke a Release (as defined in subsection (e) below) (a “Qualifying
Termination”), then the Executive will be eligible to receive the benefits set forth in either subsection (i) or (ii) below (but not both). 

(i) Not in Connection with a Change in Control. If the Qualifying Termination occurs prior to the effective date of a Change in
Control (as defined in the Equity Plan) and the Qualifying Termination is not a “Qualifying Pre-Closing Termination” (as defined in subsection (ii) below), or the Qualifying Termination occurs more than twelve (12) months after a Change in
Control (in either case, a “Standard Qualifying Termination”), the Executive shall be entitled to: 
 (1)
continuation of the Executive’s Base Salary (at the salary rate then in effect) for twelve (12) months following the Executive’s employment termination date (the “Severance Period”), in accordance with the Company’s payroll
schedule, commencing on the sixtieth (60th) day after the Executive’s effective date of termination, with the first such installment payment including any unpaid severance payments that would have been made on the normal payroll dates occurring
during the first sixty (60) days following the date of termination; 

  
 4 

 (2) an Annual Bonus for the year in which the Executive’s Qualifying
Termination occurs, subject to achievement of any performance targets or goals applicable to such Annual Bonus and otherwise to the extent that the Company, in its sole discretion, awards bonuses to its executives for the year in which the
termination occurs, and any such Annual Bonus shall be pro-rated to reflect the Executive’s employment with the Company through the date of termination and shall be payable in a lump sum at the same time as other such annual bonuses are payable
to active employees; 
 (3) any Annual Bonus earned but not yet paid for any completed full fiscal year immediately
preceding the employment termination date; and 
 (4) provided that the Executive is eligible for and timely elects COBRA
continuation coverage under the Company’s group health plan, the Company will reimburse the Executive for the monthly COBRA cost of continued coverage under such plan for the Executive, and, where applicable, his spouse and dependents, less the
amount the Executive would have been required to pay for such coverage if the Executive were an active employee of the Company, for the Severance Period, or until the Executive becomes employed by another employer offering any such benefits
(whichever is earlier), provided that the Company reserves the right to restructure the foregoing reimbursement arrangement in any manner necessary or appropriate to avoid fines, penalties or negative tax consequences to the Company or any affiliate
or the Executive (including, without limitation, to avoid any penalty imposed under the Patient Protection and Affordable Care Act or the guidance issued thereunder), as determined by the Company in its sole and absolute discretion. The Executive
agrees to provide the Company with notice of eligibility under another health plan within two (2) weeks of such eligibility. The Executive shall submit appropriate evidence of each such expense within sixty (60) days after his receipt of the invoice
or billing statement for such expense, and the Company shall provide the Executive with the requisite reimbursement on the next payroll date thereafter. The monthly reimbursements described in this clause (4) shall be paid in normal payroll
installments, commencing on the sixtieth (60th) day after the Executive’s effective date of termination. The first such installment payment shall include any unpaid severance payments that would have been made on the normal payroll dates
occurring during the first sixty (60) days following the date of termination. The COBRA health care continuation coverage period under section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”) shall run concurrently with
the Severance Period. 
 (ii) In Connection with a Change in Control. If the Qualifying Termination occurs either (A) within three
months prior to the effective date of a Change in Control but during the “Pre-Closing Period” (as defined below) (a “Qualifying Pre-Closing Termination”), or (B) on the date of, or within twelve (12) months after, the effective
date of a Change in Control (in either case, together with a Qualifying Pre-Closing Termination, a “CIC 

  
 5 

 
Qualifying Termination”), the Executive shall be entitled to the same payments and benefits set forth under Section 5(b)(i) above, except that (1) the Severance Period for purposes of
Sections 5(b)(i)(1) and 5(b)(i)(4) shall extend for eighteen (18) months instead of twelve (12) months and (2) in lieu of the Annual Bonus set forth in Section 5(b)(i)(2), the Executive shall receive the Target Annual Bonus for the year in which the
Executive’s Qualifying Termination occurs, pro-rated to reflect the Executive’s employment with the Company through the date of termination, which shall be payable to the Executive on the sixtieth (60th) day following the Executive’s
employment termination date, provided that if the Change in Control occurs after a Qualifying Termination under Section 5(b)(i) above, but prior to payment of the Annual Bonus for the year in which the Executive’s termination of employment
occurs, the pro-rated Target Annual Bonus described in this subsection (ii) shall be paid on the sixtieth (60th) day following the Change in Control. For the avoidance of doubt, if a Change in Control occurs after a Qualifying Termination under
Section 5(b)(i) above, and after payment of the pro-rated Annual Bonus described in Section 5(b)(i)(2), the Executive shall not be eligible to receive any additional payments for any Annual Bonus, including the Target Annual Bonus described in this
subsection (ii). 
 For purposes of this Agreement, the “Pre-Closing Period” means the period commencing with the Company’s
execution of a definitive agreement for a Change in Control transaction and ending upon the earlier to occur of (A) the closing of the Change in Control contemplated by such definitive agreement and (B) the termination of such definitive agreement
without the consummation of the contemplated Change in Control. 
 (iii) No Duplication of Benefits. Notwithstanding anything to the
contrary, under no circumstances shall the Executive be eligible to receive payments under both subsections (i) and (ii) of this Section 5(b). 

c. Death or Disability. If the Company terminates the Executive’s employment on account of the Executive’s Disability
(subject to the requirements of applicable law) or if the Executive dies while employed by the Company, the Company shall pay the Executive (or the Executive’s estate in the case of death) the Executive’s Base Salary (at the salary rate
then in effect) for three (3) months following the Executive’s termination of employment, in accordance with the Company’s payroll schedule, commencing on the sixtieth (60th) day after the Executive’s effective date of termination,
with the first such installment payment including any unpaid severance payments that would have been made on the normal payroll dates occurring during the first sixty (60) days following the date of termination. Except as provided in subsection (a)
above, the Executive shall not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period. 

d. Employee Benefit Plans. The Executive’s accrual of or participation in plans providing for benefits will cease on the effective
date of the Executive’s termination of employment and the Executive will be entitled to accrued benefits pursuant to such plans only as provided in such plans. The Executive will not receive, as part of his termination pay pursuant to this
Section 5, any payment or other compensation for any vacation, holiday, sick leave or other leave unused on the effective date of termination of the Executive’s employment pursuant to this Agreement, except to the extent required to be paid by
applicable law. 

  
 6 

 e. Release Requirement. The Company will be obligated to provide the severance benefits
set forth in this Section 5 (except in the case of death) only if the Executive executes and does not revoke a complete release of any and all claims that the Executive may have against the Company and its affiliates, substantially in the form
attached hereto as Exhibit A, with such changes as are required to comply with applicable law at the time of the Executive’s termination of employment or as reasonably determined by Company counsel to be necessary or appropriate (the
“Release”). Such Release shall become effective upon the expiration of the revocation period contemplated thereby, as long as the Executive does not revoke the Release during such revocation period. Notwithstanding anything to the
contrary, if the Release is not effective as of the scheduled payment date for the Executive’s receipt of the payments and/or benefits set forth in this Section 5 (other than subsection (a)) (e.g., on the sixtieth (60th) day following the
Executive’s termination date), the Executive will forfeit such payments and/or benefits. 
 f. Code section 280G.
Notwithstanding anything to the contrary, if any severance payment under this Section 5, either alone or together with any other payment which the Executive has received or has the right to receive from the Company or an affiliate (“Total
Payments”), would otherwise exceed the amount (the “Safe Harbor Amount”) that could be received by the Executive without the imposition of an excise tax under section 4999 of the Code, then the Total Payments shall be reduced to the
extent, and only to the extent, necessary to assure that their aggregate present value, as determined in accordance the applicable provisions of section 280G of the Code and the regulations thereunder, does not exceed the greater of the following
dollar amounts: (i) the Safe Harbor Amount, or (ii) the greatest after-tax amount payable to the Executive after taking into account any excise tax imposed under section 4999 of the Code on the Total Payments. The Company shall pay all of the fees,
including legal and accounting fees, associated with calculating the amounts set forth in this subsection (f). 
 6. Covenant Not to
Compete; Non-Disclosure of Information; Invention Assignment; Return of Company Property. 
 a. Covenant Not to Compete/Not to
Solicit. The Executive acknowledges and recognizes that the Company operates in a competitive field and that confidential information concerning its business operations is a substantial asset that was acquired through considerable time, money
and effort. Accordingly, in consideration of the execution of this Agreement, the Executive agrees to the following: 
 (i) During the
Restricted Period (as defined below) and within the Restricted Area (as defined below), the Executive will not, individually or in conjunction with others, directly or indirectly, engage in any activities with a Competitive Business (as defined
below), whether as an officer, director, proprietor, employer, partner, independent contractor, active investor, consultant, advisor or agent, except in connection with the Executive’s responsibilities as an employee of the Company or an
affiliate. 

  
 7 

 (ii) During the Restricted Period, the Executive will not, directly or indirectly, compete with
the Company by soliciting, inducing or influencing any Company Clients (as defined below) to discontinue or reduce the extent of such relationship with the Company. 

(iii) During the Restricted Period, the Executive will not (1) directly or indirectly recruit, solicit or otherwise influence any employee or
agent of the Company to discontinue such employment or agency relationship with the Company, or (2) employ or seek to employ, or cause or permit any Competitive Business to employ or seek to employ for any Competitive Business any person who is then
(or was at any time within one (1) year prior to the date the Executive or the Competitive Business employs or seeks to employ such person) employed by the Company. 

(iv) During the Restricted Period, the Executive will not interfere with, or disrupt or attempt to disrupt any relationship, contractual or
otherwise, between the Company and any Company Clients, customer, employee or agent of the Company. 
 b. Non-Disclosure of
Information. The Executive acknowledges that the Company’s trade secrets, private or secret processes, methods and ideas, as they exist from time to time, customer lists and other confidential information concerning the Company’s
products, services, training methods, development, technical information, marketing activities and procedures, credit and financial data concerning the Company and/or the Company’s Clients (the “Proprietary Information”) are valuable,
special and unique assets of the Company, access to and knowledge of which are essential to the performance of the Executive hereunder. In light of the highly competitive nature of the industry in which the Company’s business is conducted, the
Executive agrees that all Proprietary Information, heretofore or in the future obtained by the Executive as a result of the Executive’s association with the Company shall be considered confidential. 

In recognition of this fact, the Executive agrees that the Executive will not use or disclose any of such Proprietary Information for the
Executive’s own purposes or for the benefit of any person or other entity or organization (except the Company) under any circumstances, except as set forth in Section 6.1 below, unless such Proprietary Information has been publicly disclosed
generally or, unless upon written advice of legal counsel reasonably satisfactory to the Company, the Executive is legally required to disclose such Proprietary Information. Documents (as defined below) prepared by the Executive or that come into
the Executive’s possession during the Executive’s association with the Company that include Proprietary Information are and will remain the property of the Company, and when this Agreement terminates, such Documents shall be returned to
the Company at the Company’s principal place of business, as provided in the Notice provision (Section 10.f) of this Agreement or destroyed. 

c. Documents. “Documents” shall mean all original written, recorded, or graphic matters whatsoever, and any and all copies
thereof, including, but not limited to: papers; books; records; tangible things; correspondence; communications; telex messages; memoranda; work-papers; reports; affidavits; statements; summaries; analyses; evaluations; customer mailing lists;
client records and information; agreements; agendas; advertisements; instructions; charges; manuals; brochures; publications; directories; industry lists; schedules; price lists; client lists; 

  
 8 

 
statistical records; training manuals; computer printouts; books of account, records and invoices reflecting business operations; all things similar to any of the foregoing however denominated.
In all cases where originals are not available, the term “Documents” shall also mean identical copies of original documents or non-identical copies thereof. 

d. Company’s Clients. The “Company’s Clients” shall be any person or entity for whom the Company has a contractual
relationship, including, but not limited to, any person or entity which has entered into any contract for the distribution of any of the Company’s products within one (1) year immediately preceding the date Executive’s employment with the
Company terminates. 
 e. Restricted Period. The “Restricted Period” shall be at all times during the Executive’s
employment with the Company, and shall extend for twelve (12) months following the Executive’s termination of employment if such termination is a Standard Qualifying Termination, or for eighteen (18) months following the Executive’s
termination of employment if such termination is a CIC Qualifying Termination, provided, however, that the Restricted Period shall be extended by any period of time during which the Executive is in breach of the covenants set forth in this Section
6. The periods of time during which the Executive is in violation of the covenants set forth in this Section 6 shall be in addition to the Restricted Period specified herein. 

f. Restricted Area. The “Restricted Area” shall mean any geographic area in which the Company actively did business within
the twelve (12) months preceding the Executive’s termination of employment or which the Company planned to conduct business during that same period. 

g. Competitive Business. “Competitive Business” shall mean a company that is in any stage of research, development or
commercialization of a patch, pump or other extended insulin release device or mechanism primarily targeted to diabetic patients. Notwithstanding the foregoing, the following activities will not be prohibited “Competitive Business”
activities: (i) a passive investment of up to five percent (5%) of the outstanding stock of a publicly held corporation regardless of whether such corporation engages in a Competitive Business; (ii) providing investment banking services on behalf of
an investment banking firm regardless of whether or not such firm is providing services to an entity engaged in a Competitive Business; or (iii) the Executive commencing employment with any entity that engages in both Competitive Business activities
and activities which are not Competitive Business activities so long as the Executive provides services to such entity with respect to non-Competitive Business activities and does not engage in Competitive Business activities. 

h. Covenants as Essential Elements of this Agreement. It is understood by and between the parties hereto that the foregoing covenants
contained in Sections 6(a) and 6(b) are essential elements of this Agreement, and that but for the agreement by the Executive to comply with such covenants, the Company would not have agreed to enter into this Agreement. Such covenants by the
Executive shall be construed to be agreements independent of any other provisions of this Agreement. 

  
 9 

 i. Company Includes. For purposes of this Agreement, the Company shall include the
Company, and any parent and any direct and indirect subsidiaries and affiliates (as defined in Rule 501 under the Securities Act of 1933). 

j. Invention Assignment. The Executive agrees that all inventions, including, but not limited to, improvements, and all know-how,
processes, techniques, formulas, ideas, circuits, designs, trademarks, trade secrets and copyrightable works (collectively, “Inventions”) which result from work performed by the Executive on behalf of the Company or from access to
Proprietary Information shall be the property solely of the Company. The Executive agrees, both during and after employment with the Company, to disclose promptly and in writing, to the Company, all Inventions that the Executive, either solely or
jointly with others, make, author, discover, develop, conceive and/or reduce to practice derived from Proprietary Information. The Executive hereby assigns and agrees to assign to the Company or its designee, without further consideration, his
entire right and interest in and to all Inventions, including all rights to obtain, register and enforce patents, copyrights, mask work rights and other intellectual property protection for Inventions. The Executive agrees to execute all documents
reasonably necessary to perfect such intellectual property rights and the assignment of those rights to the Company or its designee. The Executive further agrees to assist the Company (at the Company’s expense), both during and after employment
with the Company, in obtaining, protecting and/or enforcing patents, copyrights or other forms of Inventions. 
 k. Return of Company
Property. Upon termination of the Executive’s employment with the Company for any reason whatsoever, voluntarily or involuntarily (and in all events within five (5) days of the Executive’s effective date of termination), and at any
earlier time the Company requests, the Executive will deliver to the person designated by the Company all originals and copies of all documents and property of the Company in the Executive’s possession, under the Executive’s control or to
which the Executive may have access. The Executive will not reproduce or appropriate for the Executive’s own use, or for the use of others, any property, Proprietary Information or Inventions, and shall remove from any personal computing or
communications equipment all information relating to the Company. 
 1. Permitted Conduct. Nothing in this Agreement restricts or
prohibits the Executive from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or from filing a claim
or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission (“EEOC”), the Department of Labor (“DOL”), the National
Labor Relations Board (“NLRB”), the Department of Justice (“DOJ”), the Securities and Exchange Commission (“SEC”), the Congress, and any agency Inspector General (collectively, the “Regulators”), or from
making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. The Executive does not need the prior authorization of the Company to engage in such communications with the Regulators, respond to
such inquiries from the Regulators, provide confidential information or documents to the Regulators, or make any such reports or disclosures to the Regulators. The Executive is not required to notify the Company that the Executive has engaged in
such communications with the Regulators. 

  
 10 

 7. Covenants to Survive this Agreement. The covenants of the Executive contained in
Section 6(b) hereof shall survive the termination of the Executive’s employment for any reason and the expiration or termination of this Agreement or any part thereof without regard to the reason therefor. The covenants of the Executive
contained in Section 6(a) hereof shall survive the termination of the Executive’s employment for any reason and the expiration or termination of this Agreement or any part thereof, except as otherwise expressly provided in this Agreement. Both
parties hereby expressly agree and contract that it is not the intention of either party to violate any public policy or any statutory or common law, and that if any sentence, paragraph, clause or combination of the same of Section 6 (including any
provisions incorporated by reference) is in violation of the law of any state where applicable, such sentence, paragraph, clause, or combination of the same shall be void in the jurisdictions where it is unlawful, and the remainder of such paragraph
and this Agreement shall remain binding on the parties hereto. It is the intention of both parties to make the covenants of Section 6 binding only to the extent that it may be lawfully done under existing applicable laws. In the event that any part
of any covenant of Section 6 is determined by a court of law to be overly broad thereby making the covenant unenforceable, the parties hereto agree, and it is their desire, that such court shall substitute a reasonable, judicially enforceable
limitation in place of the offensive part of the covenant and as so modified the covenant shall be as fully enforceable as set forth herein by the parties themselves in the modified form. 

8. Injunctive Relief, an Additional Remedy. The Executive acknowledges that the injury that would be suffered by the Company as
a result of breach of the provisions of Section 6 would be irreparable and that an award of monetary damages to the Company for such breach would be an inadequate remedy. Consequently, the Company will have the right in addition to any other rights
it may have, to obtain injunctive relief to restrain any breach or threatened breach or otherwise to specifically enforce any provision of this Agreement and the Company will not be obligated to post bond or the security in seeking such relief.
Without limiting the Company’s rights under this Section or any other remedies of the Company, if the Executive breaches any provisions of Section 6, and the Company obtains an injunction or final judgment that Executive has violated Section 6,
the Company will have the right to cease making any payments otherwise to the Executive under this Agreement. 
 9.
Withholding. Anything to the contrary notwithstanding, all payments required to be made by the Company hereunder to the Executive or the Executive’s estate or beneficiaries shall be subject to the withholding of such amounts, if
any, relating to tax and other payroll deductions as the Company may reasonably determine it should withhold pursuant to any applicable law or regulation. In lieu of withholding such amounts, the Company may accept other arrangements pursuant to
which it is satisfied that such tax and other payroll obligations will be satisfied in a manner complying with applicable law or regulation. 

  
 11 

 10. Miscellaneous. 

a. Executive Representations. The Executive hereby represents and warrants to the Company that he is not subject to, or a party to, any
employment agreement, non-competition covenant, non-disclosure agreement or other agreement, covenant, understanding or restriction of any nature whatsoever which would prohibit the Executive from executing this Agreement and performing fully his
duties and responsibilities hereunder, or which would in any manner, directly or indirectly, limit or affect the duties and responsibilities which may now or in the future be assigned to the Executive by the Company. Further, the Company expects the
Executive not to, and the Executive hereby acknowledges that he shall not, use any proprietary or confidential information of any prior employer in the performance of his duties. 

b. Governing Law. The validity, construction, interpretation and enforceability of this Agreement and the capacity of the parties shall
be determined and governed by the laws of the State of New Jersey without regard to conflicts of law. 
 c. Jurisdiction and Service of
Process. Any legal action or proceeding with respect to this Agreement shall be brought in the courts of the State of New Jersey or of the United States of America for the District of New Jersey. By execution and delivery of this Agreement, each
of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts. Each of the parties hereto irrevocably consents to the service of process of any of the aforesaid
courts in any such action or proceeding by mailing copies thereof by certified mail, postage prepaid, to the party at its address set forth in subsection (f). THE PARTIES IRREVOCABLY WAIVE ANY RIGHT TO TRIAL BY JURY TO ALL CLAIMS HEREUNDER. 

d. Assignment. This Agreement and any rights and benefits hereunder shall inure to the benefit of and be enforceable by the
Executive’s legal representatives, heirs or legatees. This Agreement and any rights and benefits hereunder shall inure to the benefit of and be binding upon the Company and its successors and assigns. This Agreement is personal to each of the
parties hereto, and neither party may assign or delegate any of the rights or obligations hereunder without first obtaining a written consent of the other party, except the Company may assign this Agreement without the Executive’s consent
provided that the Company merges with, or transfers all or substantially all of the Company’s assets to, a transferee or surviving company that agrees to assume this Agreement in its entirety, without modification or amendment. 

e. Collateral Agreements. This Agreement constitutes the entire Agreement between the parties respecting the employment of the
Executive, and supersedes any and all prior agreements and understandings concerning the terms and conditions of the Executive’s employment by the Company or an affiliate, including the Original Agreement, and there are no representations,
warranties or commitments relating to such employment, except as set forth or referred to herein, provided that, notwithstanding the foregoing, the Employee Confidentiality and Inventions Agreement between the Executive and the Company shall remain
in full force and effect. This Agreement may be amended only by an instrument in writing executed by the parties hereto. For the avoidance of doubt, this Agreement shall not supersede any award agreement between the Executive and the Company or an
affiliate evidencing outstanding equity awards. 

  
 12 

 f. Notices. Any notice, request, demand or other communication hereunder shall be in
writing and shall be deemed duly given when personally delivered to an officer of the Company or to the Executive, as the case may be, or when delivered by national next-business day delivery service or certified mail at the following addresses:

 If to the Company: 

Valeritas, Inc. 
 750 Route 202
South, Suite 600 
 Bridgewater, NJ 08807 

Attention: Human Resources 
 If
to the Executive: 
 8 Old Bam Court 

Newtown, PA 18940 
 g.
Counterparts. This Agreement may be executed in any number of counterparts. All executed counterparts shall constitute one Agreement notwithstanding that all signatories are not signatories to the original or the same counterpart. 

h. Mitigation. The Executive shall not be required to mitigate the amount of any payments and/or benefits under this Agreement by
seeking other employment or otherwise. The payments and/or benefits to be provided pursuant to Section 5 shall not be reduced by any compensation or benefits payable or provided to the Executive as a result of employment by another employer after
the date of termination or otherwise. 
 i. Waiver of Breach. No delay or omission by a party in exercising any right, remedy or
power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be deemed expedient or necessary by such
party in its sole discretion. 
 j. Application of Section of 409A of the Internal Revenue Code. 

(i) This Agreement is intended to comply with the requirements of section 409A of the Code and its corresponding regulations (“Section
409A”), and shall in all respects be administered in accordance with Section 409A. Notwithstanding anything in this Agreement to the contrary, distributions may only be made under this Agreement upon an event and in a manner permitted by
Section 409A or an applicable exemption. Severance benefits provided under this Agreement are intended to be exempt from Section 409A under the “separation pay exception” to the maximum extent applicable. Further, any payments that qualify
for the “short-term deferral” exception or another exception under Section 409A shall be paid under the applicable exception. For purposes of Section 409A, all payments to be made 

  
 13 

 
upon a termination of employment under this Agreement may only be made upon the Executive’s “separation from service” (within the meaning of such term under Section 409A), each
payment made under this Agreement shall be treated as a separate payment, and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. In no event shall the Executive, directly
or indirectly, designate the fiscal year of payment, except as permitted under Section 409A. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Executive’s execution of the Release, directly or
indirectly, result in the Executive designating the calendar year of payment, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year. The Executive
will be solely responsible for any tax imposed under Section 409A and in no event will the Company have any liability with respect to any tax, interest or other penalty imposed under Section 409A. 

(ii) Notwithstanding anything herein to the contrary, if, at the time of the Executive’s termination of employment with the Company, the
Executive is a “specified employee” (as such term is defined in Section 409A) and it is necessary to postpone the commencement of any payments or benefits otherwise payable under this Agreement as a result of such termination of employment
to prevent any accelerated or additional tax under Section 409A, then the Company shall postpone the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or
provided to the Executive) that are not otherwise paid within the ‘short-term deferral exception’ under Treas. Reg. section 1.409A-1(b)(4), and the ‘separation pay exception’ under Treas. Reg. section 1.409A-1(b)(9)(iii), until
the first payroll date that occurs after the date that is six months following the Executive’s “separation of service” (as such term is defined under Section 409A) with the Company. If any payments are postponed due to such
requirements, such postponed amounts shall be paid in a lump sum to the Executive on the first payroll date that occurs after the date that is six (6) months following Executive’s separation of service with the Company. If the Executive dies
during the postponement period prior to the payment of postponed amount, the amounts withheld on account of Section 409A shall be paid to the personal representative of the Executive’s estate within sixty (60) days after the date of the
Executive’s death. 
 (iii) All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in
accordance with the requirements of Section 409A, including, where applicable, the requirement that (1) any reimbursement shall be for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this
Agreement), (2) the amount of expenses eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in kind benefits to be provided, in any other calendar year, (3) the
reimbursement of an eligible expense shall be made on or before the last day of the calendar year following the year in which the expense is incurred and (4) the right to reimbursement or in kind benefits is not subject to liquidation or exchange
for another benefit. 
 [SIGNATURE PAGE FOLLOWS] 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the
day and year first written above, 
  

			
	COMPANY:
	
	Valeritas, Inc.
		
	By:	 	

		
	Name:	 	Lüke Duster
		
	Its:	 	Chairman of the Board of Directors
	
	EXECUTIVE:
	
	

	John Timberlake

 SIGNATURE PAGE TO EMPLOYMENT AGREEMENT 

OF JOHN TIMBERLAKE 

  
 15 

 EXHIBIT A 

RELEASE AND WAIVER OF CLAIMS 

In consideration of the benefits and mutual agreements set forth in the Employment Agreement, effective as of May 3, 2016 (the
“Agreement”), between Valeritas, Inc. (the “Company”) and [                    ] (the “Executive”), to which this form
is attached, the 
 Executive, intending to be legally bound, agrees to the terms and conditions set forth in this Release and Waiver of
Claims (the “Release and Waiver”). 
 1. In exchange for the consideration provided to the Executive by the Agreement that the
Executive is not entitled to receive absent the Agreement, including but not limited to the applicable severance consideration set forth in Section 5 of the Agreement, and the other commitments of the Company in the Agreement and in Paragraph 3 of
the Release and Waiver, the Executive and his or her heirs, representatives, agents and attorneys hereby generally and completely, subject to the provisions set forth below in Paragraph 2, releases the Company and any of its predecessors,
successors, parents, affiliated or subsidiary companies, and its or their present or former officers, directors, agents, members of the Board of Directors, representatives or employees, and the various Company benefit plans, committees, trustees,
fiduciaries, trusts and their respective successors and assigns, heirs, executors and personal or legal representatives (collectively referred to as the “Releasees”) from any and all claims or causes of action the Executive may have or
claim to have against the Releasees including any claims arising out of or relating in any way to the Executive’s employment with the Company and/or the termination of such employment. In waiving and releasing any and all claims against the
Releasees, whether or not now known to the Executive, the Executive understands that this means that if the Executive later discovers facts different from or in addition to those facts currently known by the Executive, or believed by the Executive
to be true, the waivers and releases of this Release and Waiver will remain effective in all respects – despite such different or additional facts and the Executive’s later discovery of such facts, even if the Executive would not have
signed this Release and Waiver if the Executive had prior knowledge of such facts. The claims released include, but are not limited to: 

(a) all claims for monetary damages arising under Title VII of the Civil Rights Act of 1964 (as amended), Sections 1981 through 1988 of Title
42 of the United States Code (as amended), the Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), the Older Workers Benefit Protection Act of 1990 (“OWBPA”), and the Americans with Disabilities Act of 1990 (as
amended); 
 (b) any and all other claims, including but not limited to claims brought under the Rehabilitation Act, the Executive
Retirement Income Security Act of 1974 (as amended), the Uniformed Services Employment and Reemployment Rights Act of 1994, the National Labor Relations Act (as amended), the Federal Worker Adjustment and Retraining Notification Act (as amended),
the Family and Medical Leave Act of 1993, the Occupational Safety and Health Act (as amended), the Equal Pay Act (as amended), the Labor Management Relations Act, New Jersey Law Against Discrimination, New Jersey Equal Pay Act, New Jersey Civil
Rights Law, New Jersey Conscientious Employee Protection Act, New Jersey Family Leave Act, New Jersey Wage and Hour Law, New Jersey WARN Laws, and the New Jersey Constitution; 

  
 16 

 (c) all claims arising under any Executive Order or derived from or based upon any state or
federal regulations; 
 (d) all common law claims, including but not limited to any and all rights to discovery, claims for wrongful
discharge, constructive discharge, violation of public policy, breach of an express or implied contract, breach of an implied covenant of good faith and fair dealing, negligent or intentional infliction of emotional distress, defamation, conspiracy,
tortious interference with contract or prospective economic advantage, promissory estoppel, equitable estoppel, fraud, misrepresentation, detrimental reliance, retaliation, and negligence; 

(e) all claims for personal injury, including physical injury, mental anguish, emotional distress, pain and suffering, embarrassment,
humiliation, damage to name or reputation, interest, liquidated damages, and punitive damages; and 
 (f) all claims for costs, interest,
and attorneys’ fees. 
 2. Paragraph 1 shall not apply to any claims the Executive may have with respect to the Company’s
severance obligations under Section 5 of the Agreement, any rights the Executive may have with respect to outstanding equity interests in the Company, rights to indemnification under the Company’s by-laws or otherwise, or any rights to recover
under any director and officer liability insurance policy maintained by the Company for the benefit of the Executive in accordance with the terms of such director and officer liability insurance policy. In addition, Paragraph 1 shall in no event
apply to any claims that, as a matter of applicable law, are not waivable, the Executive’s right to vested benefits under the written terms of the Company’s 401(k) Plan, claims for unemployment or workers’ compensation benefits, any
medical claim incurred during the Executive’s employment that is payable under applicable medical plans or an employer-insured liability plan, or claims arising after the date on which the Executive signs the Release and Waiver. The Executive
and the Company agree that nothing in this Release and Waiver restricts or prohibits the Executive from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to,
reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission
(“EEOC”), the Department of Labor (“DOL”), the National Labor Relations Board (“NLRB”), the Department of Justice (“DOJ”), the Securities and Exchange Commission (”SEC”), the Congress, and any agency
Inspector General (collectively, the “Regulators”), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. However, the Executive is waiving the Executive’s right
to receive any individual monetary relief resulting from such claims, regardless of whether the Executive or another party has filed them, and in the event the Executive obtains such monetary relief the Company will be entitled to an offset for the
payments made pursuant to Section 5 of the Agreement, except where such limitations are prohibited as a matter of law (e.g., under the Sarbanes-Oxley Act of 2002, 18 U.S.C.A. §§ 1514A). The Executive does not need the prior authorization
of the Company to engage in such communications with the Regulators, respond to such inquiries from the Regulators, provide confidential information or documents to the Regulators, or make any such reports or disclosures to the Regulators. The
Executive is not required to notify the Company that the Executive has engaged in such communications with the Regulators. 

  
 17 

 3. The Company, for and in consideration of the undertakings of the Executive set forth herein,
and intending to be legally bound, do hereby remise, release and forever discharge the Executive of and from any and all actions and causes of actions, suits, debts, claims and demands whatsoever in law or in equity, which the Company ever had, now
have, or which the Company may have, by reason of any matter, cause or thing whatsoever, from the beginning of the Executive’s employment with the Company and its affiliates up to and including the date of this Release and Waiver, arising from
or relating to any and all acts, events and omissions relating to the Executive’s employment with the Company, the termination of his employment relationship with the Company and its affiliates, or his service or status as (one or more of) an
agent, officer, director and/or employee of the Company and its affiliates, including, but not limited to, any claims, whether known or unknown, which have been asserted, could have been asserted or could be asserted now or in the future, including
any claims under any federal, state or local laws (“Released Claims”). Without limiting the foregoing, and subject to the last sentence of this Paragraph 3, Released Claims will not include any claims arising from the willful misconduct,
misrepresentation or fraud of the Executive, or any breach of any prior agreements between the Executive and the Company that impose non-competition, non-solicitation, confidentiality and/or nondisclosure obligations upon the Executive. The Company
shall not initiate or cause to be initiated against the Executive any lawsuit, compliance review, administrative claim, investigation or proceedings of any kind which pertain in any manner to the Released Claims. Notwithstanding the provisions of
Paragraph 1, the Executive shall continue to be indemnified and held harmless by the Company, from any liability, costs or obligations with respect to any and all actions and causes of actions, suits, debts, claims and demands whatsoever in law or
in equity (including, without limitation, any reasonable attorney fees or other charges incurred in defending same) to the maximum extent permitted under the applicable state law of the state in which the Company is incorporated and any policies of
insurance then in effect, limited only to the extent of any limit, from time to time, for current officers and directors of the Company. 

4. The Executive agrees that the Executive will not apply for, nor otherwise seek or accept, employment or re-employment with the Company or
any of its related or successor companies, and the Executive forever releases and discharges the Company and its related or successor companies from any obligation to consider the Executive for employment or re-employment in any capacity. 

5. The Executive acknowledges that, subject to the provisions set forth in Paragraph 2, any prior agreements between the Executive and the
Company that impose non-competition, non-solicitation, confidentiality and/or nondisclosure obligations upon the Executive shall remain in force and effect. 

6. The Executive acknowledges that the Executive has received all amounts due from the Company through the Executive’s termination of
employment, including but not limited to all wages earned and payment for all accrued but unused paid vacation time. No other amounts are due to the Executive from the Company except pursuant to Section 5 of the 

  
 18 

 
Agreement (to the extent applicable). The Executive also represents that there are no existing claims, charges, or complaints filed by the Executive against the Releasees in any federal, state or
local court or administrative agency. 
 7. The Executive acknowledges that the only consideration the Executive has received for signing
this Release and Waiver is that set forth herein and in the Agreement. No other promise, inducement, threat, agreement or understanding of any kind or description has been made with or to the Executive to cause the Executive to enter into this
Release and Waiver. The Executive further acknowledges that the consideration the Executive is receiving from the Company through this Release and Waiver and the Agreement is greater than any amount the Executive would otherwise be entitled to from
the Company. 
 8. The Executive understands that the Executive has been given a period of twenty- one (21) calendar days to review and
consider this Release and Waiver before signing it. The Executive also understands that the Executive is free to use as much of the twenty-one (21) day period as the Executive wishes or considers necessary before deciding to sign this Release and
Waiver, provided, however, that the Executive may not sign this Release and Waiver before the Executive’s termination of employment. Changes to the Company’s offer contained in this Release and Waiver that are immaterial will not restart
the twenty-one (21) day consideration period. [To be modified if termination occurs pursuant to a group termination program to reflect 45 day required consideration period and disclosures about the decisional unit, the eligibility factors for
selection for termination, and the ages and job titles of employees who were and who were not selected for termination and offered consideration for signing a release.] 

9. The Executive may revoke this Release and Waiver within seven (7) calendar days of signing it by delivering written notice of revocation to
                     at                     . If
the Executive has not revoked this Release and Waiver within that seven (7) day period, it becomes effective immediately on the eighth day after the Executive signs the Release and Waiver. 

10. The Company hereby advises the Executive to consult with an attorney. The Executive agrees that the Executive has had the opportunity to
review this Release and Waiver with an attorney, that the Company recommends that the Executive review this Release and Waiver with an attorney and that the Executive fully understands the terms and conditions of this Release and Waiver. The
Executive further acknowledges that the Executive accepts the terms of this Release and Waiver and enters into it freely, voluntarily, and without duress or coercion. 

11. Should any provision of this Release and Waiver be declared or determined by any Court of competent jurisdiction to be illegal, invalid or
unenforceable (except for Paragraph 1), the legality, validity and enforceability of the remaining parts, terms or provisions shall not be affected thereby and the illegal, unenforceable or invalid part, term or provisions shall be deemed not to be
part of this Release and Waiver. 
 12. This Release and Waiver shall be governed by New Jersey law, and the Courts of New Jersey, either
federal or state, shall have jurisdiction over, and be the proper venue for, any disputes arising out of this Release and Waiver. 

  
 19 

 I ACKNOWLEDGE THAT I HAVE CAREFULLY READ THIS RELEASE AND WAIVER OF CLAIMS AND UNDERSTAND ALL OF ITS TERMS,
INCLUDING THE FULL AND FINAL RELEASE AND WAIVER OF CLAIMS SET FORTH ABOVE. I FURTHER ACKNOWLEDGE THAT I HAVE VOLUNTARILY ENTERED INTO THIS RELEASE AND WAIVER OF CLAIMS, THAT I HAVE NOT RELIED UPON ANY REPRESENTATION OR STATEMENT, WRITTEN OR ORAL,
NOT SET FORTH IN THIS RELEASE AND WAIVER OF CLAIMS AND THAT I HAVE BEEN GIVEN THE OPPORTUNITY AND BEEN ENCOURAGED TO HAVE THIS RELEASE AND WAIVER OF CLAIMS REVIEWED BY AN ATTORNEY. 

 

					
	  
	 		 	  

			
	Name: [                    ]	 		 	On behalf of Valeritas
			
	Date:	 		 	Name:
			
		 		 	Title:
			
		 		 	Date:

  
 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]